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Introduction
The Primary Care Reimbursement Service (PCRS) 
supports the delivery of primary health care by providing 
reimbursement services to Primary Care Contractors 
(General Practitioners, Pharmacists, Dentists and 
Optometrists/Ophthalmologists), for the provision of 
health services to members of the public in their own 
community, and has executive responsibility for the Demand 
Led Schemes nationally.
The state funded Demand Led Schemes, which include 
the General Medical Services (GMS) (i.e. Medical Cards/
GP Visit Cards), Drugs Payment, Long Term Illness, 
Dental Treatment Services, European Economic Area, 
High Tech Drugs, Primary Childhood Immunisation, 
Health (Amendment) Act 1996, Methadone Treatment 
and HSE Community Ophthalmic Services, account for 
approximately 20% of the HSE’s overall budget.
In 2010 PCRS handled over 75 million claim/payment 
transactions in respect of services provided to over 3.42 
million people in their community by Doctors, Pharmacists, 
Dentists and Opticians, with an associated expenditure of 
€2.529 billion.
While executive responsibility for the Demand Led Schemes 
nationally has transferred to PCRS, the transition and 
streamlining of the Schemes is continuing to take place 
over a phased period so that the project can be continuously 
monitored and evaluated, and if required modified to deliver 
optimal results, for both the patients and the HSE.
Recent Trends
The increased uptake of the Demand Led Schemes continues 
as the economic climate presents ongoing challenges for 
people and available services. While expenditure budgets 
continue to reduce, the number of people on the Live 
Register and the demand for services keep growing.
As of 31 December 2010, the total number of eligible 
Medical Card holders was 1,615,809, which is approximately 
38.1% of the total population. In addition the total number 
of GP Visit Cards reached 117,423, approximately 2.77% 
of the population. An additional 156,347 eligible persons 
were granted Medical Cards or GP Visit cards in 2010, an 
increase of 9.9% over 2009.
A focus on delivering efficiencies aligned with reductions 
in the cost of some reimbursable items has resulted in a 
reduction in expenditure of approximately 4.28% in 2010 
(€2.529 billion in 2010 compared with €2.642 billion in 
2009).
Outlook
With increases in demand and reducing budgets the focus 
of attention will continue to be the delivery of further 
efficiencies and the streamlining and standardisation of 
services.
The specific Value for Money (VfM) projects underway 
to ensure sustained efficiencies have continued to move 
apace during 2010, with the major project to centralise the 
processing of all Medical Cards being one of the primary 
focuses in this area.
The Medical Card centralisation programme is being 
delivered on a phased basis, and has moved ahead throughout 
2010 as planned. Significant progress has been made during 
the year on this national project in providing an improved 
service to the public at less cost to the State.
Approximately 39% of the Medical Card population is 
now managed by the central office, with over a quarter of 
a million Medical Card applications and reviews processed 
centrally to date. Additional customer focused initiatives 
introduced in 2010, as part of the centralisation project 
include the new online Medical Card application service, 
the new website – www.medicalcard.ie, the use of SMS 
messaging to provide updates to applicants, the roll out 
of the national database to all local offices to support local 
customer service programs, the new call triage telephone 
system, the introduction of weekly panel listing updates for 
GPs, and the introduction of a streamlined user friendly 
review process for people over 70 years of age.
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The next phase of the programme is to go live and process 
all new applications in the Central Office from a given date 
following a consultative process with staff representatives 
and in line with the recent agreement on pay and reform 
in the public service. Taking cognisance of the fact that 
this is a critical change project there are many benefits 
accruing in the final phase, e.g. better customer service, full 
implementation on a given date providing more clarity to all 
concerned (Clients, TDs, Primary Care Contractors, HSE 
staff etc.), facilitating staff redeployment to key frontline 
services, and resulting in the provision of better Customer 
Relations Management Services to the client.
In addition to the changes introduced and the processing 
and making of payments on a national basis to General 
Practitioners, Pharmacists, Dentists and Optometrists/
Ophthalmologists, the PCRS continues to compile statistics 
and trend analyses which are provided to customers, the 
Government, stakeholders, members of the public and 
other areas within the HSE.
This progress could not be achieved without the hardworking 
staff at every level involved in the change projects, and in 
the continued delivery of day to day services while new 
initiatives are developed and introduced. I would like to 
thank everybody involved for their individual contribution 
and commitment, and their team effort, in the delivery of 
these vital support services throughout a year in which 
significant changes were taking place. I would also like 
to thank all of our customers, General Practitioners, 
Pharmacists, Dentists and Optometrists/Ophthalmologists 
for their co-operation throughout 2010.
I would also like to acknowledge the contribution of the 
Chief Executive Officer, the Directors and the support of 
the HSE Board throughout 2010.
Patrick Burke 
Primary Care Reimbursement Service
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Almost all payments for services provided in the community 
by General Practitioners, Community Pharmacies, 
Dentists and Optometrists/Ophthalmologists are made 
by the Primary Care Reimbursement Service. Payments 
in the Year 2010 were in excess of €2.529bn. Estimated 
payments by the Primary Care Reimbursement Service 
for 2011 are €2.311bn.
Claim data is processed and payments are made by the 
Primary Care Reimbursement Service under the following 
Schemes/Payment Arrangements –
General Medical Services (GMS)
Persons who are unable without undue hardship to arrange 
general practitioner medical and surgical services for 
themselves and their dependants. Since the 1st October 
2010, a person who is supplied by a Community Pharmacy 
Contractor with a drug, medicine or medical or surgical 
appliance on the prescription of a Registered Medical 
Practitioner, Registered Dentist or Registered Nurse 
Prescriber is charged 50 cent per item subject to a limit 
of €10 per family per month and this charge is recouped 
from payment to the Pharmacist.
Drugs, medicines and appliances supplied under the 
Scheme are provided through Community Pharmacies. 
In most cases the Doctor gives a completed prescription 
form to a person, who takes it to any pharmacy that has an 
agreement with the Health Service Executive to dispense 
GMS prescription forms. In rural areas the Doctor may 
dispense for those persons who opt to have their medicines 
dispensed by him/her. All GMS claims are processed and 
paid by the Primary Care Reimbursement Service.
Drugs Payment Scheme (DPS)
Under the Drugs Payment Scheme persons who are 
ordinarily resident in the State and who do not have a 
current medical card can benefit – an individual or family 
has now to pay no more than €120 in a calendar month for 
approved drugs, medicines and appliances for themselves 
or their families. In order to benefit under this Scheme a 
person must register themselves and their dependants with 
their Local Health Office. Items currently reimbursable 
under the Drugs Payment Scheme are those listed on 
the HSE Website. Other items which were reimbursable 
under the DCS and Refund of Drugs Schemes continue, in 
certain circumstances, to be reimbursable under the Drugs 
Payment Scheme. DPS claims are processed and paid by 
the Primary Care Reimbursement Service.
Long Term Illness Scheme (LTI)
On approval by the Health Service Executive, persons 
who suffer from one or more of a schedule of illnesses are 
entitled to obtain, without charge, irrespective of income, 
necessary drugs/medicines and/or appliances under the 
LTI Scheme. All LTI claims are processed and paid by the 
Primary Care Reimbursement Service.
Dental Treatment Services Scheme (DTSS)
Under the Dental Treatment Services Scheme GMS 
eligible adults have access to a range of treatments and 
clinical procedures comprised of Routine Treatments and 
Full Upper and Lower Dentures. Routine Treatments are 
now available for all eligible persons. Dentists may also 
prescribe a range of medicines to eligible persons. All claims 
under the DTSS are processed and paid by the Primary 
Care Reimbursement Service.
European Economic Area (EEA)
Residents from one of the other states of the European 
Economic Area, with established eligibility, who require 
emergency general practitioner services while on a temporary 
visit to the State are entitled to receive from a General 
Practitioner a GMS prescription form for necessary 
medication and to have such medication dispensed in a 
Pharmacy that has entered into an agreement with the 
Health Service Executive within the State. EEA claims are 
paid by the Primary Care Reimbursement Service.
Community Based Services – Payment Arrangements
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High Tech Drugs (HTD)
Arrangements are in place for the supply and dispensing 
of High Tech medicines through Community Pharmacies. 
Such medicines are generally only prescribed or initiated 
in hospital and would include items such as anti-rejection 
drugs for transplant patients or medicines used in 
conjunction with chemotherapy or growth hormones. The 
medicines are purchased by the Health Service Executive 
and supplied through Community Pharmacies for which 
Pharmacists are paid a patient care fee. The cost of the 
medicines and patient care fees are paid by the Primary 
Care Reimbursement Service.
Primary Childhood Immunisation Scheme
A National Primary Childhood Immunisation Scheme 
provides for immunisation of the total child population 
with the aim of eliminating, as far as possible, such 
conditions as Diphtheria, Polio, Measles, Mumps, Rubella 
and more recently Meningococcal C Meningitis. Payments 
to Doctors under this Scheme are made by the Primary 
Care Reimbursement Service.
Health (Amendment) Act 1996
Under the Health (Amendment) Act 1996 certain health 
services are made available without charge to persons 
who have contracted Hepatitis C directly or indirectly 
from the use of Human Immunoglobulin – Anti D or the 
receipt within the State of another blood product or blood 
transfusion. General Practitioner services, pharmaceutical 
services, dental services and optometric/ophthalmic services 
provided under the Act are paid for by the Primary Care 
Reimbursement Service.
Methadone Treatment Scheme
Methadone is prescribed and dispensed by Doctors and 
Pharmacists for approved clients under the Methadone 
Treatment Scheme – capitation fees payable to participating 
Doctors and Community Pharmacists and claims by 
pharmacies for the ingredient cost of the Methadone 
dispensed and the associated dispensing fees are processed 
and paid by the Primary Care Reimbursement Service.
Health Services Executive Community 
Ophthalmic Services Scheme (HSE-COS)
Under the Health Service Executive Community 
Ophthalmic Services Scheme, adult medical card holders 
and their dependants are entitled, free of charge, to eye 
examinations and necessary spectacles/appliances. Claims 
by Optometrists/Ophthalmologists are paid by the Primary 
Care Reimbursement Service. Claims for spectacles provided 
under the Children’s Scheme are also paid by the Primary 
Care Reimbursement Service.
Immunisations for certain GMS Eligible Persons
Agreement was reached between the Department of Health 
& Children and the Irish Medical Organisation on fee 
rates to be applied to certain immunisations for GMS 
eligible persons. The immunisations encompassed by the 
agreement are:- Pneumococcal, Influenza, Hepatitis B 
and the combined Pneumococcal/Influenza. The Health 
Service Executive facilitated claiming for any of these 
immunisations by extending the range of codes for ‘Special 
Items of Service’.
General Practitioner Visit Card (GPVC)
Certain people in Ireland who do not qualify for a medical 
card may apply to the Health Service Executive for a GP 
Visit Card. GP Visit Cards allow individuals and families 
who qualify, to visit their General Practitioner for free. All 
GP claims are processed and paid by the Primary Care 
Reimbursement Service.
Discretionary Hardship Arrangements
Medical Card patients, for whom Non GMS Reimbursable 
Items have been prescribed, may make application to the 
HSE Local Health Office (LHO) for approval to have such 
items dispensed by a Community Pharmacist. Previously, 
the LHO reimbursed Community Pharmacists directly in 
respect of such prescribed items. In July 2009 the payment 
function for these items transferred to the Primary Care 
Reimbursement Service.
8 9
Summary Statement of Activity During the Year
l Payments in the Year were in excess of €2,529.65m.
l Claim data is processed and payments are made by 
the PCRS under the following Schemes:
n General Medical Services (GMS);
n Drugs Payment (DP);
n Long Term Illness (LTI);
n Dental Treatment Services (DTS);
n European Economic Area (EEA);
n High Tech Drugs (HTD);
n Primary Childhood Immunisation;
n Health (Amendment) Act 1996;
n Methadone Treatment;
n Health Service Executive Community 
Ophthalmic Services (HSE-COS).
l At year end there were more than 3.42m persons 
registered as being eligible to benefit under the General 
Medical Services, Drugs Payment, Long Term Illness, 
Dental Treatment and Health Service Executive 
Community Ophthalmic Services Schemes.
l More than 93% of eligible GMS persons availed of 
GP, Pharmaceutical, Dental or Ophthalmic services 
provided by more than 6,567 Doctors, Pharmacists, 
Dentists and Optometrists/Ophthalmologists.
l More than 69m prescription items were paid for by 
the PCRS – an increase of over 1.4m items on 2009.
l Fees and allowances paid to Doctors totalled 
€493.83m.
l Payments to Pharmacies totalled €1,564.87m:
n GMS €1,233.26m;
n DP €173.44m;
n LTI €126.92m;
n EEA €1.74m;
n Patient Care Fees under the HTD Scheme 
€15.48m;
n The Health (Amendment) Act 1996, 
Methadone Treatment Scheme, DTS 
prescriptions and Pharmacy Training Grants 
€14.03m.
l Payments to Dentists under the DTS totalled 
€75.77m.
l Payments to Optometrists/Ophthalmologists under 
the HSE-COS totalled €26.89m.
l Payments to Wholesalers under the HTD Scheme 
totalled €345.76m.
l Administration costs in the accounting period of 2010 
were €20.49m.
l Claims processed are in respect of services provided 
in the community and availed of by almost 64.35% 
of the population.
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l Fees to Doctors include an amount of €9.05m in respect 
of the Primary Childhood Immunisation Scheme, 
€0.22m in respect of the Health (Amendment) Act 1996 
and €6.20m in respect of the Methadone Treatment 
Scheme.
l Allowances paid to Doctors include an amount of 
€5.13m paid as superannuation to Retired District 
Medical Officers and their dependants.
l Payments to Pharmacists include an amount of €1.59m 
in respect of drugs/medicines dispensed under the 
Health (Amendment) Act 1996, an amount of €11.32m 
in respect of the cost of Methadone dispensed under 
the Methadone Treatment Scheme and an amount of 
€0.85m in respect of DTS prescriptions.
l Payments to Dentists include an amount of €60,610 in 
respect of treatments under the Health (Amendment) 
Act 1996.
l Payments to Optometrists/Ophthalmologists include 
an amount of €75,870 in respect of treatments under 
the Health (Amendment) Act 1996.
l The corresponding figures for 2009 are –
n Total of Payments €2,642.99m.
n Doctors’ Fees €357.80m and Doctors’ 
Allowances €141.87m.
n Pharmacists’ Fees and Mark-Up €405.02m, 
Drugs and Medicines €1,273.77m.
n Payments to Dentists under the DTS Scheme 
€86.83m.
n Payments to Optometrists/Opthalmologists 
€23.80m.
n Investment in General Practice Development 
€2.88m.
n High Tech Drugs Scheme – Payment to 
Wholesalers €315.36m, Patient Care Fees 
€15.94m.
n Administration €19.72m.
The Year 2010
Doctors Fees €348.13m 
 Allowances €145.70m
Pharmacists Fees and Mark-Up €357.51m
 Drugs and Medicines €1,191.88m
Dentists   €75.77m
High Tech Drugs Scheme Payment to Wholesalers €345.76m
Patient Care Fees paid to Pharmacists €15.48m
Optometrists/Ophthalmologists €26.89m
Administration  €20.49m
Investment in General Practice Development €2.04m
Total of Payments for the year €2,529.65m
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Number of Agreements
Doctors 2,740 Pharmacists 1,671 Dentists 1,582 Optometrists 574
The number of agreements between the Health Service Executive and General Practitioners for the provision of services to GMS persons 
reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on entry to the GMS. 
In December 2010 there were 2,740 such agreements.
Number of Agreements as at 31st December 2010
Health Service Executive Doctors Pharmacists Dentists Optometrists
East Coast Area 293 152 123 43
South West Area 345 202 207 77
Northern Area 315 193 169 53
Midland 156 104 74 47
Mid-Western 234 151 134 47
North Eastern 203 152 100 67
North Western 160 100 70 34
South Eastern 273 185 159 66
Southern 470 257 336 71
Western 291 175 210 69
National *2,740 #1,671 +1,582 574
Corresponding figures for 2009 2,663 1,630 1,570 555
* 482 GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health 
(Amendment) Act 1996, Heartwatch and the Methadone Treatment Scheme at year end are included above.
# 12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS schemes at year end are included above.
+ 190 Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
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Persons who are unable without undue hardship to arrange General 
Practitioner medical and surgical services plus dental and optometric 
services for themselves and their dependants are provided with such 
services under the GMS Scheme. Since the 1st October 2010, a person 
who is supplied by a Community Pharmacy Contractor with a drug, 
medicine or medical or surgical appliance on the prescription of a 
Registered Medical Practitioner, Registered Dentist or Registered 
Nurse Prescriber is charged 50 cent per item subject to a limit of €10 
per family per month and this charge is recouped from payment to the 
Pharmacist. An eligible person is entitled to select a Doctor of his/her 
choice, from among those Doctors who have entered into agreements 
with the Health Service Executive. Drugs, medicines and appliances 
prescribed by participating Doctors for their GMS patients are provided 
through Community Pharmacies. Dental and ophthalmic services are 
provided by Dentists and Optometrists/Ophthalmologists who have 
contracted with the Health Service Executive. GMS prescription 
forms may be dispensed in any Pharmacy that has an agreement with 
the Health Service Executive to dispense GMS prescription forms. In 
rural areas, where a Doctor has a centre of practice three miles or more 
from the nearest Community Pharmacy participating in the Scheme, 
the Doctor dispenses for those persons served from the centre who opt 
to have their medicines dispensed by him/her. The number of eligible 
GMS persons at year end included 45,206 persons who were entitled 
and had opted to have their medicines dispensed by their GPs.
Under the terms of the Drugs Payment Scheme persons who do not 
have a medical card may apply for a Drugs Payment Scheme card on 
an individual or on a family unit basis. Prescribed medicines, which are 
reimbursable under the GMS Scheme, costing in excess of a specified 
amount per month, currently €120 per family, is claimed by the Pharmacy 
and is paid by the Primary Care Reimbursement Service.
On approval by the Health Service Executive, persons who suffer from 
one or more of a schedule of illnesses are entitled to obtain, without 
charge, irrespective of income, necessary drugs/medicines and/or 
appliances under the LTI Scheme. The Primary Care Reimbursement 
Service makes payments on behalf of the Health Service Executive for 
LTI claims submitted by Pharmacies.
Persons Eligible for Services
GMS 1,615,809 GPVC 117,423 DP 1,557,048 LTI 134,926
Number of Eligible Persons as at 31st December 2010
Health Service Executive GMS GPVC DP LTI
Eastern Areas 451,360 24,406 525,606 66,911
Midland 105,079 8,231 99,784 8,056
Mid-Western 144,125 9,398 164,541 9,025
North Eastern 163,395 12,785 139,757 10,967
North Western 125,554 10,230 58,727 7,489
South Eastern 205,672 15,572 143,700 14,355
Southern 236,322 23,528 260,032 10,180
Western 184,302 13,273 164,901 7,943
National 1,615,809 117,423 1,557,048 134,926
% of Population 38.11% 2.77% 36.72% 3.18%
Corresponding figures for 2009 1,478,560 98,325 1,587,448 127,636
GMS – General Medical Services Scheme. GPVC – GP Visit Card Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme.
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Payments to Doctors
Payments to General Practitioners are categorised as fees and/or 
allowances. For the majority of GPs who operate under the 1989 
agreement the principle fee is the capitation per person which is weighted 
for gender, age and distance from a Doctor’s centre of practice – capitation 
fees totalled €225,237,744 in 2010 – a decrease of €717,034 on 2009. 
Fees totalling €757,826 were paid to 9 GPs who continue to provide 
services under the Fee-Per-Item of service agreements.
Apart from ‘Out-of-Hours’ fees and fees for a range of special services 
the cost of services provided in normal hours by GPs for GMS persons, 
including the prescribing of necessary medicines, is encompassed by 
the capitation fee. All GMS persons can avail of full GP services and 
in many cases they can benefit from specialist clinics provided by GPs 
for issues such as Women’s Health, Family Planning and Asthma.
In addition to a capitation fee an outside normal hours fee is payable 
for non routine consultations when an eligible GMS person is seen 
by their GP or another GP acting on his/her behalf from 5pm in the 
evening to 9am on the following morning (Monday to Friday) and 
all hours on Saturdays, Sundays and Bank Holidays. The number of 
‘Out-of-Hours’ claims decreased to 703,623 in 2010 compared with 
837,143 in 2009 – and the cost of such claims decreased to €40,786,101 
from €49,507,291 in 2009. Special fees are payable for a range of 18 
services such as excisions, suturing, vaccinations, catheterization, family 
planning etc. The most frequent claimed special service in 2010 was 
Influenza Vaccination (371,659) followed by Excisions (123,808) and 
E.C.G. treatments (92,123) – there was a total of more than 790,908 
special services provided in 2010 – special fees totalling €30,370,507 
were paid in 2010.
Annual and Study Leave together with locum, nursing and secretarial 
support plus other practice support payments account for most of the 
€145,703,446 allowances paid in the year. The total paid in 2009 was 
€141,865,756.
Total of Payments to Doctors by Health Service Executive
Health Service Executive 2010
East Coast Area €29,631,918
South West Area €55,001,600
Northern Area €48,570,680
Midland €33,360,104
Mid-Western €43,392,157
North Eastern €45,856,821
North Western €36,479,276
South Eastern €62,001,485
Southern €81,018,845
Western €58,520,611
National €493,833,497
Corresponding figure for 2009 €499,665,359
The Total of Payments to Doctors includes payments in respect of eligible persons with Medical Cards and GP Visit Cards. The Total of Payments to Doctors 
also includes payments of: €9,049,544 under the Primary Childhood Immunisation Scheme; €217,975 to Doctors who provided services under the Health 
(Amendment) Act 1996; Heartwatch €1,574,300; National Cancer Screening Service €16,450,476 and €6,203,618 under the Methadone Treatment Scheme.
Total Payments accumulated by Regional Health Area
Dublin Mid-Leinster €117,993,622
Dublin North East €94,427,500
West €138,392,045
South €143,020,330
Fees €348.13m Allowances €145.70m
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Volume of Claims by Doctors
Fee-Per-Item 61,408
Special Type 298,354
Special Service 790,908
Out-of-Hours 703,623
National – Number of Claims – 2010
Number of Claims in each Health Service Executive Area
Health Service Executive Fee-Per-Item Special Type Special Service Out-of-Hours
East Coast Area 293 14,463 46,901 27,928
South West Area 16,854 42,232 76,927 62,973
Northern Area 4,301 29,708 69,459 33,934
Midland 1,661 23,446 53,417 55,364
Mid-Western 14,721 27,366 64,984 62,143
North Eastern 434 17,544 65,727 8,350
North Western 7 16,192 66,598 52,084
South Eastern 2,881 26,217 104,735 126,113
Southern 20,243 62,577 134,755 183,650
Western 13 38,609 107,405 91,084
National 61,408 298,354 790,908 703,623
Corresponding figures for 2009 59,632 261,884 713,658 837,143
A majority of Doctors are paid an annual capitation fee for each eligible person – the rate of payment is determined by the age/gender of the person and 
distance between each person’s residence and the centre of practice of their Doctor-of-Choice. A minority of Doctors (9) who have continued to provide services 
under the Fee-Per-Item of Service agreement are paid a fee for each Doctor/Patient contact.
A Special Type Consultation (STC) fee is payable when a GMS eligible person is unable to contact their registered Doctor and is seen as an emergency case by 
another. General Practitioners qualify for payment of ‘special fees’ for the special items of service separately identified under the Capitation agreement and the 
Fee-Per-Item agreement.
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Payments to Pharmacies
Total of Payments to Pharmacies by Health Service Executive
Health Service Executive GMS € *DP € LTI € #EEA €
East Coast Area 76,808,873 18,923,628 14,624,625 62,869
South Western Area 137,087,511 28,153,066 21,196,634 117,566
Northern Area 140,892,330 27,401,133 19,682,718 70,599
Midland 84,031,459 10,445,520 7,578,007 102,548
Mid-Western 113,777,116 12,659,796 7,505,324 185,344
North Eastern 107,747,376 14,245,063 11,577,379 116,941
North Western 79,199,842 5,657,576 7,564,925 216,811
South Eastern 161,636,712 16,394,868 12,992,635 190,734
Southern 195,950,585 26,131,558 15,501,349 384,585
Western 136,129,755 13,422,864 8,698,183 296,449
National €1,233,261,559 €173,435,072 €126,921,779 €1,744,446
Corresponding figures for 2009 €1,260,244,615 €259,928,189 €139,759,172 €1,957,613
* DP – Payment to Pharmacies in respect of Fertility Treatment for The Rotunda Hospital and The National Maternity Hospital are included in the above table.
# EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.
Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 – €1,591,335; Methadone Treatment Scheme – €11,324,565; DTS Scheme – €852,859;  
Pharmacy Training Grant – €256,200 and Patient Care Fees totalling €15,484,876 under the High Tech Drugs Scheme (Payments to Wholesalers under the High Tech Drugs Scheme amounted to €345,758,331).
Included in the above GMS figures is an amount of €12,769,728 which was paid in respect of Non GMS Reimbursable Items dispensed under Discretionary Hardship Arrangements.
Total Payments accumulated by Regional Health Area
GMS € *DP € LTI € #EEA €
Dublin Mid-Leinster 297,927,843 57,522,214 43,399,266 282,983
Dublin North East 248,639,706 41,646,196 31,260,097 187,540
South 357,587,297 31,740,236 23,768,432 698,604
West 329,106,713 42,526,426 28,493,984 575,319
GMS €1,233.26m DP €173.44m LTI €126.92m EEA €1.74m
A GMS person who is provided with a properly completed GMS 
prescription form by his/her GP can choose to have such prescription 
forms dispensed in any of the Pharmacies who have entered into 
agreements with the Health Service Executive for the provision of 
services under Section 59 of the Health Act, 1970.
In 2010 there were 17.51m prescription forms containing over 54m 
prescription items dispensed at a cost of over €1,220,397,029 i.e. an 
average cost of €22.47 per dispensed item. More than 93% of all eligible 
GMS persons were prescribed for in the year. The average cost of 
medicines per GMS person in 2010 was €814.24.
Payments made to Pharmacies under the GMS and DTS Schemes are 
inclusive of the ingredient cost of medicines, dispensing fees and VAT.
Under DP, LTI and EEA Schemes Pharmacies are reimbursed the 
ingredient cost of items dispensed, dispensing fees, mark-up and VAT. 
For details please see page 28.
The cost of the High Tech Drugs Scheme was €360.40m – at year 
end there were 54,974 persons registered under this Scheme – Patient 
Care Fees totalled €15.48m and payments for drugs and medicines 
totalled €345.76m.
In the year the Health Service Executive processed claims valued 
at €389.35m on drugs acting on the ‘cardiovascular system’ (GMS 
€276.68m, DP €87.19m and LTI €25.48m). The second highest cost 
category was drugs acting on the ‘nervous system’ €344.47m (GMS 
€272.50m, DP €54.99m, LTI €16.98m). The third highest amount paid 
was for drugs acting on the ‘alimentary tract and metabolism system’ 
€262.65m (GMS €183.40m, DP €45.06m, LTI €34.19m).
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Volume of Claims by Pharmacies
National – Number of Items – 2010
LTI 2.81m
EEA 0.09m
Other 0.47m
HTD 0.39m
DP 11.07m
GMS 54.42m
Number of Items in each Health Service Executive Area
Health Service Executive *GMS DP LTI EEA HTD #Other
East Coast Area 3,490,707 1,218,248 306,535 3,227 32,928 40,741
South West Area 6,430,920 1,694,209 457,328 5,759 58,161 131,448
Northern Area 5,973,123 1,612,643 413,668 3,574 42,457 116,799
Midland 3,680,650 700,339 179,196 4,776 24,616 20,148
Mid-Western 5,118,362 849,815 183,652 9,398 31,239 26,512
North Eastern 4,801,614 932,729 262,108 5,221 31,592 26,841
North Western 3,443,653 370,775 171,856 10,689 24,932 10,428
South Eastern 7,099,308 1,131,497 310,575 9,605 41,166 32,602
Southern 8,642,212 1,704,690 332,569 19,669 62,614 40,654
Western 5,744,111 855,501 190,270 14,527 41,133 25,058
National 54,424,660 11,070,446 2,807,757 86,445 390,838 471,231
Corresponding figures for 2009 50,721,919 13,372,525 2,855,361 85,520 357,365 433,301
* This group includes: GMS claim items and Stock Order items.
# This group includes: 65,471 claim items in respect of the Health (Amendment) Act 1996; 275,733 items under the Methadone Treatment Scheme and 130,027  
prescription items under the DTS Scheme.
GMS – General Medical Services Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme. EEA – European Economic Area. HTD – High Tech Drugs Scheme.  
Other – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.
GMS prescription forms processed for payment in the year totalled 
17.51m – the total of prescribed items was more than 54m – these 
accounted for approximately 78.59% of all items paid for by the Primary 
Care Reimbursement Service in 2010.
Approximately 38.49% of GMS forms contained a single item – more 
than 19.06% contained 2 items – the average number of items per form 
was 3.10 (2009 – 3.11).
GMS dispensed items paid for by the Primary Care Reimbursement 
Service in 2010 increased by more than 3,702,741 – the decrease in 
the number of DP items was less than 2,302,079 – the overall increase 
in the number of pharmacy claims processed by the Primary Care 
Reimbursement Service in the year was more than 1.4m.
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Payments to Dentists
Dentists were paid a total of €75,707,451 in 2010, in respect of 
treatments provided for more than 382,404 GMS persons under the 
DTS Scheme.
The following treatments were available to all eligible GMS persons.
ROUTINE: Routine treatments are categorised as either ‘Above the 
Line’ or ‘Below the Line’;
 ‘Above the Line’ treatments are uncomplicated procedures 
viz. Amalgam; Extractions;
 ‘Below the Line’ treatments are advanced procedures 
viz. Protracted Periodontal; Prosthetics.
‘Below the Line’ treatments – prior Health Service Executive approval 
for a specific course of treatment under this category is required. Full 
denture treatment is available, with prior Health Service Executive 
approval, to all edentulous GMS persons over 16 years.
Above the line €54.10m Below the line €21.60m
Payments to Dentists in each Health Service Executive Area
Health Service Executive 2010
Eastern Areas €19,057,294
Midland €4,774,744
Mid-Western €6,686,831
North Eastern €6,957,400
North Western €4,783,978
South Eastern €10,581,386
Southern €12,973,497
Western €9,892,321
National €75,707,451
Corresponding figure for 2009 €86,772,492
Dentists were also paid a total of €60,610 in 2010 in respect of treatments under the Health (Amendment) Act 1996.
Total Payments accumulated by Regional Health Area
Dublin Mid-Leinster €16,751,201
Dublin North East €14,038,236
South €23,554,884
West €21,363,130
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Volume of Claims by Dentists
National – Volume of Treatments – 2010
Above the Line  1,304,340
Below the Line 104,346
Volume of Treatments by Dentists in each Health Service Executive Area
Health Service Executive +Above the Line +Below the Line No. of persons  
treated under DTS
Eastern Areas 348,006 21,867 99,698
Midland 78,461 7,004 23,481
Mid-Western 116,353 9,965 34,066
North Eastern 120,419 9,197 35,406
North Western 85,765 5,713 26,858
South Eastern 173,387 16,961 50,913
Southern 226,653 17,529 64,599
Western 155,296 16,110 47,383
National 1,304,340 104,346 382,404
Corresponding figures for 2009 1,439,431 145,167 343,067
ROUTINE – Routine treatments are categorised as either ‘Above the Line’ or ‘Below the Line’: 
‘Above the Line’ (ATL) treatments are uncomplicated procedures; 
‘Below the Line’ (BTL) treatments are advanced procedures.
+ The most frequently used ATL service was Amalgam Restoration, which was used by 160,300 patients followed by Oral Examination.  
In the BTL category the most frequently used service was Protracted Periodontal followed by Prosthetics and Radiographs.
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Payments to Optometrists/Ophthalmologists
Under the Health Service Executive Community Ophthalmic Services 
Scheme, Optometric/Ophthalmic services are provided to adult medical 
card holders, which include free eye examinations and necessary 
spectacles/appliances.
Payments in respect of spectacles provided under the Children’s Scheme 
are also made by the Primary Care Reimbursement Service on behalf 
of the majority of Health Service Executive Areas.
Payments in respect of eye examinations and necessary spectacles/
appliances are provided under the Teenager’s Scheme for eligible medical 
card holders on behalf of certain Health Service Executive Areas.
In the 12-month period to the end of December 2010 claims were 
received on behalf of 269,076 GMS persons for 637,850 treatments 
costing €25,178,002.
Eye examinations by Optometrists/Ophthalmologists totalled 273,124; 
complete spectacles (distance, reading and bi-focals) provided under the 
Scheme totalled 364,726. The balance of treatments included replacement 
lenses and frames, tinted lenses, prisms and contact lenses. A breakdown 
of treatments and payments in each Health Service Executive Area is 
shown hereunder.
Payments to Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive 2010
Eastern Areas €6,872,946
Midland €1,757,890
Mid-Western €2,375,310
North Eastern €2,004,039
North Western €1,753,750
South Eastern €3,612,768
Southern €3,968,192
Western €2,833,107
National €25,178,002
Corresponding figure for 2009 €22,184,541
Opticians were also paid in respect of: Health (Amendment) Act 1996 €75,870; Optical services for Teenagers €230,715; Optical services for Children 
€1,401,894.
Total Payments accumulated by Regional Health Area
Dublin Mid-Leinster €6,456,002
Dublin North East €4,178,873
South €7,580,960
West €6,962,167
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Volume of Treatments by Optometrists/Ophthalmologists
National – Volume of Treatments – 2010
Eye Exams 273,124
Appliances 364,726
Volume of Treatments by Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive Eye Exams Appliances Volume of 
Treatments
No. of Persons 
Treated
Eastern Areas 73,992 93,301 167,293 71,279
Midland 18,513 24,031 42,544 17,803
Mid-Western 25,673 35,579 61,252 25,482
North Eastern 21,199 31,145 52,344 21,587
North Western 20,392 26,575 46,967 21,016
South Eastern 38,285 55,505 93,790 40,130
Southern 44,216 56,018 100,234 41,394
Western 30,854 42,572 73,426 30,385
National 273,124 364,726 637,850 269,076
Corresponding figures for 2009 242,336 322,270 564,606 238,844
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Cost per Person
National 2010
GMS €1,099.16
LTI €1,880.55
DP €350.69
DTS €197.98
HSE-COS €93.57
Cost per Person in each Health Service Executive Area
Health Service 
Executive
GMS LTI DP DTS HSE-COS
Doctor
Cost
€
Pharmacy
Cost
€
Total
Cost
€
Pharmacy
Cost
€
Net Cost
Per 
Claimant
€
Per 
Person
Treated
€
Per 
Adult
Treated
€
Eastern Areas 279.98 806.68 1,086.66 1,989.10 406.31 191.15 96.42
Midland 294.41 831.42 1,125.83 1,805.58 320.74 203.35 98.74
Mid-Western 282.64 841.12 1,123.76 1,614.05 305.16 196.29 93.22
North Eastern 260.28 767.89 1,028.17 1,901.05 320.74 196.50 92.84
North Western 268.66 721.11 989.77 1,817.18 313.93 178.12 83.45
South Eastern 280.24 819.43 1,099.67 1,831.50 325.75 207.83 90.03
Southern 311.79 877.55 1,189.34 1,884.20 326.60 200.83 95.86
Western 296.19 811.44 1,107.63 1,683.41 302.21 208.77 93.24
National €284.92 €814.24 €1,099.16 €1,880.55 €350.69 €197.98 €93.57
Corresponding figures for 2009 €337.94 €907.85 €1,245.79 €2,126.23 €391.97 €252.93 €92.88
The Doctor cost above does not include superannuation paid to retired DMOs.
The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2010.
Medical and pharmaceutical services delivered to GMS persons decreased in cost from €1,245.79 in 2009 to €1,099.16 in 2010 a decrease of €146.63  
per person – the cost of medical services per person decreased in cost from €337.94 in 2009 to €284.92 a decrease of 15.69% – the cost per person  
of pharmaceutical services decreased from €907.85 in 2009 to €814.24 in 2010 a decrease of 10.31%.
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Major Therapeutic Classification of Drugs, Medicines and Appliances – General Medical Services Scheme
National 2010
C - 22.43%
N - 22.10%
A - 14.87%
R - 9.33%
V - 8.32%
Other - 22.95%
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 183.40 14.87
B Blood and Blood Forming Organs 54.45 4.41
C Cardiovascular System 276.68 22.43
D Dermatologicals 24.93 2.02
G Genito Urinary System and Sex Hormones 49.93 4.05
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 14.46 1.17
J Anti-infectives for Systemic Use 36.33 2.95
L Antineoplastic and Immunomodulating Agents 11.06 0.90
M Musculo-Skeletal System 68.10 5.52
N Nervous System 272.50 22.10
P Antiparasitic Products, Insecticides and Repellents 0.98 0.08
R Respiratory System 115.01 9.33
S Sensory Organs 22.79 1.85
V Clinical Nutritional Products 46.40 3.76
Diagnostic Products 23.47 1.90
Ostomy Appliances 13.96 1.13
Urinary Appliances 7.59 0.62
Needles/Syringes/Lancets 5.74 0.46
Other Therapeutic Products 2.55 0.21
Dressings 1.68 0.14
Allergens 0.02 0.00
Miscellaneous 1.24 0.10
Total €1,233.27m 100%
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Major Therapeutic Classification of Drugs, Medicines and Appliances – Drugs Payment Scheme
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 45.06 13.41
B Blood and Blood Forming Organs 14.39 4.28
C Cardiovascular System 87.19 25.95
D Dermatologicals 12.47 3.71
G Genito Urinary System and Sex Hormones 21.18 6.30
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 3.96 1.18
J Anti-infectives for Systemic Use 9.76 2.90
L Antineoplastic and Immunomodulating Agents 5.36 1.60
M Musculo-Skeletal System 19.37 5.76
N Nervous System 54.99 16.36
P Antiparasitic Products, Insecticides and Repellents 1.00 0.30
R Respiratory System 38.12 11.35
S Sensory Organs 4.67 1.39
V Clinical Nutritional Products 8.01 2.38
Ostomy Appliances 5.62 1.67
Urinary Appliances 2.01 0.60
Diagnostic Products 1.32 0.39
Dressings 0.37 0.11
Needles/Syringes/Lancets 0.36 0.11
Other Therapeutic Products 0.35 0.11
Allergens 0.15 0.05
Miscellaneous 0.31 0.09
Total €336.02m 100%
Note:  The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by an individual or family.
National 2010
C - 25.95%
A - 13.41%
N - 16.36%
R - 11.35%
V - 5.51%
Other - 27.42%
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Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 34.19 26.94
B Blood and Blood Forming Organs 2.95 2.32
C Cardiovascular System 25.48 20.08
D Dermatologicals 0.11 0.08
G Genito Urinary System and Sex Hormones 1.30 1.03
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 0.72 0.57
J Anti-infectives for Systemic Use 1.50 1.19
L Antineoplastic and Immunomodulating Agents 0.09 0.07
M Musculo-Skeletal System 0.38 0.30
N Nervous System 16.98 13.37
P Antiparasitic Products, Insecticides and Repellents 0.00 0.00
R Respiratory System 0.49 0.39
S Sensory Organs 0.21 0.16
V Diagnostic Products 24.80 19.54
Clinical Nutritional Products 7.50 5.91
Needles/Syringes/Lancets/Swabs 7.95 6.26
Urinary Appliances 1.10 0.86
Nutritional/Ancillary Devices 0.53 0.42
Dressings 0.20 0.16
Ostomy Appliances 0.16 0.12
Other Therapeutic Products 0.04 0.04
Miscellaneous 0.24 0.19
Total €126.92m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances – Long Term Illness Scheme
National 2010
V - 33.50%
A - 26.94%
C - 20.08%
N - 13.37%
Other - 6.11%
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2010 2009 2008 2007 2006
(i) Number of Eligible Persons in December 1,733,232 1,478,560 1,352,120 1,276,178 1,221,695
Doctors (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €460,338 €466,737 €459,476 €427,418 €391,029
(ii) Doctors’ Payment per Person €284.92 €337.94 €352.67 €349.03 €314.85
Pharmacies (000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Prescriptions €1,220,397 €1,245,935 €1,129,494 €1,032,178 €924,995
Ingredient Cost €932,270 €962,305 €881,425 €824,323 €743,943
Dispensing Fee €259,635 €257,968 €225,697 €188,163 €163,537
VAT €28,492 €25,662 €22,372 €19,692 €17,516
Number of Forms 17,508 16,333 15,648 14,780 13,932
Number of Items 54,308 50,722 48,212 44,358 40,569
Cost per Form €69.71 €76.28 €72.18 €69.84 €66.39
Cost per Item €22.47 €24.56 €23.43 €23.27 €22.80
Ingredient Cost per Item €17.17 €18.97 €18.28 €18.58 €18.34
Items per Form 3.10 3.11 3.08 3.00 2.91
(000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Stock Orders €12,865 €14,309 €15,797 €16,231 €15,230
Ingredient Cost €9,895 €11,044 €12,188 €12,559 €11,777
Pharmacy Fees €2,467 €2,761 €3,047 €3,140 €2,944
VAT €503 €504 €562 €532 €509
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Cost of Medicines €1,233,262 €1,260,244 €1,145,292 €1,048,409 €940,225
(iii) Pharmacy Payment per Person €814.24 €907.85 €932.63 €856.14 €809.04
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Payments €1,693,600 €1,726,981 €1,604,768 €1,475,827 €1,331,254
(iii) Overall Payment per Person €1,099.16 €1,245.79 €1,285.30 €1,205.17 €1,123.89
Note: (i) Number of Eligible Persons in 2010 includes the number of eligible persons with Medical Cards and GP Visit Cards. 
 (ii) Doctors’ Payment per Person is exclusive of superannuation paid to retired DMOs. 
 (iii) Pharmacy Payment per Person and Overall Payment per Person is based on the actual number of persons who availed of services.
Summary of Statistical Information relating to the GMS Scheme for each of the five years 2006-2010
24 25
2010 2009 2008 2007 2006
LTI Scheme
Number of Eligible Persons in December 134,926 127,636 120,407 112,580 106,307
*Number of Claimants 67,492 65,731 62,934 59,040 53,082
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,808 2,855 2,643 2,353 2,165
Total Cost €126,922 €139,759 €137,899 €124,458 €115,461
Cost per Item €45.20 €48.95 €52.17 €52.90 €53.32
*Cost per Claimant €1,880.55 €2,126.23 €2,191.17 €2,108.03 €2,175.15
DP Scheme
Number of Eligible Persons in December 1,557,048 1,587,448 1,624,413 1,583,738 1,525,657
*Number of Claimants 494,550 663,127 687,587 667,782 597,835
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 11,070 13,373 13,907 13,430 11,872
Gross Cost €336,019 €451,707 €506,806 €491,186 €442,924
Net Cost €173,435 €259,928 €311,898 €307,334 €283,108
Gross Cost per Item €30.35 €33.78 €36.44 €36.57 €37.31
*Net Cost per Claimant €350.69 €391.97 €453.61 €460.23 €473.56
* These figures are based on the actual number of persons who availed of services under each Scheme.
Summary of Statistical Information relating to the LTI/DP Schemes for each of the five years 2006-2010
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Fees and Allowances under Capitation Agreement as at 31st December 2010
Ages Male € Female €
Under 5 years 76.98 75.09
5-15 44.68 45.19
16-44 57.03 93.26
45-64 113.91 125.17
65-69 120.00 133.87
Above rates are exclusive of Supplementary Out-of-Hours Fee of €3.76.
The Capitation rate is €280.31 per annum for persons aged 70 years and over in the community issued with a medical card.
A Capitation rate of €448.04 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by the Health 
Service Executive) for continuous periods in excess of five weeks.
Out-of-Hours Payment
Surgery (6 p.m. - 8 a.m.) €45.00
Surgery (8-9 a.m and 5-6 p.m) €15.00
Domiciliary €45.00
Additional Fee (Surgery or Domiciliary) €15.00
*Special Items of Service
(i) to (ix) €26.81
(x) and (xi) €40.23
(xii) €67.05
(xiii) €45.13
(xiv) €72.21
(xv) and (xvi) €42.75
(xvii) €64.12
(xviii) €154.13
Temporary Residents/EEA Visitors/
Emergency
Surgery €44.26
Domiciliary €44.26
Additional Fee €15.00
Rural Dispensing Fee €15.41
Fee for Second Medical Opinion €28.60
Practice Payments for Rural Areas
Rural Practice Allowance  
Per Annum €17,530.89
Opt-in GP (dispensing doctor) €41.11
Pilot GP (dispensing doctor) €47.44
Continuous GP (dispensing doctor) €13.49
Practice Support
Allowance for Practice Secretary 
up to a maximum Per Annum of €24,312.12
Allowance for Practice Nurse  
up to a maximum Per Annum of €38,204.77
Allowance for Practice Manager  
up to a maximum Per Annum of €31,258.45
Contributions to Locum Expenses
(Subject to the conditions of the Agreement)
Annual Leave
Up to a maximum of 
€1,492.60 per week
Sick Leave
Up to a maximum of 
€1,492.60 per week
Study Leave
Adoptive Leave
Maternity Leave
Paternity Leave
Up to a maximum  
of €213.23 per day
Contributions to Medical  
Indemnity Insurance
Calculation of contributions related to GMS  
panel numbers and net premium.
Asylum Seekers
A one off superannuable registration fee of 
€179.25 per person payable to Doctors in 
respect of each such patient on their GMS 
Scheme panels.
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging  
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting 
of a Diaphragm.
(viii) Removal of Adherent 
Foreign Bodies from the 
Conjunctival Surface of the Eye.
(ix) Removal of Lodged or Impacted 
Foreign Bodies from the Ear, Nose 
and Throat.
(x) Nebuliser Treatment  
in the case of Acute Asthmatic 
Attack. 
(xi) Bladder Catheterization.
(xii) Attendance at case conferences 
(in cases where such are 
convened by the HSE).
(xiii) Advice and Fitting  
of a Diaphragm.
(xiv) Counselling and  
Fitting of an IUCD.
(xv) Pneumococcal Vaccination.
(xvi) Influenza Vaccination.
(xvii) Pneumococcal/Influenza 
Vaccination.
(xviii) Hepatitis B Vaccination.
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Surgery Consultations
Day Normal Hours €12.83
Late Outside Normal Hours other than (Night) €18.25
Night Midnight to 8.00 a.m. €36.09
Domiciliary Consultations
Day €18.93
Late €24.79
Night €48.61
Temporary Residents/EEA Visitors/Emergency
Surgery €44.26
Domiciliary €44.26
Rural Practitioner’s Allowance
Per Annum €7,613.96
Locum and Practice Expense Allowance
Per Annum €1,482.23
Sessional Rate – Homes for the Aged
Per 3 Hour Session €79.11
*Special Items of Service
(i) to (vii) €24.25
(viii) and (ix) €42.75
(x) €64.12
(xi) €154.13
Immunisation Fees
(i) Registration of child with a G.P. €40.84
(ii) Complete course of immunisation 
against PT/DT, Hib, Polio and MMR
€136.08
(iii) 95% uptake bonus % not in Schedule €65.54
Health (Amendment) Act 1996
Surgery Fee €33.00
Domiciliary Fee €43.53
Methadone Treatment Scheme
Level 1 Contractor €159.97
Level 2 Contractor €176.43
Heartwatch Programme €42.50
Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme,  
Health (Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2010
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and 
Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging 
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting  
of a Diaphragm.
(viii) Pneumococcal Vaccination.
(ix) Influenza Vaccination.
(x) Pneumococcal/Influenza 
Vaccination.
(xi) Hepatitis B Vaccination.
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GMS Scheme €
*Fee-Per-Item
-   for each of the first 1,667 items dispensed by the Community Pharmacy Contractor in a month 5.00
-   for each of the next 833 items dispensed by the Community Pharmacy Contractor in that month 4.50
-   for each other item dispensed by the Community Pharmacy Contractor in that month 3.50
Extemporaneous Fee 6.53
Extemporaneous dispensing and compounding of
-   Powders 19.60
-   Ointments and Creams 13.07
Non-Dispensing – exercise of professional judgement 3.27
Phased Dispensing – each part of phased dispensing 3.27
* A Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.
Supplies to Dispensing Doctors
Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the reimbursement price with the addition of 25% on cost.
DP/LTI/EEA Schemes and Health (Amendment) Act 1996
* The Fee-Per-Item structure shown for the GMS Scheme above includes the items dispensed in these four Schemes. 
Reimbursement of ingredient cost plus 20% mark-up on ingredient cost plus Fee-Per-Item. 
20% mark-up on Incontinence products and Dressings under DP Scheme, 50% mark-up on all other Non Drug Items.
Extemporaneously dispensed preparations are reimbursed according to Statutory Instrument S.I. No. 249 of 2009. In the case of the Drugs Payment 
Scheme the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are in 
excess of the specified monthly amount (currently €120) payable to the Pharmacy by an individual or family.
High Tech Medicines Scheme
Patient Care Fee: €62.03 per month.
Methadone Treatment Scheme
Patient Care Fee: Up to a Maximum of €62.00 per month.
Scale of Fees Payable to Participating Pharmacists as at 31st December 2010
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Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2010
Treatment Type Routine 
€
Oral Examination 33.00
Prophylaxis 31.00
Restoration (Amalgam) 50.06
Restoration (Composite) 6 anterior teeth only 51.88
Exodontics (Extraction under local anaesthetic) 39.50
Surgical Extraction – Maximum 2 units:
Fee payable for each 15 minute unit 35.00
Maximum 70.00
1st Stage Endodontic Treatment (Anterior teeth only) 57.30
Denture Repairs
1st Item of Repair 47.86
Each Subsequent Item 15.34
Maximum 78.54
Apicectomy/Amputation of Roots * Dentist Estimate
Endodontics (Anterior teeth only) * Dentist Estimate
Protracted Periodontal Treatment * Dentist Estimate
Miscellaneous
(e.g. Haemorrhage and Prescriptions only) 22.65
Prosthetics
Full Upper or Lower Denture 326.22
(Other than Edentulous Persons)
Partial Upper or Lower Acrylic Denture 239.27
Complete Upper or Lower Reline 130.59
Complete Upper and Lower Reline 217.38
Full Upper and Lower Denture (Edentulous Persons Only) 478.74
* Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.
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As at 31st December 2010 €
Examinations
Eye Examination Ophthalmic Optician 22.51
Eye Examination Ophthalmologist/
Ophthalmic Medical Practitioner 25.55
Medical Eye Examination by Ophthalmologist 51.11
Eye Examination for Contact Lenses (Grant) 68.44 (H)
Eye Examination Ophthalmic (Dilation) 45.03
Appliances
Single Vision Complete Appliances
Spectacles – Distance 41.98
Spectacles – Reading 41.98
Spectacles – Uncollected 29.26
Contact Lenses (Pair) 41.97
Contact Lenses Standard or Disposable per pair (Grant) 64.19 (H)
Single Vision Spectacles – with Glass Lenses Distance 121.96 (H)
Single Vision Spectacles – with Glass Lenses Reading 121.96 (H)
Single Vision Spectacles – with Plastic Lenses Distance 131.02 (H)
Single Vision Spectacles – with Plastic Lenses Reading 131.02 (H)
Single Vision Lenses to Own Frame
Replacement Distance Lens (1) to own frame 16.31
Replacement Distance Lenses (2) to own frame 32.63
Replacement Reading Lens (1) to own frame 16.31
Replacement Reading Lenses (2) to own frame 32.63
Single Vision Lenses to Non-Standard Frame
Single Vision Lens (1) (Glass) Distance 23.49 (H)
Single Vision Lenses (2) (Glass) Distance 47.00 (H)
Single Vision Lens (1) (Glass) Reading 23.49 (H)
Single Vision Lenses (2) (Glass) Reading 47.00 (H)
Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme
€
Single Vision Lens (1) (Plastic) Distance 26.78 (H)
Single Vision Lenses (2) (Plastic) Distance 53.55 (H)
Single Vision Lens (1) (Plastic) Reading 26.78 (H)
Single Vision Lenses (2) (Plastic) Reading 53.55 (H)
Additional Specification for Lenses to All Spectacle Types
Special grant towards additional specification for lens (1)
– applies to all spectacle types 81.54 (H)
Special grant towards additional specification for lenses (2)
– applies to all spectacle types 163.08 (H)
Other Items – Single Vision
Lenticular Lens (1 Surface) 11.60
Lenticular Lenses (2 Surfaces) 23.20
Lenticular Lenses (3 Surfaces) 34.81
Lenticular Lenses (4 Surfaces) 46.41
Tinted Lens (1) 7.41
Tinted Lenses (2) 14.83
Tinted Lenses (3) 22.24
Tinted Lenses (4) 29.66
Prism (1) 6.28
Prisms (2) 12.55
Prisms (3) 18.84
Prisms (4) 25.12
Prisms (5) 31.40
Prisms (6) 37.67
Prisms (7) 43.95
Prisms (8) 50.24
Dioptric powers higher than 8.00 (1) Lens 6.15
Dioptric powers higher than 8.00 (2) Lenses 12.29
Dioptric powers higher than 8.00 (3) Lenses 18.44
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme continued
As at 31st December 2010 €
Dioptric powers higher than 8.00 (4) Lenses 24.59
Anti-Reflective Coating on Plastic Lens (1) 18.08 (H)
Anti-Reflective Coating on Plastic Lenses (2) 36.15 (H)
Dioptric powers higher than 6.00 (Plastic) (1) Lens 15.37
Dioptric powers higher than 6.00 (Plastic) (2) Lenses 30.73
Dioptric powers higher than 6.00 (Plastic) (3) Lenses 46.10
Dioptric powers higher than 6.00 (Plastic) (4) Lenses 61.47
Plastic Lens (1) for children as prescribed 4.69
Plastic Lenses (2) for children as prescribed 9.37
Plastic Lens (1) Adult 4.54 (H)
Plastic Lenses (2) Adult 9.08 (H)
Bifocals
Spectacles Bifocal Complete 83.53
Fused Bifocal Spectacles 162.72 (H)
Varifocals Spectacles – Glass or Plastic 250.16 (H)
Bifocal Lenses
Replacement Bifocal Lens (1) to own frame 37.14
Replacement Bifocal Lenses (2) to own frame 74.27
Bifocal Lens (1) To Non-Standard Frames 47.80 (H)
€
Bifocal Lenses (2) to Non-Standard Frames 95.61 (H)
Varifocal Lens (1) (Grant) 94.56 (H)
Varifocal Lenses (2) (Grant) 189.12 (H)
Other Items – Bifocals
Sphere over 6.00 and up to 9.00 extra charge (1) Lens 4.15
Sphere over 6.00 and up to 9.00 extra charge (2) Lenses 8.30
Sphere over 9.00 extra charge (1) Lens 9.22
Sphere over 9.00 extra charge (2) Lenses 18.44
Tinted Lens (1) 8.18
Tinted Lenses (2) 16.38
Prism (1) 8.74
Prisms (2) 17.46
Repairs
Replacement Frame to own lenses 12.16
Replacement Front to own lenses 5.83
Replacement Side (1) to own frame 2.45
Replacement Sides (2) to own frame 4.90
Complete New Frames 90.60 (H)
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
32
DETAILED STATISTIcAL AnALySIS of cLAImS AnD PAymEnTS 2010
 
33 34
Table 1 GMS: Summary of Statistical Information for each of the Five Years 2006-2010
Year ended December:- 2010 2009 2008 2007 2006 Year ended December:- 2010 2009 2008 2007 2006
(i) Number of Eligible 
Persons in December
1,733,232 1,478,560 1,352,120 1,276,178 1,221,695 Number of Doctor 
Contracts
2,740 2,663 2,599 2,347 2,315
Number of Pharmacist 
Contracts
1,671 1,630 1,620 1,587 1,530
DOCTORS (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €460,338 €466,737 €459,476 €427,418 €391,029 Total Cost of Stock 
Orders
€12,865 €14,309 €15,797 €16,231 €15,230
Ingredient Cost €9,895 €11,044 €12,188 €12,559 €11,777
(ii) Doctors’ Payment  
per Person
€284.92 €337.94 €352.67 €349.03 €314.85 Pharmacy Fees €2,467 €2,761 €3,047 €3,140 €2,944
VAT €503 €504 €562 €532 €509
PHARMACIES
Total Cost of 
Prescriptions
€1,220,397 €1,245,935 €1,129,494 €1,032,178 €924,995 Overall Cost  
of Medicines
€1,233,262 €1,260,244 €1,145,292 €1,048,409 €940,225
Ingredient Cost €932,270 €962,305 €881,425 €824,323 €743,943 (iii) Pharmacy 
Payment per Person
€814.24 €907.85 €932.63 €856.14 €809.04
Dispensing Fee €259,635 €257,968 €225,697 €188,163 €163,537
VAT €28,492 €25,662 €22,372 €19,692 €17,516
Number of Forms 17,508 16,333 15,648 14,780 13,932
Number of Items 54,308 50,722 48,212 44,358 40,569 Overall Payments €1,693,600 €1,726,981 €1,604,768 €1,475,827 €1,331,254
Cost per Form €69.71 €76.28 €72.18 €69.84 €66.39 (iii) Overall Payment 
per Person
€1,099.16 €1,245.79 €1,285.30 €1,205.17 €1,123.89
Cost per Item €22.47 €24.56 €23.43 €23.27 €22.80
Ingredient Cost per Item €17.17 €18.97 €18.28 €18.58 €18.34
Items per Form 3.10 3.11 3.08 3.00 2.91
Note: (i) Number of Eligible Persons in 2010 includes the number of eligible persons with Medical Cards and GP Visit Cards. 
 (ii) Doctors’ Payment per Person is exclusive of superannuation paid to retired DMOs. 
 (iii) Pharmacy Payment per Person and Overall Payment per Person is based on the actual number of persons who availed of services.
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Year ended December:- 2010 2009 2008 2007 2006 Year ended December:- 2010 2009 2008 2007 2006
LTI Scheme
Number of Eligible 
Persons in December
134,926 127,636 120,407 112,580 106,307
DP Scheme
Number of Eligible 
Persons in December
1,557,048 1,587,448 1,624,413 1,583,738 1,525,657
*Number of Claimants 67,492 65,731 62,934 59,040 53,082 *Number of Claimants 494,550 663,127 687,587 667,782 597,835
(000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,808 2,855 2,643 2,353 2,165 Number of Items 11,070 13,373 13,907 13,430 11,872
Total Cost €126,922 €139,759 €137,899 €124,458 €115,461 Gross Cost €336,019 €451,707 €506,806 €491,186 €442,924
Cost per Item €45.20 €48.95 €52.17 €52.90 €53.32 Net Cost €173,435 €259,928 €311,898 €307,334 €283,108
*Cost per Claimant €1,880.55 €2,126.23 €2,191.17 €2,108.03 €2,175.15 Gross Cost per Item €30.35 €33.78 €36.44 €36.57 €37.31
*Net Cost per Claimant €350.69 €391.97 €453.61 €460.23 €473.56
* These figures are based on the actual number of persons who availed of services under each Scheme.
Table 1.1 LTI/DP: Summary of Statistical Information for each of the Five Years 2006-2010
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Table 2 Number of Agreements
Health Service 
Executive
Doctors Pharmacists Dentists Optometrists
2010 2009 2010 2009 2010 2009 2010 2009
East Coast Area 293 283 152 141 123 125 43 41
South Western Area 345 343 202 203 207 189 77 76
Northern Area 315 298 193 189 169 160 53 50
Midland 156 151 104 100 74 76 47 46
Mid-Western 234 234 151 149 134 136 47 45
North Eastern 203 193 152 150 100 103 67 62
North Western 160 159 100 98 70 78 34 33
South Eastern 273 264 185 181 159 152 66 65
Southern 470 452 257 251 336 341 71 70
Western 291 286 175 168 210 210 69 67
NATIONAL 2,740 2,663 1,671 1,630 1,582 1,570 574 555
Note: (i) Where Doctors have panel numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the doctors HSE Area.
 (ii) 482 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, 
Heartwatch, Palliative Care and the Methadone Treatment Scheme are included in the above.
 (iii) 190 Dentists (188 – 2009) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
 (iv) 12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS Schemes at year-end are included above.
 (v) Above figures relate to the position as at 31st December 2010.
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Table 3 GMS: Payments to Doctors
2010 2009
€ €
FEES - Item of Service Contract 757,826 769,487
- Capitation 225,237,744 225,954,778
- Special Claims/Services 45,326,326 44,124,618
- Out-of-Hours 40,786,101 49,507,291
- Dispensing 2,148,999 2,285,357
- Asylum Seekers 377,142 846,494
- GP Visit Cards – 1,383,375
ALLOWANCES - Annual Leave 9,577,326 10,437,384
- Locum and Practice Expenses 12,038 12,643
- Sick Leave 1,881,783 2,223,277
- Maternity Leave/Paternity Leave 1,004,257 1,351,647
- Rural Practice 3,463,881 3,761,836
- Secretarial/Nursing 80,559,638 74,616,329
- Study Leave 1,701,105 1,785,347
- Medical Indemnity Insurance 3,619,863 2,816,513
- Rostering/Out-of-Hours 12,680,604 12,511,152
- Practice Development 4,351,743 4,353,527
- Practice Support Grant 2,001,310 2,671,843
SALARIES - Former District Medical Officers 1,489,159 1,696,801
- Benefits to retired DMOs and their dependants 5,134,708 5,537,300
SUPERANNUATION FUND - Contribution 23,360,739 23,627,456
TOTAL €465,472,292 €472,274,455
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Table 4 GMS: Cost of Prescriptions
Health Service 
Executive
Ingredient Cost Dispensing Fee VAT Total
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
East Coast Area 58,402,749 60,233,490 16,482,160 17,422,789 1,749,267 1,613,143 76,634,176 79,269,422
South Western Area 107,283,814 110,468,331 29,976,860 29,933,769 3,431,434 3,075,991 140,692,108 143,478,091
Northern Area 105,024,439 110,257,084 28,803,913 29,238,738 3,113,803 2,900,229 136,942,155 142,396,051
Midland 63,754,750 66,313,109 17,782,011 17,708,193 2,011,161 1,834,861 83,547,922 85,856,163
Mid-Western 85,613,224 88,610,101 24,366,887 23,931,783 2,643,919 2,319,769 112,624,030 114,861,653
North Eastern 80,912,163 82,676,183 22,774,805 22,385,331 2,604,905 2,249,767 106,291,873 107,311,281
North Western 59,195,992 61,038,782 16,510,082 16,259,762 1,796,939 1,592,292 77,503,013 78,890,836
South Eastern 120,875,425 122,874,913 34,491,382 33,699,763 3,781,512 3,396,313 159,148,319 159,970,989
Southern 150,059,793 155,975,463 41,000,396 40,611,288 4,380,940 3,997,631 195,441,129 200,584,382
Western 101,147,947 103,857,704 27,445,994 26,776,671 2,978,363 2,681,780 131,572,304 133,316,155
National €932,270,296 €962,305,160 €259,634,490 €257,968,087 €28,492,243 €25,661,776 €1,220,397,029 €1,245,935,023
Note: Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.
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Table 5 GMS: Cost of Stock Order Forms
Health Service 
Executive
Ingredient Cost *Pharmacy Fee VAT Total
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
East Coast Area 116,349 111,493 28,405 28,126 29,943 29,898 174,697 169,517
South Western Area 96,294 86,341 24,070 21,594 24,992 23,168 145,356 131,103
Northern Area 135,762 137,431 33,934 34,367 30,526 33,327 200,222 205,125
Midland 368,894 463,139 92,197 115,809 22,446 25,484 483,537 604,432
Mid-Western 883,170 841,912 220,795 210,536 49,121 43,400 1,153,086 1,095,848
North Eastern 1,118,433 1,063,718 279,223 265,943 57,847 51,229 1,455,503 1,380,890
North Western 1,321,216 1,481,938 329,951 370,489 45,662 55,179 1,696,829 1,907,606
South Eastern 1,920,604 2,579,326 477,716 644,769 90,073 96,197 2,488,393 3,320,292
Southern 359,072 358,812 89,539 89,737 60,845 54,488 509,456 503,037
Western 3,575,011 3,919,974 890,616 979,988 91,824 91,780 4,557,451 4,991,742
National €9,894,805 €11,044,084 €2,466,446 €2,761,358 €503,279 €504,150 €12,864,530 €14,309,592
Note: (i) Stock Order Forms are provided by HSE Areas for use by Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons who are entitled 
to be dispensed to.
 (ii) * Pharmacies are reimbursed for stock order items on the basis of the reimbursement price, with the addition of 25% on cost.
 (iii) The above figures include needles, syringes and dressings which are available for Doctors’ use.
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Table 6 DTS: Payments to Dentists
Health Service Executive
Above the Line Below the Line Total
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
Eastern Areas 14,400,735 16,981,125 4,656,559 5,516,151 19,057,294 22,497,276
Midland 3,219,794 3,748,497 1,554,950 1,863,214 4,774,744 5,611,711
Mid-Western 4,769,522 4,980,966 1,917,309 2,452,033 6,686,831 7,432,999
North Eastern 5,071,832 5,502,224 1,885,568 2,488,644 6,957,400 7,990,868
North Western 3,475,675 3,456,832 1,308,303 1,348,171 4,783,978 4,805,003
South Eastern 7,201,384 7,467,429 3,380,002 4,131,261 10,581,386 11,598,690
Southern 9,448,816 10,821,398 3,524,681 4,223,607 12,973,497 15,045,005
Western 6,515,554 7,667,247 3,376,767 4,123,693 9,892,321 11,790,940
National €54,103,312 €60,625,718 €21,604,139 €26,146,774 €75,707,451 €86,772,492
Note: Dentists were also paid a total €60,610 in 2010 (€62,114 in 2009) in respect of fees under Health (Amendment) Act 1996.
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Health Service Executive
2010 2009
Doctors
€
Pharmacies
€
Total
€
Doctors
€
Pharmacies
€
Total
€
Eastern Areas 279.98 806.68 1,086.66 334.39 896.72 1,231.11
Midland 294.41 831.42 1,125.83 349.89 943.28 1,293.17
Mid-Western 282.64 841.12 1,123.76 331.55 936.25 1,267.80
North Eastern 260.28 767.89 1,028.17 320.18 884.91 1,205.09
North Western 268.66 721.11 989.77 319.92 787.19 1,107.11
South Eastern 280.24 819.43 1,099.67 325.38 908.98 1,234.36
Southern 311.79 877.55 1,189.34 371.65 975.65 1,347.30
Western 296.19 811.44 1,107.63 342.17 900.00 1,242.17
National €284.92 €814.24 €1,099.16 €337.94 €907.85 €1,245.79
Note: The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to pharmacies 
(Tables 4 and 5) in respect of the actual cost per person who availed of services.
Table 7 GMS: Payment per Person
41 42
2010 (2009 in brackets)
Number of Doctors with an annual cost per eligible person of:-
Health Service 
Executive Up to €300 €301-€350 €351-€400 €401-€450 €451-€500 €501-€550 €551-€600 €601-€650 €651-€700 €701 & Over
Eastern Areas 151 (156) 5 (3) 5 (3) 8 (4) 11 (5) 13 (11) 23 (18) 27 (12) 20 (13) 494 (540)
Midland 12 (18) – 1 (–) – (1) 1 (–) 1 (3) 2 (–) 3 (2) 2 (2) 105 (103)
Mid-Western 21 (21) 1 (1) 1 (–) – (1) 3 (1) 2 (1) 4 (1) 6 (5) 5 (4) 156 (168)
North Eastern 19 (17) 3 (–) 2 (1) 3 (4) 3 (1) 6 (4) 13 (–) 10 (5) 10 (13) 107 (128)
North Western 9 (9) 2 (–) – 2 (2) 7 (2) 3 (6) 2 (3) 6 (2) 10 (6) 100 (115)
South Eastern 21 (27) – (2) 1 (–) 2 (3) 5 (3) 5 (2) 2 (4) 6 (4) 15 (4) 192 (203)
Southern 45 (48) 3 (2) 3 (2) 3 (4) 6 (5) 11 (4) 7 (3) 8 (7) 7 (4) 332 (336)
Western 20 (28) 1 (1) 2 (1) 3 (3) 6 (5) 5 (2) 12 (4) 6 (6) 9 (5) 189 (206)
National 298 (324) 15 (9) 15 (7) 21 (22) 42 (22) 46 (33) 65 (33) 72 (43) 78 (51) 1,675 (1,799)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.
 (ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2010.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
Table 8 GMS: Number of Doctors in Eligible Person Cost Categories
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Table 9 GMS: Number of Eligible Persons
Health Service  
Executive
Number of persons 
(including dependants) 
and % of population* 
eligible in
Health Service  
Executive
Number of persons 
(including dependants) 
and % of population* 
eligible in
December 2010 December 2010
No. % No. %
HSE DUBLIN MID-LEINSTER HSE WEST
Dublin South 23,933 0.56 Galway 93,764 2.21
Dublin South East 18,311 0.43 Mayo 62,148 1.47
Dublin South City 29,929 0.71 Roscommon 28,390 0.67
Dublin South West 57,177 1.35 Donegal 85,764 2.02
Dublin West 49,908 1.18 Sligo/Leitrim 39,790 0.94
Kildare/West Wicklow 61,265 1.44 Clare 46,227 1.09
Wicklow 38,781 0.91 North Tipperary/East Limerick 28,738 0.68
Laois/Offaly 57,887 1.37 Limerick 69,160 1.63
Longford/Westmeath 47,192 1.11 TOTAL HSE WEST 453,981 10.71
TOTAL HSE DUBLIN MID-LEINSTER 384,383 9.06
HSE SOUTH
HSE DUBLIN NORTH EAST Cork South Lee 54,528 1.29
Dublin North West 62,599 1.48 Cork North Lee 71,300 1.68
North Central Dublin 39,483 0.93 West Cork 21,452 0.50
North Dublin 69,974 1.65 Kerry 54,125 1.28
Cavan/Monaghan 53,302 1.26 North Cork 34,917 0.82
Louth 53,718 1.27 Carlow/Kilkenny 53,688 1.27
Meath 56,375 1.33 Waterford 52,660 1.24
TOTAL HSE DUBLIN NORTH EAST 335,451 7.92 South Tipperary 38,325 0.90
Wexford 60,999 1.44
TOTAL HSE SOUTH 441,994 10.42
NATIONAL 1,615,809 38.11
Note: * The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national 
population as at October 2006 is 4,239,848.
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2010
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Dublin South 449 474 923 675 697 1,372 364 384 748 689 587 1,276 962 666 1,628 981 738 1,719
Dublin South 
East 331 364 695 532 570 1,102 256 298 554 485 443 928 666 512 1,178 741 621 1,362
Dublin South 
City 869 882 1,751 1,199 1,236 2,435 564 528 1,092 1,046 793 1,839 1,913 1,353 3,266 1,670 1,702 3,372
Dublin South 
West 2,213 2,321 4,534 3,300 3,554 6,854 1,590 1,801 3,391 3,117 2,423 5,540 3,837 2,665 6,502 3,283 2,514 5,797
Dublin West 2,288 2,415 4,703 3,292 3,453 6,745 1,536 1,566 3,102 2,830 2,235 5,065 3,908 2,435 6,343 3,226 2,628 5,854
Kildare/West 
Wicklow 2,480 2,602 5,082 3,688 4,003 7,691 1,759 1,744 3,503 2,897 2,458 5,355 4,252 2,989 7,241 4,135 3,490 7,625
Wicklow 1,309 1,438 2,747 1,965 2,081 4,046 1,040 1,064 2,104 1,967 1,782 3,749 2,521 1,879 4,400 2,506 1,978 4,484
Laois/Offaly 2,244 2,456 4,700 3,292 3,419 6,711 1,571 1,575 3,146 2,857 2,344 5,201 3,828 3,039 6,867 3,611 3,192 6,803
Longford/
Westmeath 1,784 1,896 3,680 2,606 2,776 5,382 1,261 1,365 2,626 2,283 2,010 4,293 3,021 2,375 5,396 2,906 2,605 5,511
North West 
Dublin 2,755 2,942 5,697 4,112 4,316 8,428 1,638 1,781 3,419 2,951 2,381 5,332 4,727 3,338 8,065 4,263 3,622 7,885
Dublin North 
Central 1,201 1,201 2,402 1,650 1,840 3,490 982 991 1,973 1,738 1,415 3,153 2,428 1,807 4,235 2,207 1,888 4,095
National 56,345 59,587 115,932 82,433 87,448 169,881 41,113 43,428 84,541 79,067 70,136 149,203 102,306 81,412 183,718 97,215 86,716 183,931
% of Eligible 
Persons 3.49% 3.69% 7.17% 5.10% 5.41% 10.51% 2.54% 2.69% 5.23% 4.89% 4.34% 9.23% 6.33% 5.04% 11.37% 6.02% 5.37% 11.38%
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Health 
Service 
Executive
Age Classification
As at December 2010
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Dublin South 921 806 1,727 1,069 776 1,845 768 380 1,148 1,918 1,349 3,267 5,223 3,057 8,280 14,019 9,914 23,933
Dublin South 
East 613 550 1,163 751 501 1,252 750 306 1,056 1,560 1,213 2,773 4,052 2,196 6,248 10,737 7,574 18,311
Dublin South 
City 1,342 1,439 2,781 1,388 1,379 2,767 874 632 1,506 1,593 1,332 2,925 3,967 2,228 6,195 16,425 13,504 29,929
Dublin South 
West 2,624 2,209 4,833 3,084 2,307 5,391 1,608 1,193 2,801 2,237 1,822 4,059 4,582 2,893 7,475 31,475 25,702 57,177
Dublin West 2,441 2,054 4,495 2,386 1,991 4,377 1,130 781 1,911 1,428 1,191 2,619 2,940 1,754 4,694 27,405 22,503 49,908
Kildare/West 
Wicklow 2,868 2,643 5,511 2,883 2,562 5,445 1,701 1,393 3,094 2,003 1,856 3,859 4,030 2,829 6,859 32,696 28,569 61,265
Wicklow 1,932 1,742 3,674 1,898 1,670 3,568 1,155 835 1,990 1,531 1,344 2,875 3,095 2,049 5,144 20,919 17,862 38,781
Laois/Offaly 2,682 2,622 5,304 2,770 2,463 5,233 1,627 1,228 2,855 1,910 1,755 3,665 4,153 3,249 7,402 30,545 27,342 57,887
Longford/
Westmeath 2,204 2,090 4,294 2,196 2,024 4,220 1,257 937 2,194 1,579 1,497 3,076 3,820 2,700 6,520 24,917 22,275 47,192
North West 
Dublin 2,682 2,588 5,270 2,492 2,092 4,584 1,473 939 2,412 2,144 1,607 3,751 4,839 2,917 7,756 34,076 28,523 62,599
Dublin North 
Central 1,780 1,637 3,417 1,599 1,591 3,190 1,105 721 1,826 2,080 1,633 3,713 5,128 2,861 7,989 21,898 17,585 39,483
National 76,674 73,368 150,042 78,694 71,595 150,289 46,390 36,076 82,466 60,453 54,430 114,883 137,648 93,275 230,923 858,338 757,471 1,615,809
% of Eligible 
Persons 4.75% 4.54% 9.29% 4.87% 4.43% 9.30% 2.87% 2.23% 5.10% 3.74% 3.37% 7.11% 8.52% 5.77% 14.29% 53.12% 46.88% 100.00%
Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
As at December 2010
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
North Dublin 2,680 2,798 5,478 4,057 4,261 8,318 1,787 1,963 3,750 3,298 2,579 5,877 4,493 2,897 7,390 4,658 3,603 8,261
Cavan/
Monaghan 1,851 1,959 3,810 2,837 2,936 5,773 1,533 1,596 3,129 2,884 2,622 5,506 3,366 2,913 6,279 3,157 2,928 6,085
Louth 2,125 2,221 4,346 3,136 3,165 6,301 1,483 1,560 3,043 2,870 2,627 5,497 3,741 3,057 6,798 3,475 3,203 6,678
Meath 2,439 2,467 4,906 3,248 3,541 6,789 1,531 1,641 3,172 2,794 2,535 5,329 3,947 3,064 7,011 3,830 3,417 7,247
Galway 3,198 3,320 6,518 4,702 5,041 9,743 2,435 2,416 4,851 4,752 4,315 9,067 6,206 5,367 11,573 5,775 5,329 11,104
Mayo 1,783 1,941 3,724 2,914 3,028 5,942 1,515 1,737 3,252 3,233 2,951 6,184 3,272 2,904 6,176 3,438 3,106 6,544
Roscommon 803 887 1,690 1,365 1,390 2,755 719 764 1,483 1,402 1,219 2,621 1,521 1,276 2,797 1,581 1,461 3,042
Donegal 2,911 3,130 6,041 4,402 4,777 9,179 2,391 2,621 5,012 4,590 4,476 9,066 5,186 4,592 9,778 5,439 4,992 10,431
Sligo/Leitrim 1,245 1,303 2,548 1,751 1,886 3,637 897 1,086 1,983 1,819 1,742 3,561 2,200 2,010 4,210 2,147 1,975 4,122
Clare 1,584 1,638 3,222 2,375 2,363 4,738 1,171 1,255 2,426 2,443 2,320 4,763 2,759 2,381 5,140 2,789 2,444 5,233
North 
Tipperary/ 
East Limerick
938 947 1,885 1,427 1,519 2,946 759 783 1,542 1,452 1,308 2,760 1,733 1,498 3,231 1,693 1,518 3,211
National 56,345 59,587 115,932 82,433 87,448 169,881 41,113 43,428 84,541 79,067 70,136 149,203 102,306 81,412 183,718 97,215 86,716 183,931
% of Eligible 
Persons 3.49% 3.69% 7.18% 5.10% 5.41% 10.51% 2.54% 2.69% 5.23% 4.89% 4.34% 9.23% 6.33% 5.04% 11.37% 6.02% 5.37% 11.39%
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Health 
Service 
Executive
Age Classification
As at December 2010
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
North Dublin 3,119 2,536 5,655 3,041 2,199 5,240 2,357 1,427 3,784 3,399 2,865 6,264 5,910 4,047 9,957 38,799 31,175 69,974
Cavan/
Monaghan 2,531 2,451 4,982 2,418 2,352 4,770 1,335 1,137 2,472 1,619 1,510 3,129 4,242 3,125 7,367 27,773 25,529 53,302
Louth 2,448 2,476 4,924 2,321 2,125 4,446 1,265 995 2,260 1,714 1,519 3,233 3,789 2,403 6,192 28,367 25,351 53,718
Meath 2,474 2,434 4,908 2,413 2,100 4,513 1,484 1,147 2,631 1,701 1,647 3,348 3,811 2,710 6,521 29,672 26,703 56,375
Galway 4,576 4,618 9,194 4,237 4,262 8,499 2,415 2,052 4,467 3,096 2,899 5,995 7,407 5,346 12,753 48,799 44,965 93,764
Mayo 3,226 3,129 6,355 3,526 3,607 7,133 1,891 1,765 3,656 2,055 2,045 4,100 5,266 3,816 9,082 32,119 30,029 62,148
Roscommon 1,475 1,455 2,930 1,541 1,481 3,022 832 741 1,573 957 1,035 1,992 2,599 1,886 4,485 14,795 13,595 28,390
Donegal 4,300 4,177 8,477 4,581 4,326 8,907 2,275 2,228 4,503 2,433 2,361 4,794 5,426 4,150 9,576 43,934 41,830 85,764
Sligo/Leitrim 1,948 1,999 3,947 2,066 2,072 4,138 1,157 966 2,123 1,473 1,437 2,910 3,810 2,801 6,611 20,513 19,277 39,790
Clare 2,281 2,202 4,483 2,338 2,165 4,503 1,302 1,155 2,457 1,581 1,486 3,067 3,561 2,634 6,195 24,184 22,043 46,227
North 
Tipperary/ 
East Limerick
1,351 1,342 2,693 1,407 1,247 2,654 878 629 1,507 1,006 990 1,996 2,535 1,778 4,313 15,179 13,559 28,738
National 76,674 73,368 150,042 78,694 71,595 150,289 46,390 36,076 82,466 60,453 54,430 114,883 137,648 93,275 230,923 858,338 757,471 1,615,809
% of Eligible 
Persons 4.75% 4.54% 9.29% 4.87% 4.43% 9.30% 2.87% 2.23% 5.10% 3.74% 3.37% 7.11% 8.52% 5.77% 14.29% 53.12% 46.88% 100.00%
Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
As at December 2010
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Limerick 2,258 2,508 4,766 3,089 3,246 6,335 1,624 1,707 3,331 3,333 3,042 6,375 4,287 3,742 8,029 3,893 3,824 7,717
Cork –  
South Lee 1,758 1,794 3,552 2,290 2,565 4,855 1,191 1,163 2,354 2,159 2,089 4,248 3,454 2,770 6,224 2,982 2,773 5,755
Cork –  
North Lee 2,633 2,807 5,440 3,640 3,880 7,520 1,758 1,921 3,679 3,443 3,095 6,538 4,926 3,988 8,914 4,474 4,157 8,631
West Cork 554 572 1,126 894 986 1,880 525 506 1,031 954 927 1,881 963 777 1,740 1,077 919 1,996
Kerry 1,572 1,663 3,235 2,353 2,484 4,837 1,234 1,258 2,492 2,344 2,220 4,564 3,018 2,666 5,684 3,004 2,867 5,871
North Cork 1,216 1,321 2,537 1,597 1,764 3,361 852 821 1,673 1,583 1,478 3,061 2,290 1,680 3,970 2,081 1,929 4,010
Carlow/
Kilkenny 1,793 1,904 3,697 2,735 2,789 5,524 1,339 1,449 2,788 2,919 2,605 5,524 3,424 3,091 6,515 3,264 3,080 6,344
Waterford 1,814 1,899 3,713 2,499 2,752 5,251 1,231 1,383 2,614 2,717 2,364 5,081 3,388 2,769 6,157 3,122 2,872 5,994
South  
Tipperary 1,122 1,296 2,418 1,701 1,874 3,575 948 967 1,915 1,992 1,895 3,887 2,249 1,878 4,127 2,096 1,924 4,020
Wexford 2,145 2,221 4,366 3,110 3,256 6,366 1,629 1,734 3,363 3,226 2,856 6,082 3,820 3,034 6,854 3,711 3,417 7,128
National 56,345 59,587 115,932 82,433 87,448 169,881 41,113 43,428 84,541 79,067 70,136 149,203 102,306 81,412 183,718 97,215 86,716 183,931
% of Eligible 
Persons 3.49% 3.69% 7.18% 5.10% 5.41% 10.51% 2.54% 2.69% 5.23% 4.89% 4.34% 9.23% 6.33% 5.04% 11.37% 6.02% 5.37% 11.39%
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Health 
Service 
Executive
Age Classification
As at December 2010
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Limerick 3,308 3,286 6,594 3,609 3,433 7,042 2,193 1,709 3,902 2,707 2,524 5,231 5,880 3,958 9,838 36,181 32,979 69,160
Cork –  
South Lee 2,581 2,448 5,029 2,544 2,242 4,786 1,813 1,281 3,094 2,655 2,243 4,898 6,029 3,704 9,733 29,456 25,072 54,528
Cork –  
North Lee 3,477 3,364 6,841 3,684 3,356 7,040 2,181 1,677 3,858 2,563 2,288 4,851 4,800 3,188 7,988 37,579 33,721 71,300
West Cork 1,133 1,053 2,186 1,158 1,102 2,260 762 569 1,331 923 897 1,820 2,405 1,796 4,201 11,348 10,104 21,452
Kerry 2,564 2,551 5,115 2,933 2,781 5,714 1,792 1,510 3,302 2,153 2,117 4,270 5,331 3,710 9,041 28,298 25,827 54,125
North Cork 1,631 1,565 3,196 1,883 1,696 3,579 988 786 1,774 1,231 1,142 2,373 3,260 2,123 5,383 18,612 16,305 34,917
Carlow/
Kilkenny 2,636 2,672 5,308 2,536 2,389 4,925 1,466 1,168 2,634 1,758 1,666 3,424 4,063 2,942 7,005 27,933 25,755 53,688
Waterford 2,546 2,513 5,059 2,733 2,588 5,321 1,613 1,272 2,885 1,872 1,734 3,606 4,089 2,890 6,979 27,624 25,036 52,660
South  
Tipperary 1,904 1,863 3,767 2,133 1,988 4,121 1,090 975 2,065 1,415 1,314 2,729 3,312 2,389 5,701 19,962 18,363 38,325
Wexford 3,076 2,854 5,930 3,076 2,728 5,804 1,853 1,542 3,395 2,159 2,112 4,271 4,294 3,146 7,440 32,099 28,900 60,999
National 76,674 73,368 150,042 78,694 71,595 150,289 46,390 36,076 82,466 60,453 54,430 114,883 137,648 93,275 230,923 858,338 757,471 1,615,809
% of Eligible 
Persons 4.75% 4.54% 9.29% 4.87% 4.43% 9.30% 2.87% 2.23% 5.10% 3.74% 3.37% 7.11% 8.52% 5.77% 14.29% 53.12% 46.88% 100.00%
Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
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Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation
Health Service 
Executive
Mileage Classification
As at December 2010
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Dublin South 55.17 39.04 94.21 2.65 1.76 4.41 0.61 0.49 1.10 0.08 0.07 0.15 0.07 0.06 0.13
Dublin South East 52.98 37.07 90.05 4.16 3.00 7.16 1.10 0.94 2.04 0.27 0.26 0.53 0.14 0.08 0.22
Dublin South City 53.07 43.57 96.64 0.94 0.82 1.76 0.75 0.62 1.37 0.09 0.07 0.16 0.04 0.05 0.09
Dublin South West 50.80 41.30 92.10 3.49 2.96 6.45 0.58 0.53 1.11 0.14 0.12 0.26 0.04 0.04 0.08
Dublin West 52.35 42.92 95.27 1.67 1.38 3.05 0.63 0.54 1.17 0.16 0.16 0.32 0.10 0.08 0.18
Kildare/West Wicklow 36.80 32.03 68.83 7.26 6.48 13.74 4.71 3.98 8.69 2.45 2.21 4.66 2.15 1.94 4.09
Wicklow 38.12 32.24 70.36 5.64 4.79 10.43 6.53 5.70 12.23 1.87 1.74 3.61 1.79 1.59 3.38
Laois/Offaly 32.91 29.33 62.24 5.86 5.48 11.34 10.52 9.13 19.65 3.38 3.22 6.60 0.10 0.08 0.18
Longford/Westmeath 33.59 29.92 63.51 5.44 4.98 10.42 10.22 8.93 19.15 3.43 3.26 6.69 0.13 0.12 0.25
North West Dublin 49.70 41.33 91.03 3.10 2.68 5.78 1.03 0.93 1.96 0.40 0.41 0.81 0.21 0.22 0.43
Dublin North Central 53.41 42.53 95.94 1.35 1.36 2.71 0.47 0.42 0.89 0.16 0.15 0.31 0.07 0.07 0.14
National 36.74 31.88 68.62 5.73 5.20 10.93 8.42 7.73 16.15 1.59 1.46 3.05 0.65 0.60 1.25
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Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation continued
Health Service 
Executive
Mileage Classification
As at December 2010
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
North Dublin 50.84 40.80 91.64 2.21 1.69 3.90 1.31 1.04 2.35 0.63 0.61 1.24 0.47 0.41 0.88
Cavan/Monaghan 28.67 26.29 54.96 8.66 8.04 16.70 13.64 12.61 26.25 1.00 0.81 1.81 0.14 0.14 0.28
Louth 39.35 35.40 74.75 5.31 4.69 10.00 7.96 6.96 14.92 0.13 0.12 0.25 0.05 0.03 0.08
Meath 33.23 29.63 62.86 6.74 6.15 12.89 11.23 10.32 21.55 1.16 1.00 2.16 0.27 0.27 0.54
Galway 30.05 26.85 56.90 6.96 6.53 13.49 11.22 10.93 22.15 2.75 2.59 5.34 1.07 1.05 2.12
Mayo 29.03 26.27 55.30 6.95 6.70 13.65 9.25 9.01 18.26 4.34 4.20 8.54 2.10 2.14 4.24
Roscommon 19.92 17.84 37.76 9.42 9.12 18.54 18.93 17.47 36.40 3.32 3.08 6.40 0.53 0.38 0.91
Donegal 24.80 23.29 48.09 8.56 8.39 16.95 12.32 11.99 24.31 4.09 3.75 7.84 1.46 1.35 2.81
Sligo/Leitrim 27.48 25.83 53.31 9.26 8.62 17.88 13.56 12.76 26.32 0.92 0.90 1.82 0.32 0.34 0.66
Clare 31.42 28.27 59.69 7.42 6.86 14.28 11.87 11.10 22.97 1.19 1.06 2.25 0.42 0.39 0.81
North Tipperary/ 
East Limerick 30.81 26.95 57.76 5.40 4.98 10.38 14.13 13.03 27.16 2.04 1.77 3.81 0.43 0.45 0.88
National 36.74 31.88 68.62 5.73 5.20 10.93 8.42 7.73 16.15 1.59 1.46 3.05 0.65 0.60 1.25
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Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation continued
Health Service 
Executive
Mileage Classification
As at December 2010
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Limerick 37.85 34.83 72.68 6.07 5.28 11.35 8.01 7.23 15.24 0.28 0.25 0.53 0.10 0.10 0.20
Cork-South Lee 38.95 33.15 72.10 6.39 5.41 11.80 8.24 7.06 15.30 0.35 0.29 0.64 0.09 0.06 0.15
Cork-North Lee 39.57 35.84 75.41 5.23 4.28 9.51 7.13 6.46 13.59 0.50 0.47 0.97 0.28 0.24 0.52
West Cork 23.24 19.82 43.06 7.24 6.83 14.07 13.84 12.12 25.96 5.73 5.37 11.10 2.85 2.96 5.81
Kerry 30.44 27.46 57.90 6.21 5.80 12.01 8.78 7.98 16.76 3.78 3.69 7.47 3.08 2.79 5.87
North Cork 29.43 25.46 54.89 7.70 6.85 14.55 14.83 13.25 28.08 0.83 0.69 1.52 0.52 0.45 0.97
Carlow/Kilkenny 34.47 31.61 66.08 6.08 5.79 11.87 11.11 10.26 21.37 0.31 0.27 0.58 0.06 0.04 0.10
Waterford 39.30 35.36 74.66 4.57 4.18 8.75 6.59 6.43 13.02 1.66 1.31 2.97 0.34 0.26 0.60
South Tipperary 29.30 26.55 55.85 6.55 5.91 12.46 15.21 14.67 29.88 0.87 0.65 1.52 0.15 0.13 0.28
Wexford 31.62 28.82 60.44 5.75 5.09 10.84 13.74 12.25 25.99 1.14 0.89 2.03 0.38 0.33 0.71
National 36.74 31.88 68.62 5.73 5.20 10.93 8.42 7.73 16.15 1.59 1.46 3.05 0.65 0.60 1.25
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Health Service  
Executive
Number of persons (including 
dependants) and % of 
population* eligible in Health Service  
Executive
Number of persons (including 
dependants) and % of 
population* eligible in
December 2010 December 2010
No. % No. %
HSE DUBLIN MID-LEINSTER HSE WEST
Dublin South 1,052 0.02 Galway 7,663 0.19
Dublin South East 938 0.02 Mayo 3,817 0.09
Dublin South City 899 0.02 Roscommon 1,793 0.04
Dublin South West 2,613 0.06 Donegal 6,849 0.16
Dublin West 3,790 0.09 Sligo/Leitrim 3,381 0.08
Kildare/West Wicklow 3,729 0.09 Clare 2,713 0.06
Wicklow 2,178 0.05 North Tipperary/East Limerick 2,003 0.05
Laois/Offaly 4,524 0.11 Limerick 4,682 0.11
Longford/Westmeath 3,707 0.09 TOTAL HSE WEST 32,901 0.78
TOTAL HSE DUBLIN MID-LEINSTER 23,430 0.55
HSE SOUTH
HSE DUBLIN NORTH EAST Cork South Lee 5,684 0.13
Dublin North West 3,983 0.09 Cork North Lee 6,721 0.16
North Central Dublin 1,750 0.04 West Cork 2,285 0.05
North Dublin 3,474 0.08 Kerry 4,971 0.12
Cavan/Monaghan 4,240 0.10 North Cork 3,867 0.09
Louth 3,705 0.09 Carlow/Kilkenny 4,653 0.11
Meath 4,840 0.12 Waterford 3,308 0.08
TOTAL HSE DUBLIN NORTH EAST 21,992 0.52 South Tipperary 2,426 0.06
Wexford 5,185 0.12
TOTAL HSE SOUTH 39,100 0.92
NATIONAL 117,423 2.77
Note: * The figures show the number of eligible persons for each Local Health Office.  The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national 
population as at October 2006 is 4,239,848.
Table 9.3 GPVC: Number of Eligible Persons
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Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2010
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 1,250 1,300 2,550 1,859 1,887 3,746 925 932 1,857 1,267 771 2,038 2,188 1,206 3,394 2,448 1,935 4,383
Midland 492 483 975 683 640 1,323 319 377 696 388 274 662 809 549 1,358 747 671 1,418
Mid-Western 508 482 990 647 721 1,368 327 388 715 541 352 893 928 612 1,540 896 795 1,691
North Eastern 680 759 1,439 971 1,042 2,013 402 451 853 655 442 1,097 1,212 815 2,027 1,277 1,151 2,428
North Western 449 481 930 696 782 1,478 432 403 835 641 436 1,077 920 580 1,500 876 789 1,665
South Eastern 799 829 1,628 1,054 1,131 2,185 548 585 1,133 961 625 1,586 1,624 1,014 2,638 1,481 1,307 2,788
Southern 1,233 1,236 2,469 1,606 1,701 3,307 871 859 1,730 1,334 912 2,246 2,313 1,497 3,810 2,159 1,996 4,155
Western 691 753 1,444 890 919 1,809 428 422 850 675 497 1,172 1,331 847 2,178 1,240 1,198 2,438
National 6,102 6,323 12,425 8,406 8,823 17,229 4,252 4,417 8,669 6,462 4,309 10,771 11,325 7,120 18,445 11,124 9,842 20,966
% of Eligible 
Persons 5.20% 5.38% 10.58% 7.16% 7.51% 14.67% 3.62% 3.76% 7.38% 5.50% 3.67% 9.17% 9.64% 6.06% 15.71% 9.47% 8.38% 17.86%
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Health 
Service 
Executive
Age Classification
As at December 2010
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 1,694 1,274 2,968 1,293 1,034 2,327 524 572 1,096 18 25 43 5 3 8 13,471 10,939 24,410
Midland 511 483 994 300 280 580 88 126 214 6 4 10 – 1 1 4,343 3,888 8,231
Mid-Western 597 541 1,138 418 360 778 117 139 256 9 12 21 2 – 2 4,990 4,402 9,392
North Eastern 775 709 1,484 533 501 1,034 169 218 387 10 11 21 1 – 1 6,685 6,099 12,784
North Western 717 697 1,414 465 509 974 137 197 334 6 13 19 – 1 1 5,339 4,888 10,227
South Eastern 1,075 875 1,950 674 624 1,298 155 207 362 8 2 10 – – – 8,379 7,199 15,578
Southern 1,593 1,343 2,936 1,124 963 2,087 322 418 740 19 28 47 1 – 1 12,575 10,953 23,528
Western 937 837 1,774 599 578 1,177 167 225 392 14 22 36 2 1 3 6,974 6,299 13,273
National 7,899 6,759 14,658 5,406 4,849 10,255 1,679 2,102 3,781 90 117 207 11 6 17 62,756 54,667 117,423
% of Eligible 
Persons 6.73% 5.75% 12.48% 4.60% 4.13% 8.73% 1.43% 1.79% 3.22% 0.08% 0.10% 0.18% 0.01% 0.01% 0.02% 53.44% 4.55% 100.00%
Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups continued
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Table 10 GMS: Size of Panels of Doctors
As at December 2010 (2009 in brackets)
Health Service 
Executive
Number of Doctors with panels of:-
Up to 250 251-500 501-1,000 1,001-1,500 1,501-2,000 2,001-2,500
East Coast Area 66 (55) 49 (51) 64 (59) 14 (11) – –
South Western Area 41 (40) 29 (37) 96 (100) 56 (46) 26 (21) 4 (3)
Northern Area 41 (34) 38 (43) 66 (69) 45 (45) 24 (11) 5 (3)
Midland 16 (9) 12 (14) 42 (45) 35 (35) 18 (12) 1 (–)
Mid-Western 26 (23) 33 (36) 73 (83) 44 (32) 14 (12) 2 (1)
North Eastern 19 (10) 9 (16) 60 (71) 59 (51) 22 (11) 5 (3)
North Western 12 (10) 20 (23) 51 (50) 41 (39) 14 (15) 6 (3)
South Eastern 16 (14) 24 (24) 110 (120) 60 (56) 22 (19) 7 (1)
Southern 85 (84) 67 (61) 153 (155) 69 (63) 14 (10) 4 (3)
Western 34 (30) 41 (45) 101 (108) 56 (51) 19 (9) 2 (1)
National 356 (309) 322 (350) 816 (860) 479 (429) 173 (120) 36 (18)
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Table 11 GMS: Payments to Doctors in each Health Service Executive Area
Health Service Executive 2010€
2009
€
East Coast Area 26,935,195 28,086,765
South Western Area 49,992,878 50,599,550
Northern Area 44,386,873 45,733,538
Midland 30,297,742 30,794,005
Mid-Western 40,117,150 40,618,410
North Eastern 43,660,859 43,156,720
North Western 35,382,535 36,550,156
South Eastern 59,845,673 59,744,270
Southern 75,013,546 76,157,054
Western 54,705,133 55,296,686
National €460,337,584 €466,737,154
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Health Service 
Executive
No. of Temporary 
Resident Claims
No. of EEA  
Visitor Claims
No. of Emergency 
Claims
Second Medical 
Opinion Claims
No. of Out-of-
Hours Claims
Total No.  
of Claims
2010 2009 2010 2009 2010 2009 2010 2009 2010 2009 2010 2009
East Coast Area 8,252 6,254 2,373 2,573 3,829 2,797 9 6 27,928 32,706 42,391 44,336
South Western 
Area 20,570 16,546 4,773 5,174 16,880 12,937 9 14 62,973 81,815 105,205 116,486
Northern Area 15,142 11,307 2,025 2,394 12,536 14,092 5 – 33,934 45,482 63,642 73,275
Midland 17,734 17,254 2,295 2,533 3,369 2,388 48 9 55,364 68,574 78,810 90,758
Mid-Western 13,763 14,843 5,393 5,340 7,286 4,540 924 644 62,143 69,117 89,509 94,484
North Eastern* 11,878 11,966 2,358 2,428 3,283 1,904 25 19 8,350 10,169 25,894 26,486
North Western 7,035 5,463 6,694 7,238 2,418 2,084 45 70 52,084 68,358 68,276 83,213
South Eastern 17,768 15,013 4,778 4,676 3,643 2,830 28 34 126,113 135,943 152,330 158,496
Southern 42,401 34,170 12,031 12,277 6,901 5,165 1,244 1,012 183,650 215,184 246,227 267,808
Western 21,992 17,798 7,815 8,381 8,720 7,560 82 151 91,084 109,795 129,693 143,685
National 176,535 150,614 50,535 53,014 68,865 56,297 2,419 1,959 703,623 837,143 1,001,977 1,099,027
* Note: HSE North Eastern Area figures do not include statistics from North East Doc.
Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims
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Table 12.1 GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims
Health 
Service 
Executive
Cost of Temporary 
Resident Claims
Cost of EEA  
Visitor Claims
Cost of Emergency 
Claims
Cost of Second 
Medical Opinion 
Claims
Cost of Out-of-
Hours Claims
Total Cost  
of Claims
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
East Coast 
Area 393,454 312,097 110,436 124,816 175,878 134,897 280 192 1,305,512 1,610,238 1,985,560 2,182,240
South 
Western Area 1,018,899 865,291 221,942 253,212 910,918 684,341 280 457 2,986,192 4,104,053 5,138,231 5,907,354
Northern 
Area 708,572 553,250 94,098 116,882 556,296 677,326 150 – 1,554,897 2,223,675 2,914,013 3,571,133
Midland 833,628 849,597 106,876 123,449 154,761 115,819 1,475 291 2,674,514 3,502,092 3,771,254 4,591,248
Mid-Western 644,732 743,035 250,412 259,478 343,566 226,722 28,613 20,883 3,012,519 3,531,354 4,279,842 4,781,472
North 
Eastern* 566,330 594,459 109,507 118,280 156,031 94,913 777 610 398,112 515,104 1,230,757 1,323,366
North 
Western 329,983 271,337 311,815 353,272 110,174 102,791 1,397 2,319 2,533,537 3,497,795 3,286,906 4,227,514
South Eastern 829,023 737,735 222,162 227,003 167,517 137,081 863 1,138 5,871,783 6,695,156 7,091,348 7,798,113
Southern 2,100,515 1,793,957 561,869 599,846 344,464 278,383 38,442 32,851 8,739,734 10,821,508 11,785,024 13,526,545
Western 1,055,012 902,781 364,074 408,267 400,770 367,017 2,547 4,989 4,409,494 5,585,294 6,231,897 7,268,348
National 8,480,148 7,623,539 2,353,191 2,584,505 3,320,375 2,819,290 74,824 63,730 33,486,294 42,086,269 47,714,832 55,177,333
* Note HSE North Eastern Area figures do not include statistics from North East Doc.
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Table 13 GMS: Analysis of Special Items of Service
Type of Service Number of Claims Cost of Claims
2010 2009 2010
€
2009
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 123,808 103,183 3,590,371 3,336,932
(ii) Suturing: Cuts and Lacerations 40,288 36,416 1,168,474 1,178,427
(iii) Hydroceles: Draining of 1,274 1,378 36,912 43,880
(iv) Haemorrhages: Dental/Nasal 2,191 2,427 63,422 78,640
(v) Veins: Recognised treatment 4,800 4,499 138,239 145,061
(vi) ECG: Tests and interpretation 92,123 76,757 2,669,677 2,480,452
(vii) Diaphragm: Instruction in the fitting of 1,129 1,186 32,732 38,754
(viii) Eye: Removal of adherent foreign body 10,014 9,580 290,295 310,301
(ix) Ear/Nose/Throat: Removal of foreign body 33,303 28,774 964,735 929,154
(x) Nebuliser: Treatment in the case of acute asthmatic attack 57,691 50,945 2,493,436 2,334,488
(xi) Bladder: Catheterization 7,410 6,877 322,164 316,521
(xii) Case Conference: Convened by HSE 445 834 29,707 59,826
(xiii) Diaphragm: Advice and fitting of 1,030 743 50,166 37,765
(xiv) IUCD: Counselling and fitting of 12,327 10,006 962,735 790,666
(xv) Pneumococcal: Vaccination 14,332 14,588 612,650 625,251
(xvi) Influenza: Vaccination 371,659 349,890 15,887,673 14,961,300
(xvii) Pneumococcal/Influenza: Vaccination 14,123 13,482 905,535 863,658
(xviii) Hepatitis B: Vaccination 2,961 2,093 151,584 122,777
National 790,908 713,658 €30,370,507 €28,653,853
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Type of Service East Coast Area South Western Area
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 8,063 233,787 12,039 349,321
(ii) Suturing: Cuts and Lacerations 1,367 39,623 2,854 82,854
(iii) Hydroceles: Draining of 41 1,192 68 1,976
(iv) Haemorrhages: Dental/Nasal 58 1,685 108 3,124
(v) Veins: Recognised treatment 7 202 528 15,325
(vi) ECG: Tests and interpretation 4,437 128,548 6,389 185,313
(vii) Diaphragm: Instruction in the fitting of 18 522 242 7,008
(viii) Eye: Removal of Adherent foreign body 242 7,012 958 27,849
(ix) Ear/Nose/Throat: Removal of foreign body 1,811 52,451 3,274 94,913
(x) Nebuliser: Treatment in the case of acute asthmatic attack 1,407 61,045 4,364 189,378
(xi) Bladder: Catheterization 229 9,962 250 10,859
(xii) Case Conference: Convened by HSE 42 3,040 10 735
(xiii) Diaphragm: Advice and fitting of 47 2,294 115 5,617
(xiv) IUCD: Counselling and fitting of 759 59,285 1,548 120,925
(xv) Pneumococcal: Vaccination 858 36,680 1,514 64,705
(xvi) Influenza: Vaccination 26,350 1,126,452 40,747 1,741,609
(xvii) Pneumococcal/Influenza: Vaccination 1,060 67,967 1,633 104,692
(xviii) Hepatitis B: Vaccination 105 5,395 286 14,438
Total 46,901 €1,837,142 76,927 €3,020,641
Table 13.1 GMS: Analysis of Special Items of Service by HSE Area
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Type of Service Northern Area Midland
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 9,304 270,011 7,642 221,665
(ii) Suturing: Cuts and Lacerations 2,545 73,898 3,898 113,078
(iii) Hydroceles: Draining of 12 350 67 1,945
(iv) Haemorrhages: Dental/Nasal 125 3,629 818 23,678
(v) Veins: Recognised treatment 12 350 905 26,181
(vi) ECG: Tests and interpretation 5,499 159,525 7,217 209,356
(vii) Diaphragm: Instruction in the fitting of 42 1,214 55 1,600
(viii) Eye: Removal of Adherent foreign body 534 15,519 898 26,052
(ix) Ear/Nose/Throat: Removal of foreign body 3,382 98,107 2,761 80,025
(x) Nebuliser: Treatment in the case of acute asthmatic attack 2,309 100,110 4,558 198,169
(xi) Bladder: Catheterization 144 6,273 618 26,910
(xii) Case Conference: Convened by HSE 15 1,087 24 1,749
(xiii) Diaphragm: Advice and fitting of 83 4,059 132 6,424
(xiv) IUCD: Counselling and fitting of 1,314 102,520 840 65,700
(xv) Pneumococcal: Vaccination 1,873 80,071 994 42,493
(xvi) Influenza: Vaccination 40,488 1,730,848 21,307 910,874
(xvii) Pneumococcal/Influenza: Vaccination 1,374 88,101 602 38,600
(xviii) Hepatitis B: Vaccination 404 20,754 81 4,162
Total 69,459 €2,756,426 53,417 €1,998,661
Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service Mid-Western North Eastern
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 7,693 222,980 11,033 319,817
(ii) Suturing: Cuts and Lacerations 3,279 95,032 3,631 105,306
(iii) Hydroceles: Draining of 93 2,684 92 2,667
(iv) Haemorrhages: Dental/Nasal 111 3,211 64 1,851
(v) Veins: Recognised treatment 388 10,512 1,305 37,813
(vi) ECG: Tests and interpretation 6,588 190,764 6,194 179,596
(vii) Diaphragm: Instruction in the fitting of 74 2,150 51 1,482
(viii) Eye: Removal of Adherent foreign body 547 15,860 433 12,566
(ix) Ear/Nose/Throat: Removal of foreign body 2,736 78,549 2,760 80,071
(x) Nebuliser: Treatment in the case of acute asthmatic attack 3,975 172,098 5,438 236,176
(xi) Bladder: Catheterization 599 26,012 495 21,517
(xii) Case Conference: Convened by HSE 76 5,578 11 796
(xiii) Diaphragm: Advice and fitting of 134 6,466 161 7,885
(xiv) IUCD: Counselling and fitting of 799 62,299 1,089 85,137
(xv) Pneumococcal: Vaccination 1,038 44,375 1,013 43,306
(xvi) Influenza: Vaccination 35,483 1,516,886 30,440 1,301,310
(xvii) Pneumococcal/Influenza: Vaccination 1,186 76,046 1,107 70,981
(xviii) Hepatitis B: Vaccination 185 9,502 410 20,967
Total 64,984 €2,541,004 65,727 €2,529,244
Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service North Western South Eastern
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 10,486 304,181 15,330 444,738
(ii) Suturing: Cuts and Lacerations 3,812 110,515 6,012 174,415
(iii) Hydroceles: Draining of 130 3,772 170 4,923
(iv) Haemorrhages: Dental/Nasal 121 3,503 120 3,474
(v) Veins: Recognised treatment 18 522 256 7,446
(vi) ECG: Tests and interpretation 11,773 340,852 14,873 431,084
(vii) Diaphragm: Instruction in the fitting of 277 8,011 74 2,147
(viii) Eye: Removal of Adherent foreign body 924 26,818 985 28,535
(ix) Ear/Nose/Throat: Removal of foreign body 2,404 69,688 3,397 98,476
(x) Nebuliser: Treatment in the case of acute asthmatic attack 5,964 258,417 7,354 318,938
(xi) Bladder: Catheterization 1,271 55,280 1,174 51,092
(xii) Case Conference: Convened by HSE 28 2,017 108 5,667
(xiii) Diaphragm: Advice and fitting of 58 2,837 77 3,761
(xiv) IUCD: Counselling and fitting of 902 70,440 2,004 156,658
(xv) Pneumococcal: Vaccination 1,023 43,733 1,969 84,153
(xvi) Influenza: Vaccination 26,294 1,124,066 48,616 2,078,154
(xvii) Pneumococcal/Influenza: Vaccination 943 60,465 1,968 126,188
(xviii) Hepatitis B: Vaccination 170 8,649 248 12,742
Total 66,598 €2,493,766 104,735 €4,032,591
Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service Southern Western
Number of 
Claims
Cost of 
Claims 
€
Number of 
Claims
Cost of 
Claims 
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 22,883 662,296 19,335 561,574
(ii) Suturing: Cuts and Lacerations 7,086 205,329 5,804 168,426
(iii) Hydroceles: Draining of 246 7,115 355 10,287
(iv) Haemorrhages: Dental/Nasal 293 8,454 373 10,813
(v) Veins: Recognised treatment 801 23,106 580 16,782
(vi) ECG: Tests and interpretation 14,116 408,604 15,037 436,035
(vii) Diaphragm: Instruction in the fitting of 110 3,196 186 5,402
(viii) Eye: Removal of Adherent foreign body 2,976 86,015 1,517 44,068
(ix) Ear/Nose/Throat: Removal of foreign body 6,033 174,817 4,745 137,638
(x) Nebuliser: Treatment in the case of acute asthmatic attack 10,089 427,877 12,233 531,228
(xi) Bladder: Catheterization 1,361 59,119 1,269 55,141
(xii) Case Conference: Convened by HSE 99 6,706 32 2,332
(xiii) Diaphragm: Advice and fitting of 125 6,043 98 4,779
(xiv) IUCD: Counselling and fitting of 2,113 164,895 959 74,875
(xv) Pneumococcal: Vaccination 2,107 90,074 1,943 83,061
(xvi) Influenza: Vaccination 60,884 2,602,765 41,050 1,754,710
(xvii) Pneumococcal/Influenza: Vaccination 2,852 182,870 1,398 89,624
(xviii) Hepatitis B: Vaccination 581 29,852 491 25,124
Total 134,755 €5,149,133 107,405 €4,011,899
Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
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NATIONAL
2010 (2009 in brackets)
Doctors with 
panels of:-
Visiting Rate:-*
4-4.9 5-5.9 6-6.9 7-7.9 8-8.9 9-9.9 10-10.9 11-11.9 12 and Over
100-249 – – – – – – – – –
250-499 – (1) – 1 (1) – – – – – –
500-999 – 1 (2) 1 – – – – – – –
1,000-1,499 – – – 1 (1) – – – – –
Over 1,500 – – – 1 (–) – – (1) – (1) – 1 (–)
TOTAL – (1) 1 (2) 2 (1) 2 (1) – – (1) – (1) – 1 (–)
Note: (i) The overall visiting rate in 2010 of the Doctors who continued on a Fee-Per-Item of service contract was 8.31 (Surgery: 8.20 Domiciliary: 0.11), (2009 – Total: 8.26 Surgery: 8.13 
Domiciliary: 0.13).
 (ii) Only Doctors with panels of 100 persons or over are included in the above table.
 (iii) * Visiting Rate is the total number of consultations divided by the total number of persons on panel.
Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service
65 66
Health 
Service 
Executive
Age Classification
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Eastern Areas 93.50 110.61 102.27 68.56 78.47 73.67 87.10 92.01 89.62 226.71 176.54 204.21 328.61 305.92 319.34 491.84 445.65 470.98
Midland 115.91 114.29 115.07 83.70 91.74 87.82 98.33 95.92 97.10 257.01 196.83 229.41 359.91 331.12 347.20 561.04 478.48 522.17
Mid-Western 131.33 136.35 133.92 102.39 117.43 110.04 99.30 155.02 127.89 277.30 208.40 244.24 390.73 361.49 377.14 552.32 494.70 524.56
North Eastern 83.25 104.39 94.01 69.82 77.56 73.78 78.19 82.88 80.60 212.90 152.61 184.17 279.90 242.61 263.13 388.06 356.12 372.82
North Western 82.25 91.42 86.98 56.49 80.93 69.20 66.34 80.21 73.69 187.33 148.04 167.99 282.81 235.21 260.34 390.64 362.50 377.17
South Eastern 93.90 113.36 103.94 73.72 96.93 85.68 90.23 117.64 104.43 252.17 195.98 225.62 343.23 333.08 338.60 503.29 459.96 482.46
Southern 127.50 153.47 140.83 97.17 111.59 104.67 118.34 129.04 123.74 286.82 225.66 257.26 387.46 371.18 380.17 556.23 523.62 540.53
Western 106.78 116.53 111.80 75.89 94.13 85.25 82.03 95.42 88.90 237.76 187.46 213.88 348.82 306.06 328.95 461.50 443.03 452.67
National €102.39 €117.77 €110.30 €76.88 €91.04 €84.17 €90.32 €104.18 €97.44 €241.40 €186.53 €215.61 €339.91 €313.17 €328.06 €489.71 €448.65 €470.35
% of National 
Average 13.42% 15.43% 14.45% 10.07% 11.93% 11.03% 11.83% 13.65% 12.77% 31.63% 24.44% 28.25% 44.53% 41.03% 42.98% 64.16% 58.78% 61.62%
Table 15 GMS: Cost of Medicines by Gender within Age Groups
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Table 15 GMS: Cost of Medicines by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years & Over Total
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Eastern Areas 892.91 808.53 853.04 1,331.26 1,289.61 1,312.38 1,506.04 1,643.66 1,561.06 1,521.41 1,481.55 1,503.51 1,862.84 1,790.85 1,835.48 841.94 726.85 790.20
Midland 996.93 890.41 944.64 1,525.25 1,402.39 1,466.93 1,660.28 1,761.78 1,703.80 1,702.97 1,704.78 1,703.84 2,144.30 2,016.72 2,089.79 882.64 778.26 833.35
Mid-Western 886.25 828.54 857.62 1,325.39 1,251.98 1,290.00 1,442.86 1,450.85 1,446.41 1,503.87 1,393.55 1,450.29 1,736.57 1,726.28 1,732.34 830.14 741.05 787.75
North Eastern 718.81 674.05 696.57 1,136.07 1,154.97 1,145.12 1,353.67 1,429.98 1,387.65 1,496.85 1,437.69 1,468.36 1,786.03 1,751.63 1,771.92 678.27 606.04 643.97
North Western 617.13 595.16 606.21 1,031.44 994.12 1,013.14 1,266.84 1,245.62 1,256.61 1,302.90 1,297.44 1,300.21 1,645.12 1,566.98 1,611.56 659.51 590.36 625.85
South Eastern 898.11 833.42 866.19 1,298.35 1,273.39 1,286.35 1,485.14 1,520.91 1,501.29 1,563.52 1,495.46 1,530.41 1,850.59 1,780.42 1,821.18 810.69 732.07 773.21
Southern 956.81 862.49 910.50 1,375.51 1,343.42 1,360.17 1,514.43 1,543.21 1,526.97 1,542.75 1,496.18 1,520.54 1,739.47 1,733.76 1,737.19 883.52 794.18 841.55
Western 768.63 723.60 746.20 1,144.47 1,094.47 1,119.41 1,306.63 1,352.20 1,328.05 1,430.52 1,409.00 1,419.87 1,745.56 1,694.28 1,724.04 758.73 690.50 725.93
National €854.68 €784.98 €820.60 €1,280.28 €1,235.02 €1,258.72 €1,455.13 €1,507.51 €1,478.04 €1,513.39 €1,466.30 €1,491.08 €1,812.97 €1,757.72 €1,790.65 €806.34 €714.41 €763.25
% of National 
Average 111.98% 102.85% 107.51% 167.74% 161.81% 164.92% 190.65% 197.51% 193.65% 198.28% 192.11% 195.36% 237.53% 230.29% 234.61% 105.65% 93.60% 100.00%
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Health Service Executive
Number of Forms Number of Items Items per Form
2010 2009 2010 2009 2010 2009
East Coast Area 1,069,987 993,022 3,487,693 3,252,646 3.26 3.28
South Western Area 2,023,789 1,884,323 6,427,743 5,995,036 3.18 3.18
Northern Area 1,793,302 1,720,016 5,970,590 5,683,891 3.33 3.30
Midland 1,181,149 1,112,330 3,676,790 3,464,279 3.11 3.11
Mid-Western 1,633,307 1,528,655 5,109,996 4,783,532 3.13 3.13
North Eastern 1,581,461 1,438,637 4,786,318 4,423,611 3.03 3.07
North Western 1,218,124 1,145,110 3,426,880 3,211,631 2.81 2.80
South Eastern 2,303,273 2,124,830 7,073,893 6,546,461 3.07 3.08
Southern 2,780,296 2,610,466 8,635,135 8,093,563 3.11 3.10
Western 1,923,329 1,775,985 5,713,145 5,267,269 2.97 2.97
National 17,508,017 16,333,374 54,308,183 50,721,919 3.10 3.11
Table 16 GMS: Number of Prescription Forms and Items
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Table 16.1  GMS: Number of Stock Order Forms and Items
Health Service Executive
Number of Forms Number of Items Items per Form
2010 2009 2010 2009 2010 2009
East Coast Area 643 613 3,014 2,726 4.69 4.45
South Western Area 780 751 3,177 3,013 4.07 4.01
Northern Area 588 719 2,533 2,822 4.31 3.92
Midland 689 730 3,860 4,089 5.60 5.60
Mid-Western 1,477 1,316 8,366 7,487 5.66 5.69
North Eastern 2,708 2,313 15,296 13,085 5.65 5.66
North Western 2,837 3,061 16,773 17,660 5.91 5.77
South Eastern 4,276 4,568 25,415 27,928 5.94 6.11
Southern 1,360 1,286 7,077 6,757 5.20 5.25
Western 4,890 5,091 30,966 32,998 6.33 6.48
National 20,248 20,448 116,477 118,565 5.75 5.80
Note: (i) Stock Order Forms are provided by HSE Areas for use by Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons  
who are entitled to be dispensed to.
 (ii) The above figures include needles, syringes and dressings which are available for Doctors’ use.
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Table 16.2  GMS: Payment to Pharmacists in Respect of Prescriptions
Health Service 
Executive
Cost Cost per Form Cost per Item Ingredient Cost  per Item
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
2010
€
2009
€
East Coast Area 76,634,176 79,269,422 71.62 79.83 21.97 24.37 16.75 18.52
South Western Area 140,692,108 143,478,091 69.52 76.14 21.89 23.93 16.69 18.43
Northern Area 136,942,155 142,396,051 76.36 82.79 22.94 25.05 17.59 19.40
Midland 83,547,922 85,856,163 70.73 77.19 22.72 24.78 17.34 19.14
Mid-Western 112,624,030 114,861,653 68.95 75.14 22.04 24.01 16.75 18.52
North Eastern 106,291,873 107,311,281 67.21 74.59 22.21 24.26 16.90 18.69
North Western 77,503,013 78,890,836 63.62 68.89 22.62 24.56 17.27 19.01
South Eastern 159,148,319 159,970,989 69.10 75.29 22.50 24.44 17.09 18.77
Southern 195,441,129 200,584,382 70.30 76.84 22.63 24.78 17.38 19.27
Western 131,572,304 133,316,155 68.41 75.07 23.03 25.31 17.70 19.72
National €1,220,397,029 €1,245,935,023 €69.71 €76.28 €22.47 €24.56 €17.17 €18.97
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Prescription forms having:-
2010 2009
No. of Forms % of Total No. of Forms % of Total
One Item 6,744,821 38.49 6,260,489 38.08
Two Items 3,339,872 19.06 3,133,752 19.06
Three Items 1,892,069 10.80 1,788,810 10.88
Four Items 1,288,139 7.35 1,230,428 7.48
Five Items 1,040,607 5.94 993,697 6.04
Six Items 941,146 5.37 912,282 5.55
Seven Items 1,013,721 5.78 981,195 5.97
Eight or more Items 1,263,407 7.21 1,140,953 6.94
Table 16.3  GMS: Number of Items on Prescription Forms
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Table 16.4  DP: Number of Items on Claim Forms
Claim forms having:-
2010 2009
No. of Forms % of Total No. of Forms % of Total
One Item 1,419,270 38.23 2,004,397 40.84
Two Items 703,868 18.96 993,484 20.24
Three Items 450,192 12.13 616,005 12.55
Four Items 335,217 9.03 430,221 8.77
Five Items 255,643 6.89 301,242 6.14
Six Items 185,682 5.00 202,985 4.14
Seven Items 126,701 3.41 132,144 2.69
Eight or more Items 235,910 6.35 227,500 4.63
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Table 16.5  LTI: Number of Items on Claim Forms
Claim forms having:-
2010 2009
No. of Forms % of Total No. of Forms % of Total
One Item 294,979 33.50 305,806 33.97
Two Items 150,979 17.14 154,991 17.21
Three Items 105,561 11.99 107,973 11.99
Four Items 93,022 10.56 92,888 10.32
Five Items 79,474 9.02 78,834 8.76
Six Items 60,780 6.90 60,763 6.75
Seven Items 40,915 4.65 41,885 4.65
Eight or more Items 54,950 6.24 57,202 6.35
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Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense
Health Service Executive 2010 2009
No. of Doctors No. of Persons No. of Doctors No. of Persons
Eastern Areas – – – –
Midland 8 4,703 8 4,450
Mid-Western 11 2,612 11 2,572
North Eastern 5 1,527 5 1,414
North Western 30 12,827 31 12,053
South Eastern 17 7,105 19 7,667
Southern 9 933 11 1,544
Western 32 15,499 32 15,139
National 112 45,206 117 44,839
Note: * In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest Community Pharmacy the Doctor dispenses for persons served from that centre who opt to be 
dispensed to. The Doctor is paid a dispensing fee for each such person. A Doctor’s medicine requirements are obtained on a Stock Order from a Community Pharmacy – the stock ordered is 
approved in advance by a HSE Area.
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Table 18 GMS: Advance Payments to Pharmacists
Health Service Executive
Amount Advanced to Pharmacists as at 31st December:-
2010
€
2009
€
Eastern 3,264,521 3,362,872
Midland 756,146 809,506
Mid-Western 905,500 1,054,886
North Eastern 1,323,443 1,345,799
North Western 1,028,383 1,100,378
South Eastern 1,395,183 1,666,976
Southern 1,742,774 1,920,544
Western 1,510,271 1,592,977
NATIONAL €11,926,221 €12,853,938
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Table 19 GMS: Notes on Some of the More Commonly Prescribed Products
AMOXICILLIN
AMOXICILLIN AND 
ENZYME INHIBITOR
FUROSEMIDE
FUROSEMIDE WITH 
POTASSIUM SPARING 
DIURETICS
SALBUTAMOL
DICLOFENAC
ATORVASTATIN AND 
PRAVASTATIN
Amoxicillin, alone or potentiated by 
an inhibitor of bacterial enzymes is a 
broad spectrum Penicillin antibiotic 
indicated for the treatment of a wide 
range of infections.
Salbutamol is a beta-adrenergic 
stimulant used mainly in the treatment 
of chronic asthma and chronic 
bronchitis.
Diclofenac is a Non-Steroidal Anti-
inflammatory Drug (NSAID) mainly 
used to treat pain and inflammation 
associated with muscular conditions 
and rheumatoid arthritis.
Atorvastatin and Pravastatin are 
indicated, in combination with dietary 
measures, for lowering cholesterol 
levels.
The diuretic Furosemide, alone or in 
combination with potassium – sparing 
diuretics, is used to treat hypertension.
OMEPRAZOLE
LANSOPRAZOLE
BECLOMETASONE
AMLODIPINE
ACETYLSALICYLIC 
ACID-ASPIRIN
ATENOLOL
Beclometasone is a potent steroid 
having an anti-inflammatory action 
within the lungs. It is used mainly 
by inhalation for the treatment of 
bronchial asthma.
Amlodipine is a calcium – channel 
blocker (similar to nifedipine) with 
peripheral and coronary vasodilator 
properties. It is given by mouth in the 
management of hypertension and of 
angina pectoris.
Acetylsalicylic Acid – Aspirin has anti-
inflammatory and additionally analgesic 
and antipyretic (body temperature 
lowering) action. Acetylsalicylic Acid 
– Aspirin also has action against 
thrombosis or clot formation by 
inhibition of platelet cell aggregration 
in the blood.
Atenolol is a beta blocker. Members 
of this class of drugs are used in the 
treatment of hypertension, angina 
pectoris and cardiac arrythmias.
Omeprazole and Lansoprazole are 
proton pump inhibitors which prevent 
secretion of gastric acid. They are used 
in the treatment of reflux oesophagitis 
and peptic ulceration.
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Acetylsalicylic Acid-Aspirin (Antithrombotic) 2,598,610 4.77 5,196,051 0.55
2 Atorvastatin 1,844,356 3.39 71,385,529 7.58
3 Levothyroxine Sodium 1,109,106 2.04 1,950,591 0.21
4 Bisoprolol 972,171 1.79 4,588,404 0.49
5 Paracetamol 969,784 1.78 1,426,599 0.15
6 Calcium, Combinations 948,746 1.74 6,649,153 0.71
7 Salbutamol (Inhaled) 935,483 1.72 4,470,905 0.47
8 Amlodipine 823,907 1.51 7,511,296 0.80
9 Ramipril 773,076 1.42 5,474,528 0.58
10 Esomeprazole 761,024 1.40 30,934,153 3.28
11 Amoxicillin and Enzyme Inhibitor 732,019 1.35 4,578,549 0.49
12 Warfarin 706,694 1.30 1,528,060 0.16
13 Lansoprazole 689,995 1.27 22,756,232 2.42
14 Omeprazole 657,307 1.21 17,186,823 1.82
15 Furosemide 642,876 1.18 569,323 0.06
16 Clinical Nutritional Products 600,598 1.10 43,681,431 4.64
17 Rosuvastatin 587,368 1.08 15,988,064 1.70
18 Diclofenac (Systemic) 568,754 1.05 4,743,253 0.50
19 Metformin 558,220 1.03 1,613,052 0.17
20 Zopiclone 550,710 1.01 2,766,898 0.29
21 Prednisolone (Systemic) 511,612 0.94 1,805,004 0.19
22 Pantoprazole 508,325 0.93 8,749,362 0.93
23 Diazepam 500,529 0.92 465,927 0.05
24 Pravastatin 494,196 0.91 9,323,028 0.99
25 Salmeterol and other drugs for obstructive airway diseases 483,763 0.89 32,366,449 3.44
26 Perindopril 464,370 0.85 7,878,464 0.84
27 Diagnostic Products 460,192 0.85 17,251,562 1.83
28 Escitalopram 457,003 0.84 13,291,194 1.41
29 Atenolol 439,520 0.81 1,766,189 0.19
30 Alprazolam 432,543 0.79 690,661 0.07
31 Zolpidem 421,885 0.78 1,176,068 0.12
32 Amoxicillin 400,186 0.74 1,246,153 0.13
33 Paracetamol, Combs. excl. Psycholeptics 388,110 0.71 2,410,702 0.26
34 Codeine, Combs. excl. Psycholeptics 361,604 0.66 2,919,563 0.31
35 Gliclazide 352,035 0.65 2,039,655 0.22
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Diclofenac (Topical) 349,096 0.64 1,560,096 0.17
37 Clopidogrel 345,622 0.64 16,756,535 1.78
38 Folic Acid 336,684 0.62 299,068 0.03
39 Ferrous Fumarate 333,142 0.61 573,877 0.06
40 Tramadol 331,061 0.61 2,874,022 0.31
41 Lactulose 329,473 0.61 1,064,887 0.11
42 Venlafaxine 323,424 0.59 6,995,920 0.74
43 Alendronic Acid 322,901 0.59 9,679,189 1.03
44 Tiotropium Bromide 313,173 0.58 14,779,036 1.57
45 Artificial tears and other indifferent preparations 311,911 0.57 1,742,153 0.18
46 Carbocisteine 309,792 0.57 971,593 0.10
47 Doxazosin 292,987 0.54 7,052,166 0.75
48 Beclometasone (Inhaled) 287,288 0.53 4,819,448 0.51
49 Alginic Acid 283,986 0.52 1,539,651 0.16
50 Citalopram 283,912 0.52 3,787,658 0.40
51 Domperidone 283,595 0.52 741,953 0.08
52 Glucosamine 282,792 0.52 4,283,074 0.45
53 Pregabalin 281,703 0.52 23,938,065 2.54
54 Macrogol, Combinations 269,807 0.50 4,027,429 0.43
55 Needles/Syringes/Lancets 255,576 0.47 3,298,373 0.35
56 Clarithromycin 254,557 0.47 3,560,729 0.38
57 Drospirenone and Estrogen 248,707 0.46 1,684,209 0.18
58 Bendroflumethiazide 248,566 0.46 391,462 0.04
59 Lercanidipine 247,266 0.45 3,073,875 0.33
60 Digoxin 243,719 0.45 191,293 0.02
61 Bendroflumethiazide and Potassium 241,946 0.44 798,976 0.08
62 Ibuprofen 236,356 0.43 556,700 0.06
63 Lisinopril 222,338 0.41 1,707,091 0.18
64 Valsartan 221,388 0.41 4,907,188 0.52
65 Tamsulosin 219,971 0.40 5,569,705 0.59
66 Mirtazapine 219,492 0.40 3,176,750 0.34
67 Formoterol and other drugs for obstructive airway diseases 216,664 0.40 11,833,463 1.26
68 Allopurinol 215,177 0.40 826,651 0.09
69 Isosorbide Mononitrate 208,153 0.38 1,666,937 0.18
70 Nebivolol 202,497 0.37 2,737,058 0.29
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Olanzapine 198,882 0.37 21,297,097 2.26
72 Amitriptyline 196,031 0.36 288,763 0.03
73 Furosemide and Potassium-Sparing Agents 194,227 0.36 621,371 0.07
74 Temazepam 190,939 0.35 368,545 0.04
75 Simvastatin 186,531 0.34 3,253,614 0.35
76 Losartan 184,599 0.34 4,014,684 0.43
77 Quetiapine 181,483 0.33 10,354,010 1.10
78 Flurazepam 181,053 0.33 733,203 0.08
79 Sodium Valproate 179,682 0.33 1,862,653 0.20
80 Betamethasone (Topical) 173,973 0.32 741,498 0.08
81 Ranitidine 173,368 0.32 2,767,088 0.29
82 Betahistine 172,248 0.32 1,176,409 0.12
83 Flucloxacillin 170,588 0.31 1,300,811 0.14
84 Mefenamic Acid 165,260 0.30 600,704 0.06
85 Levonorgestrel and Estrogen (Fixed Comb. Contraceptive) 164,345 0.30 550,938 0.06
86 Risedronic Acid 163,448 0.30 5,541,448 0.59
87 Other Emollients and Protectives 161,812 0.30 376,399 0.04
88 Montelukast 161,692 0.30 5,870,757 0.62
89 Sertraline 157,834 0.29 3,253,065 0.35
90 Valsartan and Diuretics 156,899 0.29 3,915,064 0.42
91 Nicotine 155,080 0.28 4,836,476 0.51
92 Latanoprost 148,950 0.27 3,593,672 0.38
93 Metoprolol 147,731 0.27 201,953 0.02
94 Etoricoxib 145,776 0.27 4,324,456 0.46
95 Glyceryl Trinitrate 145,433 0.27 1,343,516 0.14
96 Tolterodine 144,068 0.26 6,216,939 0.66
97 Fluoxetine 143,755 0.26 2,332,799 0.25
98 Ostomy Requisites 141,364 0.26 13,268,472 1.41
99 Hypromellose 138,913 0.26 829,734 0.09
100 Telmisartan 136,586 0.25 3,162,255 0.34
Total 39,243,949 72.12% €620,843,548 65.93%
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Atorvastatin 71,385,529 7.58 1,844,356 3.39
2 Clinical Nutritional Products 43,681,431 4.64 600,598 1.10
3 Salmeterol and other drugs for obstructive airway diseases 32,366,449 3.44 483,763 0.89
4 Esomeprazole 30,934,153 3.28 761,024 1.40
5 Pregabalin 23,938,065 2.54 281,703 0.52
6 Lansoprazole 22,756,232 2.42 689,995 1.27
7 Olanzapine 21,297,097 2.26 198,882 0.37
8 Diagnostic Products 17,251,562 1.83 460,192 0.85
9 Omeprazole 17,186,823 1.82 657,307 1.21
10 Clopidogrel 16,756,535 1.78 345,622 0.64
11 Rosuvastatin 15,988,064 1.70 587,368 1.08
12 Tiotropium Bromide 14,779,036 1.57 313,173 0.58
13 Escitalopram 13,291,194 1.41 457,003 0.84
14 Ostomy Requisites 13,268,472 1.41 141,364 0.26
15 Formoterol and other drugs for obstructive airway diseases 11,833,463 1.26 216,664 0.40
16 Quetiapine 10,354,010 1.10 181,483 0.33
17 Alendronic Acid 9,679,189 1.03 322,901 0.59
18 Pravastatin 9,323,028 0.99 494,196 0.91
19 Fentanyl 8,764,404 0.93 62,116 0.11
20 Pantoprazole 8,749,362 0.93 508,325 0.93
21 Perindopril 7,878,464 0.84 464,370 0.85
22 Amlodipine 7,511,296 0.80 823,907 1.51
23 Urinary Requisites 7,240,200 0.77 78,100 0.14
24 Donepezil 7,124,643 0.76 120,571 0.22
25 Doxazosin 7,052,166 0.75 292,987 0.54
26 Venlafaxine 6,995,920 0.74 323,424 0.59
27 Risperidone 6,775,361 0.72 133,160 0.24
28 Calcium, Combinations 6,649,153 0.71 948,746 1.74
29 Lamotrigine 6,581,472 0.70 126,199 0.23
30 Tolterodine 6,216,939 0.66 144,068 0.26
31 Memantine 6,148,491 0.65 66,667 0.12
32 Montelukast 5,870,757 0.62 161,692 0.30
33 Tamsulosin 5,569,705 0.59 219,971 0.40
34 Risedronic Acid 5,541,448 0.59 163,448 0.30
35 Ramipril 5,474,528 0.58 773,076 1.42
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Levetiracetam 5,443,226 0.58 63,919 0.12
37 Simvastatin and Ezetimibe 5,392,535 0.57 106,051 0.19
38 Acetylsalicylic Acid-Aspirin (Antithrombotic) 5,196,051 0.55 2,598,610 4.77
39 Valsartan 4,907,188 0.52 221,388 0.41
40 Nicotine 4,836,476 0.51 155,080 0.28
41 Budesonide (Inhaled) 4,833,614 0.51 72,845 0.13
42 Beclometasone (Inhaled) 4,819,448 0.51 287,288 0.53
43 Buprenorphine 4,813,007 0.51 85,273 0.16
44 Diclofenac (Systemic) 4,743,253 0.50 568,754 1.05
45 Bisoprolol 4,588,404 0.49 972,171 1.79
46 Amoxicillin and Enzyme Inhibitor 4,578,549 0.49 732,019 1.35
47 Salbutamol (Inhaled) 4,470,905 0.47 935,483 1.72
48 Aripiprazole 4,433,196 0.47 26,734 0.05
49 Etoricoxib 4,324,456 0.46 145,776 0.27
50 Insulin Glargine, Long Acting 4,310,046 0.46 57,694 0.11
51 Glucosamine 4,283,074 0.45 282,792 0.52
52 Varenicline 4,111,061 0.44 54,562 0.10
53 Macrogol, Combinations 4,027,429 0.43 269,807 0.50
54 Losartan 4,014,684 0.43 184,599 0.34
55 Gabapentin 3,943,775 0.42 85,960 0.16
56 Valsartan and Diuretics 3,915,064 0.42 156,899 0.29
57 Anastrazole 3,909,550 0.41 39,328 0.07
58 Duloxetine 3,847,738 0.41 105,869 0.19
59 Mesalazine 3,835,891 0.41 58,391 0.11
60 Citalopram 3,787,658 0.40 283,912 0.52
61 Rabeprazole 3,735,145 0.40 126,630 0.23
62 Salbutamol and other drugs for obstructive airway diseases 3,716,894 0.39 128,624 0.24
63 Ezetimibe 3,696,812 0.39 97,022 0.18
64 Alendronic Acid, Combinations 3,670,942 0.39 113,920 0.21
65 Latanoprost 3,593,672 0.38 148,950 0.27
66 Clarithromycin 3,560,729 0.38 254,557 0.47
67 Insulin Aspart, Fast Acting 3,413,812 0.36 55,582 0.10
68 Orlistat 3,356,196 0.36 55,319 0.10
69 Tinzaparin 3,339,305 0.35 14,784 0.03
70 Needles/Syringes/Lancets 3,298,373 0.35 255,576 0.47
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Simvastatin 3,253,614 0.35 186,531 0.34
72 Sertraline 3,253,065 0.35 157,834 0.29
73 Calcipotriol, Combinations 3,180,944 0.34 39,733 0.07
74 Mirtazapine 3,176,750 0.34 219,492 0.40
75 Sildenafil 3,165,375 0.34 104,290 0.19
76 Telmisartan 3,162,255 0.34 136,586 0.25
77 Solifenacin 3,132,183 0.33 65,211 0.12
78 Ibandronic Acid 3,077,621 0.33 100,358 0.18
79 Lercanidipine 3,073,875 0.33 247,266 0.45
80 Oxycodone 3,042,313 0.32 87,976 0.16
81 Omega-3-triglycerides 3,027,448 0.32 116,570 0.21
82 Codeine Combs. excl. Psycholeptics 2,919,563 0.31 361,604 0.66
83 Tramadol 2,874,022 0.31 331,061 0.61
84 Ranitidine 2,767,088 0.29 173,368 0.32
85 Zopiclone 2,766,898 0.29 550,710 1.01
86 Insulin Detemir, Long Acting 2,765,154 0.29 32,540 0.06
87 Nebivolol 2,737,058 0.29 202,497 0.37
88 Perindopril and Diuretics 2,564,272 0.27 113,869 0.21
89 Fluticasone (Inhaled) 2,555,795 0.27 49,618 0.09
90 Levodopa Decarboxylase Inhibitor and COMT Inhibitor 2,495,660 0.26 23,118 0.04
91 Insulin Aspart, Comb. Intermediate/Fast Acting 2,483,233 0.26 31,235 0.06
92 Timolol, Combinations 2,456,592 0.26 96,037 0.18
93 Strontium Ranelate 2,419,627 0.26 55,320 0.10
94 Paracetamol Combs. excl. Psycholeptics 2,410,702 0.26 388,110 0.71
95 Fluoxetine 2,332,799 0.25 143,755 0.26
96 Candesartan 2,256,666 0.24 100,440 0.18
97 Sitagliptin 2,130,113 0.23 48,131 0.09
98 Alfuzosin 2,120,317 0.23 77,652 0.14
99 Losartan and Diuretics 2,101,805 0.22 85,085 0.16
100 Rivastigmine 2,080,918 0.22 23,295 0.04
Total €740,746,524 78.67% 28,599,881 52.51%
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Acetylsalicylic Acid-Aspirin (Antithrombotic) 547,430 4.94 1,148,144 0.50
2 Atorvastatin 514,347 4.65 21,135,739 9.13
3 Levothyroxine Sodium 269,126 2.43 498,637 0.22
4 Rosuvastatin 240,722 2.17 6,760,806 2.92
5 Esomeprazole 229,344 2.07 9,858,315 4.26
6 Salbutamol (Inhaled) 218,747 1.98 992,025 0.43
7 Bisoprolol 217,530 1.96 1,017,473 0.44
8 Calcium, Combinations 214,411 1.94 1,640,509 0.71
9 Diclofenac (Systemic) 169,278 1.53 1,649,616 0.71
10 Amlodipine 168,704 1.52 1,473,541 0.64
11 Salmeterol and other drugs for obstructive airway diseases 146,487 1.32 9,680,255 4.18
12 Omeprazole 144,723 1.31 3,770,391 1.63
13 Lansoprazole 140,709 1.27 5,202,276 2.25
14 Ramipril 138,593 1.25 971,623 0.42
15 Amoxicillin and Enzyme Inhibitor 128,712 1.16 806,725 0.35
16 Codeine Combs. excl. Psycholeptics 125,210 1.13 1,012,300 0.44
17 Prednisolone (Systemic) 122,611 1.11 512,643 0.22
18 Escitalopram 106,154 0.96 3,279,537 1.42
19 Clinical Nutritional Products 105,786 0.96 5,014,792 2.17
20 Perindopril 104,424 0.94 1,827,783 0.79
21 Pantoprazole 100,098 0.90 1,765,644 0.76
22 Clopidogrel 95,979 0.87 4,802,488 2.07
23 Warfarin 95,136 0.86 211,997 0.09
24 Formoterol and other drugs for obstructive airway diseases 93,646 0.85 5,272,303 2.28
25 Zopiclone 91,024 0.82 450,611 0.19
26 Glucosamine 88,214 0.80 1,384,766 0.60
27 Atenolol 86,569 0.78 343,684 0.15
28 Pravastatin 85,140 0.77 1,620,816 0.70
29 Venlafaxine 85,039 0.77 1,891,779 0.82
30 Montelukast 84,547 0.76 3,146,745 1.36
31 Zolpidem 84,048 0.76 247,959 0.11
32 Paracetamol 80,847 0.73 121,374 0.05
33 Alprazolam 73,403 0.66 111,747 0.05
34 Pregabalin 71,196 0.64 6,256,657 2.70
35 Clarithromycin 70,937 0.64 1,103,766 0.48
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Folic Acid 70,767 0.64 54,505 0.02
37 Valsartan 63,707 0.58 1,435,344 0.62
38 Doxazosin 62,999 0.57 1,620,887 0.70
39 Nebivolol 62,210 0.56 871,967 0.38
40 Omega-3-triglycerides 61,156 0.55 1,687,165 0.73
41 Diazepam 60,504 0.55 41,727 0.02
42 Alendronic Acid 58,143 0.53 1,802,534 0.78
43 Allopurinol 57,905 0.52 241,218 0.10
44 Beclometasone (Inhaled) 55,806 0.50 957,336 0.41
45 Tramadol 55,734 0.50 490,771 0.21
46 Valsartan and Diuretics 54,598 0.49 1,381,416 0.60
47 Diclofenac (Topical) 52,927 0.48 269,086 0.12
48 Citalopram 50,510 0.46 657,368 0.28
49 Simvastatin and Ezetimibe 49,960 0.45 2,557,400 1.10
50 Etoricoxib 49,264 0.45 1,549,147 0.67
51 Tiotropium Bromide 48,869 0.44 2,310,649 1.00
52 Amoxicillin 48,377 0.44 194,960 0.08
53 Lercanidipine 48,127 0.43 623,010 0.27
54 Amitriptyline 47,131 0.43 80,254 0.03
55 Furosemide 47,043 0.42 47,331 0.02
56 Losartan 46,089 0.42 1,036,426 0.45
57 Domperidone 45,541 0.41 120,833 0.05
58 Ezetimibe 44,938 0.41 1,722,267 0.74
59 Artificial tears and other indifferent preparations 44,908 0.41 327,301 0.14
60 Telmisartan 43,658 0.39 1,017,669 0.44
61 Methotrexate 43,593 0.39 479,812 0.21
62 Bendroflumethiazide 43,134 0.39 68,006 0.03
63 Lisinopril 42,762 0.39 314,799 0.14
64 Tadalafil 42,466 0.38 1,205,137 0.52
65 Alginic Acid 42,086 0.38 246,467 0.11
66 Drospirenone and Estrogen 41,028 0.37 282,284 0.12
67 Ostomy Requisites 40,080 0.36 3,615,815 1.56
68 Mometasone 39,848 0.36 588,932 0.25
69 Mesalazine 39,788 0.36 3,294,067 1.42
70 Bendroflumethiazide and Potassium 38,944 0.35 129,791 0.06
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Olmesartan Medoxomil 38,866 0.35 779,391 0.34
72 Cetirizine 38,787 0.35 175,514 0.08
73 Fluticasone Furoate 37,632 0.34 458,919 0.20
74 Tamsulosin 37,039 0.33 959,003 0.41
75 Olanzapine 36,673 0.33 3,181,473 1.37
76 Betamethasone (Topical) 36,327 0.33 171,045 0.07
77 Fluticasone (Nasal) 36,188 0.33 235,665 0.10
78 Risedronic Acid 35,590 0.32 1,201,252 0.52
79 Sertraline 35,076 0.32 746,411 0.32
80 Antifungal Combs. (Topical) 34,938 0.32 128,440 0.06
81 Ranitidine 34,821 0.31 547,071 0.24
82 Simvastatin 34,805 0.31 602,177 0.26
83 Mefenamic Acid 34,537 0.31 119,580 0.05
84 Sildenafil 32,709 0.30 977,477 0.42
85 Estradiol 32,581 0.29 366,990 0.16
86 Metformin 32,553 0.29 84,808 0.04
87 Duloxetine 32,117 0.29 1,228,676 0.53
88 Lithium 31,700 0.29 62,033 0.03
89 Ibandronic Acid 31,667 0.29 960,762 0.41
90 Fluoxetine 31,004 0.28 514,814 0.22
91 Carbocisteine 30,773 0.28 102,996 0.04
92 Perindopril and Diuretics 30,519 0.28 686,882 0.30
93 Desloratadine 29,596 0.27 319,055 0.14
94 Candesartan 29,328 0.26 658,935 0.28
95 Quetiapine 28,398 0.26 1,716,324 0.74
96 Losartan and Diuretics 28,257 0.26 706,356 0.31
97 Mirtazapine 28,235 0.26 395,883 0.17
98 Macrogol, Combinations 27,796 0.25 423,901 0.18
99 Levocetirizine 27,570 0.25 289,888 0.13
100 Diltiazem 27,063 0.24 378,177 0.16
Total 8,066,616 72.86% €159,489,045 68.90%
Table 19.3 DPS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Atorvastatin 21,135,739 9.13 514,347 4.65
2 Esomeprazole 9,858,315 4.26 229,344 2.07
3 Salmeterol and other drugs for obstructive airway diseases 9,680,255 4.18 146,487 1.32
4 Rosuvastatin 6,760,806 2.92 240,722 2.17
5 Pregabalin 6,256,657 2.70 71,196 0.64
6 Formoterol and other drugs for obstructive airway diseases 5,272,303 2.28 93,646 0.85
7 Lansoprazole 5,202,276 2.25 140,709 1.27
8 Clinical Nutritional Products 5,014,792 2.17 105,786 0.96
9 Clopidogrel 4,802,488 2.07 95,979 0.87
10 Omeprazole 3,770,391 1.63 144,723 1.31
11 Ostomy Requisites 3,615,815 1.56 40,080 0.36
12 Mesalazine 3,294,067 1.42 39,788 0.36
13 Escitalopram 3,279,537 1.42 106,154 0.96
14 Olanzapine 3,181,473 1.37 36,673 0.33
15 Montelukast 3,146,745 1.36 84,547 0.76
16 Simvastatin and Ezetimibe 2,557,400 1.10 49,960 0.45
17 Follitropin Beta 2,422,385 1.05 510 0.00
18 Tiotropium Bromide 2,310,649 1.00 48,869 0.44
19 Calcipotriol, Combinations 2,237,655 0.97 24,886 0.22
20 Venlafaxine 1,891,779 0.82 85,039 0.77
21 Perindopril 1,827,783 0.79 104,424 0.94
22 Alendronic Acid 1,802,534 0.78 58,143 0.53
23 Pantoprazole 1,765,644 0.76 100,098 0.90
24 Ezetimibe 1,722,267 0.74 44,938 0.41
25 Quetiapine 1,716,324 0.74 28,398 0.26
26 Omega-3-triglycerides 1,687,165 0.73 61,156 0.55
27 Plastic IUCD with Progestogens 1,685,158 0.73 14,200 0.13
28 Diclofenac (Systemic) 1,649,616 0.71 169,278 1.53
29 Calcium, Combinations 1,640,509 0.71 214,411 1.94
30 Doxazosin 1,620,887 0.70 62,999 0.57
31 Pravastatin 1,620,816 0.70 85,140 0.77
32 Etoricoxib 1,549,147 0.67 49,264 0.45
33 Amlodipine 1,473,541 0.64 168,704 1.52
34 Valsartan 1,435,344 0.62 63,707 0.58
35 Progesterone 1,414,228 0.61 10,893 0.10
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Glucosamine 1,384,766 0.60 88,214 0.80
37 Valsartan and Diuretics 1,381,416 0.60 54,598 0.49
38 Anastrazole 1,365,003 0.59 13,571 0.12
39 Urinary Requisites 1,314,347 0.57 10,307 0.09
40 Varenicline 1,281,226 0.55 16,708 0.15
41 Duloxetine 1,228,676 0.53 32,117 0.29
42 Fentanyl 1,214,045 0.52 7,038 0.06
43 Tadalafil 1,205,137 0.52 42,466 0.38
44 Risedronic Acid 1,201,252 0.52 35,590 0.32
45 Lamotrigine 1,152,264 0.50 26,404 0.24
46 Acetylsalicylic Acid-Aspirin (Antithrombotic) 1,148,144 0.50 547,430 4.94
47 Orlistat 1,129,966 0.49 18,345 0.17
48 Clarithromycin 1,103,766 0.48 70,937 0.64
49 Tinzaparin 1,049,219 0.45 5,828 0.05
50 Losartan 1,036,426 0.45 46,089 0.42
51 Telmisartan 1,017,669 0.44 43,658 0.39
52 Bisoprolol 1,017,473 0.44 217,530 1.96
53 Gabapentin 1,012,519 0.44 19,911 0.18
54 Codeine Combs. excl. Psycholeptics 1,012,300 0.44 125,210 1.13
55 Salbutamol (Inhaled) 992,025 0.43 218,747 1.98
56 Sildenafil 977,477 0.42 32,709 0.30
57 Sumatriptan 977,376 0.42 16,342 0.15
58 Fumaric Acid Derivatives, Combinations 974,024 0.42 1,624 0.01
59 Ramipril 971,623 0.42 138,593 1.25
60 Ibandronic Acid 960,762 0.41 31,667 0.29
61 Tamsulosin 959,003 0.41 37,039 0.33
62 Beclometasone (Inhaled) 957,336 0.41 55,806 0.50
63 Nebivolol 871,967 0.38 62,210 0.56
64 Isotretinoin 851,021 0.37 12,745 0.12
65 Fluticasone (Inhaled) 835,575 0.36 21,174 0.19
66 Alendronic Acid, Combinations 827,948 0.36 25,786 0.23
67 Tolterodine 824,596 0.36 18,704 0.17
68 Lignocaine (Local Anaesthetic) 821,547 0.35 3,547 0.03
69 Strontium Ranelate 811,623 0.35 18,357 0.17
70 Amoxicillin and Enzyme Inhibitor 806,725 0.35 128,712 1.16
Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Olmesartan Medoxomil 779,391 0.34 38,866 0.35
72 Aripiprazole 747,286 0.32 4,994 0.05
73 Sertraline 746,411 0.32 35,076 0.32
74 Rabeprazole 732,317 0.32 23,282 0.21
75 Losartan and Diuretics 706,356 0.31 28,257 0.26
76 Perindopril and Diuretics 686,882 0.30 30,519 0.28
77 Diagnostic Products 671,984 0.29 19,043 0.17
78 Solifenacin 668,452 0.29 13,719 0.12
79 Proguanil, Combinations 659,616 0.28 9,695 0.09
80 Candesartan 658,935 0.28 29,328 0.26
81 Citalopram 657,368 0.28 50,510 0.46
82 Budesonide (Inhaled) 648,690 0.28 15,984 0.14
83 Telmisartan and Diuretics 635,680 0.27 25,347 0.23
84 Lercanidipine 623,010 0.27 48,127 0.43
85 Zolmitriptan 617,410 0.27 13,806 0.12
86 Letrozole 614,159 0.27 6,660 0.06
87 Simvastatin 602,177 0.26 34,805 0.31
88 Modafinil 600,598 0.26 2,911 0.03
89 Mometasone 588,932 0.25 39,848 0.36
90 Oxycodone 561,413 0.24 14,897 0.13
91 Ranitidine 547,071 0.24 34,821 0.31
92 Etonogestrel 545,736 0.24 4,118 0.04
93 Fluoxetine 514,814 0.22 31,004 0.28
94 Prednisolone (Systemic) 512,643 0.22 122,611 1.11
95 Tacrolimus (Topical) 500,728 0.22 7,627 0.07
96 Risperidone 499,487 0.22 11,296 0.10
97 Levothyroxine Sodium 498,637 0.22 269,126 2.43
98 Latanoprost 496,405 0.21 21,762 0.20
99 Tramadol 490,771 0.21 55,734 0.50
100 Methotrexate 479,812 0.21 43,593 0.39
Total €185,271,903 80.05% 6,868,277 62.01%
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Diagnostic Products 283,805 10.11 12,829,302 15.83
2 Metformin 252,828 9.00 823,452 1.02
3 Acetylsalicylic Acid-Aspirin (Antithrombotic) 247,234 8.81 522,920 0.65
4 Atorvastatin 180,923 6.44 7,066,391 8.72
5 Needles/Syringes/Lancets 157,753 5.62 3,921,282 4.84
6 Gliclazide 131,090 4.67 806,645 1.00
7 Ramipril 86,277 3.07 624,185 0.77
8 Insulin Aspart, Fast Acting 83,872 2.99 5,044,817 6.23
9 Perindopril 63,572 2.26 1,222,889 1.51
10 Rosuvastatin 56,940 2.03 1,598,455 1.97
11 Amlodipine 55,899 1.99 523,088 0.65
12 Insulin Glargine, Long Acting 49,303 1.76 3,669,222 4.53
13 Sodium Valproate 46,990 1.67 561,784 0.69
14 Lamotrigine 46,860 1.67 2,952,219 3.64
15 Bisoprolol 43,515 1.55 210,639 0.26
16 Carbamazepine 38,921 1.39 322,787 0.40
17 Clinical Nutritional Products 35,453 1.26 4,888,354 6.03
18 Insulin Detemir, Long Acting 32,501 1.16 2,688,415 3.32
19 Levetiracetam 28,046 1.00 2,471,263 3.05
20 Pravastatin 25,892 0.92 496,885 0.61
21 Doxazosin 24,472 0.87 670,823 0.83
22 Lisinopril 21,007 0.75 162,843 0.20
23 Sitagliptin 20,698 0.74 926,876 1.14
24 Atenolol 20,674 0.74 86,309 0.11
25 Phenytoin 19,225 0.68 122,233 0.15
26 Losartan 17,898 0.64 420,461 0.52
27 Valsartan 17,186 0.61 396,997 0.49
28 Metformin and Sitagliptin 15,378 0.55 750,367 0.93
29 Lercanidipine 15,198 0.54 200,383 0.25
30 Levothyroxine Sodium 14,963 0.53 33,319 0.04
31 Folic Acid 14,362 0.51 16,062 0.02
32 Clopidogrel 14,302 0.51 710,226 0.88
33 Furosemide 12,388 0.44 13,546 0.02
34 Nebivolol 12,362 0.44 188,419 0.23
35 Simvastatin 12,294 0.44 219,780 0.27
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Insulin Aspart, Comb. Intermediate/Fast Acting 11,914 0.42 832,745 1.03
37 Valsartan and Diuretics 11,137 0.40 291,313 0.36
38 Telmisartan 10,007 0.36 240,330 0.30
39 Simvastatin and Ezetimibe 9,344 0.33 486,336 0.60
40 Tadalafil 9,243 0.33 262,289 0.32
41 Warfarin 9,182 0.33 21,586 0.03
42 Bendroflumethiazide 9,045 0.32 14,007 0.02
43 Sildenafil 8,970 0.32 270,982 0.33
44 Omega-3-triglycerides 8,766 0.31 255,503 0.32
45 Ezetimibe 8,757 0.31 336,189 0.41
46 Insulin Lispro, Fast Acting 8,734 0.31 511,136 0.63
47 Glimepiride 8,260 0.29 48,133 0.06
48 Insulin (Human), Intermediate Acting 8,157 0.29 288,909 0.36
49 Olmesartan Medoxomil 8,008 0.29 165,277 0.20
50 Candesartan 7,975 0.28 187,046 0.23
51 Phenobarbital 7,948 0.28 29,893 0.04
52 Liraglutide 7,647 0.27 1,051,705 1.30
53 Insulin (Human), Comb. Intermediate/Fast Acting 7,627 0.27 406,901 0.50
54 Indapamide 7,537 0.27 27,767 0.03
55 Pioglitazone 7,516 0.27 386,462 0.48
56 Glucagon 7,422 0.26 210,310 0.26
57 Topiramate 7,371 0.26 518,468 0.64
58 Levodopa and Decarboxylase Inhibitor 7,342 0.26 128,076 0.16
59 Pancreatic Enzymes 7,221 0.26 749,305 0.92
60 Losartan and Diuretics 6,079 0.22 159,700 0.20
61 Fenofibrate 6,055 0.22 123,765 0.15
62 Metformin and Rosiglitazone 5,843 0.21 313,504 0.39
63 Calcium, Combinations 5,631 0.20 43,794 0.05
64 Urinary Requisites 5,572 0.20 710,594 0.88
65 Lisinopril and Diuretics 5,503 0.20 42,926 0.05
66 Omeprazole 5,486 0.20 153,879 0.19
67 Oxcarbazepine 5,472 0.19 171,562 0.21
68 Irbesartan 5,464 0.19 136,346 0.17
69 Metoprolol 5,461 0.19 8,167 0.01
70 Pregabalin 5,390 0.19 496,104 0.61
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Bendroflumethiazide and Potassium 5,223 0.19 17,365 0.02
72 Insulin Glulisine, Fast Acting 4,939 0.18 249,091 0.31
73 Rosiglitazone 4,754 0.17 255,897 0.32
74 Diltiazem 4,709 0.17 70,085 0.09
75 Telmisartan and Diuretics 4,650 0.17 118,718 0.15
76 Lansoprazole 4,405 0.16 154,743 0.19
77 Esomeprazole 4,295 0.15 180,999 0.22
78 Baclofen 4,213 0.15 38,815 0.05
79 Enalapril 4,043 0.14 32,324 0.04
80 Gabapentin 4,037 0.14 247,518 0.31
81 Levodopa Decarboxylase Inhibitor and COMT Inhibitor 3,919 0.14 435,760 0.54
82 Insulin (Human), Fast Acting 3,911 0.14 110,352 0.14
83 Exenatide 3,865 0.14 412,386 0.51
84 Ropinirole 3,666 0.13 449,526 0.55
85 Clobazam 3,645 0.13 25,454 0.03
86 Salbutamol (Inhaled) 3,639 0.13 22,602 0.03
87 Valsartan and Amlodipine 3,549 0.13 102,112 0.13
88 Rasagiline 3,244 0.12 323,980 0.40
89 Zonisamide 3,199 0.11 354,177 0.44
90 Evening Primrose Oil (Naudicelle) 3,142 0.11 77,949 0.10
91 Quinapril 3,119 0.11 38,893 0.05
92 Atenolol and other Diuretics 3,087 0.11 15,283 0.02
93 Isosorbide Mononitrate 3,057 0.11 25,255 0.03
94 Perindopril and Diuretics 3,040 0.11 86,429 0.11
95 Clonazepam 2,985 0.11 68,294 0.08
96 Selegiline 2,968 0.11 92,839 0.11
97 Allopurinol 2,947 0.10 15,005 0.02
98 Pramipexole 2,885 0.10 464,105 0.57
99 Nifedipine 2,881 0.10 40,051 0.05
100 Metformin and Pioglitazone 2,850 0.10 136,236 0.17
Total 2,578,033 91.82% €72,906,890 90.02%
91 92
Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Diagnostic Products 12,829,302 15.83 283,805 10.11
2 Atorvastatin 7,066,391 8.72 180,923 6.44
3 Insulin Aspart, Fast Acting 5,044,817 6.23 83,872 2.99
4 Clinical Nutritional Products 4,888,354 6.03 35,453 1.26
5 Needles/Syringes/Lancets 3,921,282 4.84 157,753 5.62
6 Insulin Glargine, Long Acting 3,669,222 4.53 49,303 1.76
7 Lamotrigine 2,952,219 3.64 46,860 1.67
8 Insulin Detemir, Long Acting 2,688,415 3.32 32,501 1.16
9 Levetiracetam 2,471,263 3.05 28,046 1.00
10 Rosuvastatin 1,598,455 1.97 56,940 2.03
11 Perindopril 1,222,889 1.51 63,572 2.26
12 Liraglutide 1,051,705 1.30 7,647 0.27
13 Sitagliptin 926,876 1.14 20,698 0.74
14 Insulin Aspart, Comb. Intermediate/Fast Acting 832,745 1.03 11,914 0.42
15 Metformin 823,452 1.02 252,828 9.00
16 Gliclazide 806,645 1.00 131,090 4.67
17 Apomorphine 783,392 0.97 991 0.04
18 Metformin and Sitagliptin 750,367 0.93 15,378 0.55
19 Pancreatic Enzymes 749,305 0.92 7,221 0.26
20 Urinary Requisites 710,594 0.88 5,572 0.20
21 Clopidogrel 710,226 0.88 14,302 0.51
22 Doxazosin 670,823 0.83 24,472 0.87
23 Ramipril 624,185 0.77 86,277 3.07
24 Sodium Valproate 561,784 0.69 46,990 1.67
25 Amlodipine 523,088 0.65 55,899 1.99
26 Acetylsalicylic Acid-Aspirin (Antithrombotic) 522,920 0.65 247,234 8.81
27 Topiramate 518,468 0.64 7,371 0.26
28 Insulin Lispro, Fast Acting 511,136 0.63 8,734 0.31
29 Pravastatin 496,885 0.61 25,892 0.92
30 Pregabalin 496,104 0.61 5,390 0.19
31 Simvastatin and Ezetimibe 486,336 0.60 9,344 0.33
32 Pramipexole 464,105 0.57 2,885 0.10
33 Ropinirole 449,526 0.55 3,666 0.13
34 Levodopa, Decarboxylase Inhibitor and COMT Inhibitor 435,760 0.54 3,919 0.14
35 Losartan 420,461 0.52 17,898 0.64
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Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Exenatide 412,386 0.51 3,865 0.14
37 Insulin (Human), Comb. Intermediate/Fast Acting 406,901 0.50 7,627 0.27
38 Valsartan 396,997 0.49 17,186 0.61
39 Pioglitazone 386,462 0.48 7,516 0.27
40 Zonisamide 354,177 0.44 3,199 0.11
41 Ezetimibe 336,189 0.41 8,757 0.31
42 Meropenem 329,240 0.41 167 0.01
43 Rasagiline 323,980 0.40 3,244 0.12
44 Carbamazepine 322,787 0.40 38,921 1.39
45 Metformin and Rosiglitazone 313,504 0.39 5,843 0.21
46 Nutritional/Ancillary Devices 303,496 0.37 2,483 0.09
47 Valsartan and Diuretics 291,313 0.36 11,137 0.40
48 Insulin (Human), Intermediate Acting 288,909 0.36 8,157 0.29
49 Colistin Parenteral 285,913 0.35 1,891 0.07
50 Sildenafil 270,982 0.33 8,970 0.32
51 Tadalafil 262,289 0.32 9,243 0.33
52 Rosiglitazone 255,897 0.32 4,754 0.17
53 Omega-3-triglycerides 255,503 0.32 8,766 0.31
54 Insulin Glulisine, Fast Acting 249,091 0.31 4,939 0.18
55 Gabapentin 247,518 0.31 4,037 0.14
56 Telmisartan 240,330 0.30 10,007 0.36
57 Rotigotine 227,812 0.28 1,280 0.05
58 Simvastatin 219,780 0.27 12,294 0.44
59 Bisoprolol 210,639 0.26 43,515 1.55
60 Glucagon 210,310 0.26 7,422 0.26
61 Lercanidipine 200,383 0.25 15,198 0.54
62 Nebivolol 188,419 0.23 12,362 0.44
63 Other Alimentary Tract/Metabolism Products 188,157 0.23 1,767 0.06
64 Candesartan 187,046 0.23 7,975 0.28
65 Esomeprazole 180,999 0.22 4,295 0.15
66 Oxcarbazepine 171,562 0.21 5,472 0.19
67 Olmesartan Medoxomil 165,277 0.20 8,008 0.29
68 Lisinopril 162,843 0.20 21,007 0.75
69 Orlistat 160,912 0.20 2,615 0.09
70 Losartan and Diuretics 159,700 0.20 6,079 0.22
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Lansoprazole 154,743 0.19 4,405 0.16
72 Omeprazole 153,879 0.19 5,486 0.20
73 Modafinil 151,716 0.19 880 0.03
74 Desmopressin 147,313 0.18 2,141 0.08
75 Irbesartan 136,346 0.17 5,464 0.19
76 Metformin and Pioglitazone 136,236 0.17 2,850 0.10
77 Midazolam 132,259 0.16 2,158 0.08
78 Azithromycin 131,927 0.16 2,166 0.08
79 Multivitamins and Trace Elements 131,108 0.16 2,415 0.09
80 Levodopa and Decarboxylase Inhibitor 128,076 0.16 7,342 0.26
81 Fenofibrate 123,765 0.15 6,055 0.22
82 Phenytoin 122,233 0.15 19,225 0.68
83 Telmisartan and Diuretics 118,718 0.15 4,650 0.17
84 Insulin (Human), Fast Acting 110,352 0.14 3,911 0.14
85 Dressings 105,105 0.13 1,775 0.06
86 Lacosamide 102,321 0.13 1,187 0.04
87 Valsartan and Amlodipine 102,112 0.13 3,549 0.13
88 Ostomy Requisites 100,580 0.12 1,192 0.04
89 Levocarnitine 99,863 0.12 270 0.01
90 Tolterodine 98,508 0.12 2,168 0.08
91 Selegiline 92,839 0.11 2,968 0.11
92 Melatonin 91,054 0.11 1,353 0.05
93 Salmeterol and other drugs for obstructive airway diseases 89,859 0.11 1,278 0.05
94 Perindopril and Diuretics 86,429 0.11 3,040 0.11
95 Atenolol 86,309 0.11 20,674 0.74
96 Perindopril and Amlodipine 85,576 0.11 2,423 0.09
97 Candesartan and Diuretics 78,587 0.10 2,783 0.10
98 Olanzapine 78,365 0.10 822 0.03
99 Evening Primrose Oil (Naudicelle) 77,949 0.10 3,142 0.11
100 Diltiazem 70,085 0.09 4,709 0.17
Total €76,171,412 94.04% 2,475,119 88.20%
Table 19.6 LTI: The Top 100 Products of Highest cost in the Order of their Total Ingredient Cost continued
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Adalimumab 39,178 9.99 54,285,269 17.72
2 Etanercept 37,412 9.54 42,470,280 13.87
3 Tacrolimus 28,352 7.23 7,493,723 2.45
4 Mycophenolic Acid 27,538 7.02 5,883,844 1.92
5 Bicalutamide 24,353 6.21 2,217,896 0.72
6 Ciclosporin 17,582 4.48 2,028,214 0.66
7 Darbepoetin alfa 15,471 3.94 7,083,532 2.31
8 Triptorelin 14,713 3.75 5,447,910 1.78
9 Interferon beta-1a 14,389 3.67 16,558,800 5.41
10 Pegfilgrastim 11,997 3.06 14,901,540 4.86
11 Teriparatide 11,728 2.99 5,355,432 1.75
12 Erythropoietin 11,128 2.84 9,067,167 2.96
13 Leuprorelin 10,778 2.75 5,374,985 1.76
14 Somatropin 9,409 2.40 6,746,060 2.20
15 Interferon beta-1b 8,413 2.14 9,863,895 3.22
16 Capecitabine 7,237 1.85 1,806,003 0.59
17 Methoxy Polyethylene Glycol – Epoetin beta 5,845 1.49 1,270,338 0.42
18 Cinacalcet 5,628 1.43 1,909,359 0.62
19 Glatiramer Acetate 5,461 1.39 6,635,831 2.17
20 Goserelin 5,169 1.32 1,826,923 0.60
21 Follitropin beta 4,863 1.24 4,119,631 1.35
22 Dornase alfa 4,359 1.11 4,072,792 1.33
23 Filgrastim 3,922 1.00 2,835,425 0.93
24 Palivizumab 3,906 1.00 4,072,318 1.33
25 Choriogonadotropin alfa 3,845 0.98 193,247 0.06
26 Imatinib 2,957 0.75 7,962,472 2.60
27 Octreotide 2,922 0.74 3,299,257 1.08
28 Follitropin alfa 2,902 0.74 3,397,704 1.11
29 Sildenafil 2,702 0.69 1,969,501 0.64
30 Ribavirin 2,444 0.62 1,331,229 0.43
31 Human Menopausal Gonadotrophin 2,123 0.54 1,433,060 0.47
32 Peginterferon alfa-2a 2,097 0.53 2,105,734 0.69
33 Riluzole 2,083 0.53 686,271 0.22
34 Lenalidomide 2,029 0.52 13,482,422 4.40
35 Bosentan 1,991 0.51 6,073,440 1.98
Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Temozolomide 1,878 0.48 2,206,027 0.72
37 Parathyroid Hormone 1,856 0.47 841,326 0.27
38 Tobramycin 1,698 0.43 4,297,014 1.40
39 Ganirelix 1,424 0.36 427,346 0.14
40 Fulvestrant 1,343 0.34 886,239 0.29
41 Thalidomide 1,311 0.33 844,515 0.28
42 Sirolimus 1,269 0.32 320,912 0.11
43 Anagrelide 1,259 0.32 666,495 0.22
44 Entecavir 1,211 0.31 695,893 0.23
45 Linezolid 1,208 0.31 1,823,492 0.60
46 Erlotinib 1,118 0.29 2,563,302 0.84
47 Paricalcitol 1,087 0.28 192,205 0.06
48 Lutropin alfa 1,028 0.26 570,471 0.19
49 Lanreotide 1,005 0.26 1,159,568 0.38
50 Lamivudine 978 0.25 97,242 0.03
51 Sunitinib 972 0.25 3,151,564 1.03
52 Valganciclovir 903 0.23 1,353,313 0.44
53 Deferasirox 897 0.23 811,701 0.27
54 Degarelix 833 0.21 165,622 0.05
55 Voriconazole 689 0.18 1,841,609 0.60
56 Adefovir Dipivoxil 636 0.16 348,031 0.11
57 Buserelin 610 0.16 95,875 0.03
58 Golimumab 592 0.15 993,283 0.32
59 Sorafenib 587 0.15 2,028,046 0.66
60 Lapatinib 572 0.15 1,227,157 0.40
61 Nafarelin 556 0.14 93,089 0.03
62 Peginterferon alfa-2b 537 0.14 393,448 0.13
63 Posaconazole 462 0.12 915,646 0.30
64 Etoposide 455 0.12 42,441 0.01
65 Ibandronic Acid 434 0.11 116,089 0.04
66 Anakinra 431 0.11 446,940 0.15
67 Clodronic Acid 409 0.10 117,436 0.04
68 Interferon alfa-2b 408 0.10 337,715 0.11
69 Vinorelbine 388 0.10 160,198 0.05
70 Flutamide 378 0.10 51,081 0.02
Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Note:  Based on data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Interferon alfa-2a 350 0.09 103,809 0.03
72 Cetrorelix 316 0.08 82,344 0.03
73 Lenograstim 303 0.08 235,414 0.08
74 Dasatinib 301 0.08 1,359,430 0.44
75 Pegvisomant 281 0.07 1,145,115 0.37
76 Fludarabine 277 0.07 219,815 0.07
77 Vancomycin Oral 270 0.07 51,166 0.02
78 Sitaxentan 265 0.07 688,141 0.22
79 Nilotinib 242 0.06 1,112,039 0.36
80 Everolimus 212 0.05 763,058 0.25
81 Iloprost 167 0.04 618,892 0.20
82 Ustekinumab 151 0.04 671,133 0.22
83 Sodium Phenylbutyrate 143 0.04 194,950 0.06
84 Ambrisentan 126 0.03 363,241 0.12
85 Risedronic Acid 116 0.03 26,841 0.01
86 Bexarotene 81 0.02 224,718 0.07
87 Sodium Oxybate 77 0.02 49,268 0.02
88 Epoprostenol 35 0.01 372,012 0.12
89 Deferiprone 33 0.01 17,556 0.01
90 Topotecan 22 0.01 30,645 0.01
91 Miglustat 19 0.01 217,996 0.07
92 Histrelin 18 0.01 33,780 0.01
93 Urofollitropin 18 0.00 22,255 0.01
94 Nitisinone 17 0.00 60,309 0.02
95 Certolizumab Pegol 11 0.00 46,353 0.02
96 Zinc Acetate 11 0.00 1,387 0.00
97 Aldesleukin 10 0.00 14,111 0.00
98 Follitropin alfa and Lutropin alfa 10 0.00 14,014 0.00
99 Emtricitabine 6 0.00 387 0.00
100 Becaplermin 4 0.00 1,955 0.00
Total 392,240 100.00% €306,285,969 100.00%
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Adalimumab 54,285,269 17.72 39,178 9.99
2 Etanercept 42,470,280 13.87 37,412 9.54
3 Interferon beta-1a 16,558,800 5.41 14,389 3.67
4 Pegfilgrastim 14,901,540 4.86 11,997 3.06
5 Lenalidomide 13,482,422 4.40 2,029 0.52
6 Interferon beta-1b 9,863,895 3.22 8,413 2.14
7 Erythropoietin 9,067,167 2.96 11,128 2.84
8 Imatinib 7,962,472 2.60 2,957 0.75
9 Tacrolimus 7,493,723 2.45 28,352 7.23
10 Darbepoetin alfa 7,083,532 2.31 15,471 3.94
11 Somatropin 6,746,060 2.20 9,409 2.40
12 Glatiramer Acetate 6,635,831 2.17 5,461 1.39
13 Bosentan 6,073,440 1.98 1,991 0.51
14 Mycophenolic Acid 5,883,844 1.92 27,538 7.02
15 Triptorelin 5,447,910 1.78 14,713 3.75
16 Leuprorelin 5,374,985 1.76 10,778 2.75
17 Teriparatide 5,355,432 1.75 11,728 2.99
18 Tobramycin 4,297,014 1.40 1,698 0.43
19 Follitropin beta 4,119,631 1.35 4,863 1.24
20 Dornase alfa 4,072,792 1.33 4,359 1.11
21 Palivizumab 4,072,318 1.33 3,906 1.00
22 Follitropin alfa 3,397,704 1.11 2,902 0.74
23 Octreotide 3,299,257 1.08 2,922 0.74
24 Sunitinib 3,151,564 1.03 972 0.25
25 Filgrastim 2,835,425 0.93 3,922 1.00
26 Erlotinib 2,563,302 0.84 1,118 0.29
27 Bicalutamide 2,217,896 0.72 24,353 6.21
28 Temozolomide 2,206,027 0.72 1,878 0.48
29 Peginterferon alfa-2a 2,105,734 0.69 2,097 0.53
30 Ciclosporin 2,028,214 0.66 17,582 4.48
31 Sorafenib 2,028,046 0.66 587 0.15
32 Sildenafil 1,969,501 0.64 2,702 0.69
33 Cinacalcet 1,909,359 0.62 5,628 1.43
34 Voriconazole 1,841,609 0.60 689 0.18
35 Goserelin 1,826,923 0.60 5,169 1.32
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Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Linezolid 1,823,492 0.60 1,208 0.31
37 Capecitabine 1,806,003 0.59 7,237 1.85
38 Human Menopausal Gonadotrophin 1,433,060 0.47 2,123 0.54
39 Dasatinib 1,359,430 0.44 301 0.08
40 Valganciclovir 1,353,313 0.44 903 0.23
41 Ribavirin 1,331,229 0.43 2,444 0.62
42 Methoxy Polyethylene Glycol – Epoetin beta 1,270,338 0.42 5,845 1.49
43 Lapatinib 1,227,157 0.40 572 0.15
44 Lanreotide 1,159,568 0.38 1,005 0.26
45 Pegvisomant 1,145,115 0.37 281 0.07
46 Nilotinib 1,112,039 0.36 242 0.06
47 Golimumab 993,283 0.32 592 0.15
48 Posaconazole 915,646 0.30 462 0.12
49 Fulvestrant 886,239 0.29 1,343 0.34
50 Thalidomide 844,515 0.28 1,311 0.33
51 Parathyroid Hormone 841,326 0.27 1,856 0.47
52 Deferasirox 811,701 0.27 897 0.23
53 Everolimus 763,058 0.25 212 0.05
54 Entecavir 695,893 0.23 1,211 0.31
55 Sitaxentan 688,141 0.22 265 0.07
56 Riluzole 686,271 0.22 2,083 0.53
57 Ustekinumab 671,133 0.22 151 0.04
58 Anagrelide 666,495 0.22 1,259 0.32
59 Iloprost 618,892 0.20 167 0.04
60 Lutropin alfa 570,471 0.19 1,028 0.26
61 Anakinra 446,940 0.15 431 0.11
62 Ganirelix 427,346 0.14 1,424 0.36
63 Peginterferon alfa-2b 393,448 0.13 537 0.14
64 Epoprostenol 372,012 0.12 35 0.01
65 Ambrisentan 363,241 0.12 126 0.03
66 Adefovir Dipivoxil 348,031 0.11 636 0.16
67 Interferon alfa-2b 337,715 0.11 408 0.10
68 Sirolimus 320,912 0.11 1,269 0.32
69 Lenograstim 235,414 0.08 303 0.08
70 Bexarotene 224,718 0.07 81 0.02
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Fludarabine 219,815 0.07 277 0.07
72 Miglustat 217,996 0.07 19 0.01
73 Sodium Phenylbutyrate 194,950 0.06 143 0.04
74 Choriogonadotropin alfa 193,247 0.06 3,845 0.98
75 Paricalcitol 192,205 0.06 1,087 0.28
76 Degarelix 165,622 0.05 833 0.21
77 Vinorelbine 160,198 0.05 388 0.10
78 Clodronic Acid 117,436 0.04 409 0.10
79 Ibandronic Acid 116,089 0.04 434 0.11
80 Interferon alfa-2a 103,809 0.03 350 0.09
81 Lamivudine 97,242 0.03 978 0.25
82 Buserelin 95,875 0.03 610 0.16
83 Nafarelin 93,089 0.03 556 0.14
84 Cetrorelix 82,344 0.03 316 0.08
85 Nitisinone 60,309 0.02 17 0.00
86 Vancomycin (Oral) 51,166 0.02 270 0.07
87 Flutamide 51,081 0.02 378 0.10
88 Sodium Oxybate 49,268 0.02 77 0.02
89 Certolizumab Pegol 46,353 0.02 11 0.00
90 Etoposide 42,441 0.01 455 0.12
91 Histrelin 33,780 0.01 18 0.01
92 Topotecan 30,645 0.01 22 0.01
93 Risedronic Acid 26,841 0.01 116 0.03
94 Urofollitropin 22,255 0.01 18 0.00
95 Deferiprone 17,556 0.01 33 0.01
96 Aldesleukin 14,111 0.00 10 0.00
97 Follitropin alfa and Lutropin alfa 14,014 0.00 10 0.00
98 Pazopanib 9,402 0.00 3 0.00
99 Interferon alfa-n1 4,482 0.00 1 0.00
100 Efalizumab 3,536 0.00 3 0.00
Total €306,299,660 100.00% 392,226 100.00%
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 7,421,528 13.64 143,640,336 15.25
A01 Stomatological Preparations 93,087 0.17 336,606 0.04
A02 Drugs for Acid Related Disorders 3,274,473 6.02 88,357,627 9.38
A03 Drugs for Functional Gastrointestinal Disorders 506,672 0.93 2,132,239 0.23
A04 Anti-emetics and Antinauseants 22,272 0.04 1,851,007 0.20
A05 Bile and Liver Therapy 15,306 0.03 751,672 0.08
A06 Laxatives 762,269 1.40 6,167,726 0.65
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 256,222 0.47 5,440,203 0.58
A08 Anti-obesity Preparations, excl. Diet Products 57,169 0.11 3,464,432 0.37
A09 Digestives, incl. Enzymes 14,903 0.03 1,176,948 0.12
A10 Drugs used in Diabetes 1,281,000 2.35 25,525,476 2.71
A11 Vitamins 87,744 0.16 891,721 0.09
A12 Mineral Supplements 1,050,379 1.93 7,544,348 0.80
A14 Anabolic Agents for Systemic Use 32 0.00 331 0.00
B Blood and Blood Forming Organs 4,569,454 8.39 31,147,707 3.31
B01 Antithrombotic Agents 3,756,506 6.90 29,436,668 3.13
B02 Antihemorrhagics 13,512 0.02 185,263 0.02
B03 Anti-anemic Preparations 799,426 1.47 1,525,727 0.16
B05 Blood Substitutes and Perfusion Solutions 10 0.00 49 0.00
101 102
Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 13,076,598 24.03 212,513,917 22.56
C01 Cardiac Therapy 787,035 1.45 7,830,080 0.83
C02 Antihypertensives 306,704 0.56 7,261,316 0.77
C03 Diuretics 1,695,007 3.11 4,828,893 0.51
C04 Peripheral Vasodilators 50,302 0.09 785,519 0.08
C05 Vasoprotectives 129,267 0.24 861,642 0.09
C07 Beta Blocking Agents 2,034,874 3.74 11,188,487 1.19
C08 Calcium Channel Blockers 1,369,534 2.52 14,112,118 1.50
C09 Agents Acting on the Renin-Angiotensin System 3,184,630 5.85 52,075,130 5.53
C10 Lipid Modifying Agents 3,519,245 6.47 113,570,732 12.06
D Dermatologicals 1,484,717 2.73 14,253,125 1.51
D01 Antifungals for Dermatological Use 353,307 0.65 2,582,415 0.27
D02 Emollients and Protectives 231,873 0.43 612,293 0.07
D03 Preparations for Treatment of Wounds and Ulcers 850 0.00 47,211 0.01
D04 Antipruritics, incl. Antihistamines, Anesthetics, etc. 9 0.00 312 0.00
D05 Antipsoriatics 73,423 0.13 4,380,198 0.46
D06 Antibiotics and Chemotherapeutics for Dermatological Use 140,696 0.26 1,185,817 0.13
D07 Corticosteroids, Dermatological Preparations 593,487 1.09 3,047,358 0.32
D10 Anti-Acne Preparations 65,285 0.12 1,050,050 0.11
D11 Other Dermatological Preparations 25,787 0.05 1,347,471 0.14
G Genito Urinary System and Sex Hormones 1,993,903 3.67 39,306,347 4.18
G01 Gynecological Anti-infectives and Antiseptics 27,373 0.05 143,351 0.02
G02 Other Gynecologicals 26,962 0.05 1,846,180 0.20
G03 Sex Hormones and Modulators of the Genital System 1,015,483 1.87 8,331,294 0.88
G04 Urologicals 924,085 1.70 28,985,522 3.08
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones 
and Insulins
1,786,929 3.29 5,822,915 0.62
H01 Pituitary, Hypothalamic Hormones and Analogues 13,962 0.03 758,328 0.08
H02 Corticosteroids for Systemic Use 591,958 1.09 2,636,512 0.28
H03 Thyroid Therapy 1,173,419 2.16 2,203,398 0.23
H04 Pancreatic Hormones 7,457 0.01 219,618 0.03
H05 Calcium Homeostasis 133 0.00 5,059 0.00
J Anti-infectives for Systemic Use 2,661,241 4.89 23,205,460 2.46
J01 Antibacterials for Systemic Use 2,525,629 4.64 19,722,155 2.09
J02 Antimycotics for Systemic Use 91,368 0.17 1,162,439 0.13
J04 Antimycobacterials 5,561 0.01 127,027 0.01
J05 Antivirals for Systemic Use 38,679 0.07 2,193,814 0.23
J07 Vaccines 4 0.00 25 0.00
L Antineoplastic and Immunomodulating Agents 272,342 0.50 9,633,276 1.02
L01 Antineoplastic Agents 24,758 0.05 903,410 0.10
L02 Endocrine Therapy 100,116 0.18 7,386,143 0.78
L04 Immunosuppressive Agents 147,468 0.27 1,343,723 0.14
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 3,489,164 6.41 50,714,821 5.38
M01 Anti-inflammatory and Antirheumatic Products 1,728,975 3.18 18,501,546 1.96
M02 Topical Products for Joint and Muscular Pain 604,644 1.11 3,983,957 0.42
M03 Muscle Relaxants 48,415 0.09 817,273 0.09
M04 Antigout Preparations 224,269 0.41 937,816 0.10
M05 Drugs for treatment of Bone Diseases 781,126 1.43 25,382,740 2.69
M09 Other Drugs for Disorders of the Musculo-Skeletal System 101,735 0.19 1,091,489 0.12
N Nervous System 10,587,109 19.44 213,092,052 22.62
N01 Anesthetics 10,615 0.02 1,447,122 0.15
N02 Analgesics 2,591,251 4.76 31,146,547 3.31
N03 Anti-epileptics 1,076,951 1.98 46,348,152 4.92
N04 Antiparkinson Drugs 258,281 0.47 8,624,782 0.92
N05 Psycholeptics 3,730,631 6.85 54,198,567 5.75
N06 Psychoanaleptics 2,500,251 4.59 60,491,008 6.42
N07 Other Nervous System Drugs 419,129 0.77 10,835,874 1.15
P Antiparasitic Products, Insecticides and Repellents 81,839 0.15 584,668 0.06
P01 Antiprotozoals 59,553 0.11 448,398 0.05
P02 Anthelmintics 9,709 0.02 27,973 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 12,577 0.02 108,297 0.01
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 4,067,914 7.47 95,767,539 10.16
R01 Nasal Preparations 352,159 0.65 3,332,698 0.35
R02 Throat Preparations 11,303 0.02 24,057 0.00
R03 Drugs for Obstructive Airway Diseases 2,939,392 5.40 88,123,366 9.36
R05 Cough and Cold Preparations 355,115 0.65 1,250,716 0.13
R06 Antihistamines for Systemic Use 409,760 0.75 3,031,589 0.32
R07 Other Respiratory System Products 185 0.00 5,113 0.00
S Sensory Organs 1,289,437 2.37 13,132,120 1.39
S01 Ophthalmologicals 1,204,001 2.21 12,797,330 1.36
S02 Otologicals 38,201 0.07 203,322 0.02
S03 Ophthalmological and Otological Preparations 47,235 0.09 131,468 0.01
V Various 1,642,485 3.02 89,350,818 9.48
V01 Allergens 174 0.00 14,534 0.00
V03 Other Therapeutic Products 15,290 0.03 2,469,823 0.26
V04 Diagnostic Products 460,192 0.85 17,251,562 1.83
V06 Clinical Nutritional Products 600,598 1.10 43,681,431 4.64
V07 All Other Non-Therapeutic Products 566,231 1.04 25,933,468 2.75
          Needles/Syringes/Lancets 257,699 0.47 3,593,694 0.38
          Ostomy Requisites 141,364 0.26 13,268,472 1.41
          Urinary Requisites 78,100 0.14 7,240,200 0.77
          Dressings 26,884 0.05 1,110,401 0.12
          Miscellaneous 62,184 0.12 720,701 0.07
TOTAL 54,424,660 100.00% €942,165,101 100.00%
105 106
Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 1,327,786 11.99 32,388,343 13.99
A01 Stomatological Preparations 16,197 0.15 62,071 0.03
A02 Drugs for Acid Related Disorders 730,237 6.60 22,265,848 9.62
A03 Drugs for Functional Gastrointestinal Disorders 91,160 0.82 481,688 0.21
A04 Anti-emetics and Antinauseants 8,042 0.07 563,813 0.24
A05 Bile and Liver Therapy 5,596 0.05 344,132 0.15
A06 Laxatives 73,695 0.67 668,678 0.29
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 86,197 0.78 3,993,447 1.72
A08 Anti-obesity Preparations, excl. Diet Products 19,221 0.17 1,183,259 0.51
A09 Digestives, incl. Enzymes 1,888 0.02 108,566 0.05
A10 Drugs used in Diabetes 57,021 0.51 792,159 0.34
A11 Vitamins 15,537 0.14 202,641 0.09
A12 Mineral Supplements 222,872 2.01 1,705,517 0.73
A14 Anabolic Agents for Systemic Use 89 0.00 1,109 0.00
A16 Other Alimentary Tract/Metabolism Products 34 0.00 15,415 0.01
B Blood and Blood Forming Organs 868,785 7.85 8,445,733 3.65
B01 Antithrombotic Agents 759,754 6.86 8,198,154 3.54
B02 Antihemorrhagics 2,917 0.03 44,484 0.02
B03 Anti-anemic Preparations 106,113 0.96 203,091 0.09
B05 Blood Substitutes and Perfusion Solutions 1 0.00 4 0.00
Note:  The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by an individual or family.
107 108
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 2,990,716 27.01 61,518,589 26.57
C01 Cardiac Therapy 94,900 0.86 1,623,329 0.70
C02 Antihypertensives 65,237 0.59 1,682,421 0.73
C03 Diuretics 200,166 1.81 926,026 0.40
C04 Peripheral Vasodilators 3,317 0.03 52,465 0.02
C05 Vasoprotectives 33,472 0.30 234,980 0.10
C07 Beta Blocking Agents 451,905 4.08 2,735,246 1.18
C08 Calcium Channel Blockers 278,381 2.51 2,884,384 1.25
C09 Agents Acting on the Renin-Angiotensin System 805,094 7.27 14,734,312 6.36
C10 Lipid Modifying Agents 1,058,244 9.56 36,645,426 15.83
D Dermatologicals 350,045 3.16 7,687,938 3.32
D01 Antifungals for Dermatological Use 89,557 0.81 871,291 0.37
D02 Emollients and Protectives 23,820 0.22 73,153 0.03
D03 Preparations for Treatment of Wounds and Ulcers 479 0.00 64,024 0.03
D04 Antipruritics including Antihistamines, Anesthetics, etc. 269 0.00 14,590 0.01
D05 Antipsoriatics 40,032 0.36 3,656,549 1.58
D06 Antibiotics and Chemotherapeutics for Dermatological Use 27,080 0.25 399,875 0.17
D07 Corticosteroids Dermatological Preparations 120,781 1.09 712,705 0.31
D10 Anti-Acne Preparations 35,483 0.32 1,129,587 0.49
D11 Other Dermatological Preparations 12,544 0.11 766,164 0.33
G Genito Urinary System and Sex Hormones 463,077 4.18 15,554,041 6.71
G01 Gynecological Anti-infectives and Antiseptics 4,265 0.04 25,151 0.01
G02 Other Gynecologicals 17,257 0.15 1,789,979 0.77
G03 Sex Hormones and Modulators of the Genital System 236,835 2.14 7,230,199 3.12
G04 Urologicals 204,720 1.85 6,508,712 2.81
Note:  The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by the individual or family.
Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 426,937 3.86 1,756,053 0.76
H01 Pituitary, Hypothalamic Hormones and Analogues 4,608 0.04 434,021 0.19
H02 Corticosteroids for Systemic Use 143,536 1.30 756,066 0.33
H03 Thyroid Therapy 278,572 2.52 558,772 0.24
H04 Pancreatic Hormones 183 0.00 5,694 0.00
H05 Calcium Homeostasis 38 0.00 1,500 0.00
J Anti-infectives for Systemic Use 511,648 4.62 6,233,188 2.69
J01 Antibacterials for Systemic Use 464,717 4.20 4,563,807 1.97
J02 Antimycotics for Systemic Use 27,230 0.25 466,636 0.20
J04 Antimycobacterials 2,442 0.02 59,843 0.03
J05 Antivirals for Systemic Use 17,257 0.15 1,142,883 0.49
J07 Vaccines 2 0.00 19 0.00
L Antineoplastic and Immunomodulating Agents 103,043 0.93 3,989,529 1.72
L01 Antineoplastic Agents 8,639 0.08 482,000 0.21
L02 Endocrine Therapy 30,097 0.27 2,831,372 1.22
L04 Immunosuppressive Agents 64,307 0.58 676,157 0.29
Note:  The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by the individual or family.
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 792,411 7.16 12,992,714 5.61
M01 Anti-inflammatory and Antirheumatic Products 448,817 4.05 5,917,073 2.56
M02 Topical Products for Joint and Muscular Pain 85,646 0.77 589,435 0.25
M03 Muscle Relaxants 5,057 0.05 75,967 0.03
M04 Antigout Preparations 61,845 0.56 291,421 0.13
M05 Drugs for treatment of Bone Diseases 176,478 1.60 5,881,809 2.54
M09 Other Drugs for Disorders of the Musculo-Skeletal System 14,568 0.13 237,009 0.10
N Nervous System 1,712,412 15.47 38,882,065 16.80
N01 Anesthetics 4,250 0.04 829,393 0.36
N02 Analgesics 378,578 3.42 6,162,054 2.66
N03 Anti-epileptics 174,207 1.57 9,505,378 4.11
N04 Antiparkinson Drugs 23,691 0.22 1,012,261 0.44
N05 Psycholeptics 571,659 5.16 7,859,221 3.39
N06 Psychoanaleptics 513,897 4.64 11,826,117 5.11
N07 Other Nervous System Drugs 46,130 0.42 1,687,641 0.73
P Antiparasitic Products, Insecticides and Repellents 28,862 0.27 718,598 0.31
P01 Antiprotozoals 27,524 0.25 706,971 0.31
P02 Anthelmintics 566 0.01 3,078 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 772 0.01 8,549 0.00
Note:  The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by the individual or family.
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 1,057,441 9.55 27,440,182 11.85
R01 Nasal Preparations 143,473 1.30 1,505,733 0.65
R02 Throat Preparations 1,783 0.02 3,770 0.00
R03 Drugs for Obstructive Airway Diseases 750,823 6.78 24,749,324 10.69
R05 Cough and Cold Preparations 38,174 0.34 161,925 0.07
R06 Antihistamines for Systemic Use 123,176 1.11 1,019,087 0.44
R07 Other Respiratory System Products 12 0.00 343 0.00
S Sensory Organs 217,825 1.97 2,410,787 1.05
S01 Ophthalmologicals 195,641 1.77 2,334,415 1.01
S02 Otologicals 7,514 0.07 41,137 0.02
S03 Ophthalmological and Otological Preparations 14,670 0.13 35,235 0.02
V Various 219,458 1.98 11,509,258 4.97
V01 Allergens 1,451 0.01 119,721 0.05
V03 Other Therapeutic Products 1,867 0.02 284,922 0.12
V04 Diagnostic Products 19,049 0.17 672,127 0.29
V06 Clinical Nutritional Products 105,786 0.96 5,014,792 2.17
V07 All Other Non-Therapeutic Products 91,305 0.82 5,417,696 2.34
          Ostomy Requisites 40,080 0.36 3,615,815 1.56
          Needles/Syringes/Lancets 22,606 0.20 133,458 0.06
          Urinary Requisites 10,307 0.09 1,314,347 0.57
          Dressings 8,191 0.07 223,626 0.10
          Miscellaneous 10,121 0.10 130,450 0.05
TOTAL 11,070,446 100.00% €231,527,018 100.00%
Note:  The above costs are inclusive of the monthly payment of €120 payable to the Pharmacy by the individual or family.
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 742,157 26.44 22,383,857 27.60
A01 Stomatological Preparations 437 0.02 1,988 0.00
A02 Drugs for Acid Related Disorders 18,972 0.68 573,093 0.71
A03 Drugs for Functional Gastrointestinal Disorders 1,736 0.06 74,018 0.09
A04 Anti-emetics and Antinauseants 1,512 0.05 71,495 0.09
A05 Bile and Liver Therapy 788 0.03 42,352 0.05
A06 Laxatives 7,215 0.26 73,273 0.09
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 911 0.03 25,785 0.03
A08 Anti-obesity Preparations, excl. Diet Products 2,695 0.10 165,912 0.20
A09 Digestives, incl. Enzymes 7,241 0.26 756,639 0.93
A10 Drugs Used in Diabetes 679,497 24.20 19,928,373 24.59
A11 Vitamins 12,299 0.44 320,042 0.39
A12 Mineral Supplements 6,773 0.24 58,996 0.07
A13 Tonics 8 0.00 60 0.00
A14 Anabolic Agents for Systemic Use 12 0.00 548 0.00
A16 Other Alimentary Tract and Metabolism Products 2,061 0.07 291,283 0.36
B Blood and Blood Forming Organs 290,950 10.36 1,392,696 1.72
B01 Antithrombotic Agents 272,968 9.72 1,304,087 1.61
B02 Antihemorrhagics 890 0.03 22,694 0.03
B03 Anti-anemic Preparations 16,666 0.59 26,560 0.03
B05 Blood Substitutes and Perfusion Solutions 426 0.02 39,355 0.05
111 112
Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 866,744 30.88 18,108,261 22.35
C01 Cardiac Therapy 10,734 0.38 127,254 0.16
C02 Antihypertensives 25,140 0.90 698,150 0.86
C03 Diuretics 42,329 1.51 177,837 0.22
C04 Peripheral Vasodilators 671 0.02 13,795 0.02
C05 Vasoprotectives 165 0.01 1,081 0.00
C07 Beta Blocking Agents 91,752 3.27 570,666 0.70
C08 Calcium Channel Blockers 82,002 2.92 874,550 1.08
C09 Agents Acting on the Renin-Angiotensin System 299,751 10.68 4,951,373 6.11
C10 Lipid Modifying Agents 314,200 11.19 10,693,555 13.20
D Dermatologicals 4,444 0.15 60,189 0.08
D01 Antifungals for Dermatological Use 1,488 0.05 12,937 0.02
D02 Emollients and Protectives 873 0.03 7,227 0.01
D03 Preparations for Treatment of Wounds and Ulcers 18 0.00 539 0.00
D04 Antipruritics, incl. Antihistamines, Anesthetics, etc. 54 0.00 1,744 0.00
D05 Antipsoriatics 196 0.01 14,886 0.02
D06 Antibiotics and Chemotherapeutics for Dermatological Use 260 0.01 2,151 0.00
D07 Corticosteroids, Dermatological Preparations 860 0.03 4,504 0.01
D08 Antiseptics and Disinfectants 366 0.01 2,414 0.00
D10 Anti-Acne Preparations 114 0.00 1,222 0.00
D11 Other Dermatological Preparations 215 0.01 12,565 0.02
G Genito Urinary System and Sex Hormones 30,789 1.09 963,298 1.19
G01 Gynecological Anti-infectives and Antiseptics 98 0.00 20,931 0.03
G02 Other Gynecologicals 48 0.00 2,456 0.00
G03 Sex Hormones and Modulators of the Genital System 1,754 0.06 35,939 0.04
G04 Urologicals 28,889 1.03 903,972 1.12
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 28,153 1.00 436,460 0.54
H01 Pituitary, Hypothalamic Hormones and Analogues 2,141 0.08 147,313 0.18
H02 Corticosteroids for Systemic Use 3,159 0.11 42,065 0.05
H03 Thyroid Therapy 15,424 0.55 36,430 0.05
H04 Pancreatic Hormones 7,422 0.26 210,310 0.26
H05 Calcium Homeostasis 7 0.00 342 0.00
J Anti-infectives for Systemic Use 15,590 0.56 1,038,065 1.29
J01 Antibacterials for Systemic Use 14,706 0.52 993,263 1.23
J02 Antimycotics for Systemic Use 538 0.02 26,003 0.03
J04 Antimycobacterials 141 0.01 4,463 0.01
J05 Antivirals for Systemic Use 198 0.01 14,289 0.02
J07 Vaccines 7 0.00 47 0.00
L Antineoplastic and Immunomodulating Agents 1,447 0.05 66,143 0.09
L01 Antineoplastic Agents 443 0.02 48,123 0.06
L02 Endocrine Therapy 45 0.00 5,222 0.01
L04 Immunosuppressive Agents 959 0.03 12,798 0.02
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 15,974 0.58 253,131 0.31
M01 Anti-inflammatory and Antirheumatic Products 4,115 0.15 47,151 0.06
M02 Topical Products for Joint and Muscular Pain 473 0.02 3,349 0.00
M03 Muscle Relaxants 5,567 0.20 108,454 0.13
M04 Antigout Preparations 3,031 0.11 15,794 0.02
M05 Drugs for treatment of Bone Diseases 2,259 0.08 73,264 0.09
M09 Other Drugs for Disorders of the Musculo-Skeletal System 529 0.02 5,119 0.01
N Nervous System 295,458 10.52 12,828,413 15.83
N01 Anesthetics 290 0.01 22,944 0.03
N02 Analgesics 7,415 0.26 86,019 0.11
N03 Anti-epileptics 221,851 7.90 8,617,443 10.63
N04 Antiparkinson Drugs 30,136 1.07 3,026,431 3.73
N05 Psycholeptics 18,806 0.67 460,206 0.57
N06 Psychoanaleptics 15,274 0.55 517,106 0.64
N07 Other Nervous System Drugs 1,686 0.06 98,264 0.12
P Antiparasitic Products, Insecticides and Repellents 136 0.00 1,989 0.00
P01 Antiprotozoals 126 0.00 1,923 0.00
P02 Anthelmintics 3 0.00 11 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 7 0.00 55 0.00
Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 13,262 0.47 356,716 0.45
R01 Nasal Preparations 1,277 0.05 13,388 0.02
R02 Throat Preparations 33 0.00 92 0.00
R03 Drugs for Obstructive Airway Diseases 9,039 0.32 256,120 0.32
R05 Cough and Cold Preparations 1,457 0.05 72,856 0.09
R06 Antihistamines for Systemic Use 1,456 0.05 14,260 0.02
S Sensory Organs 7,353 0.26 114,981 0.14
S01 Ophthalmologicals 7,193 0.26 114,233 0.14
S02 Otologicals 51 0.00 491 0.00
S03 Ophthalmological and Otological Preparations 109 0.00 257 0.00
V Various 495,300 17.64 23,025,841 28.41
V03 Other Therapeutic Products 241 0.01 37,818 0.05
V04 Diagnostic Products 283,818 10.11 12,830,232 15.83
V06 Clinical Nutritional Products 35,453 1.26 4,888,354 6.03
V07 All Other Non-Therapeutic Products 175,788 6.26 5,269,437 6.50
          Needles/Syringes/Lancets/Swabs 157,753 5.62 3,921,282 4.84
          Urinary Requisites 5,572 0.20 710,594 0.88
          Nutritional/Ancillary Devices 2,483 0.09 303,496 0.37
          Dressings 1,775 0.06 105,105 0.13
          Ostomy Requisites 1,192 0.04 100,580 0.12
          Miscellaneous 7,013 0.25 128,380 0.16
TOTAL 2,807,757 100.00% €81,030,040 100.00%
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Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 1,547 0.40 718,013 0.23
A07A Intestinal Anti-infectives 270 0.07 51,166 0.02
A11CC Vitamin D and Analogues 1,087 0.28 192,205 0.06
A16AX Other Alimentary Tract and Metabolism Products 190 0.05 474,642 0.15
B Blood and Blood Forming Organs 32,646 8.32 18,411,943 6.01
B01 Antithrombotic Agents 202 0.05 990,905 0.32
B03 Anti-anemic Preparations 32,444 8.27 17,421,038 5.69
C Cardiovascular System 5,084 1.30 9,094,324 2.97
C02 Antihypertensives 5,084 1.30 9,094,324 2.97
D Dermatologicals 4 0.00 1,955 0.00
D03A Cicatrizants 4 0.00 1,955 0.00
G Genito Urinary System and Sex Hormones 14,789 3.77 9,750,383 3.18
G03GA Gonadotropins 14,789 3.77 9,750,383 3.18
Note:  Based on the data available from claims submitted, the ingredient costs shown is the gross cost before discount.
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl.Sex Hormones and Insulins 35,143 8.96 21,092,676 6.89
H01 Pituitary and Hypothalamic Hormones and Analogues 15,931 4.06 12,986,559 4.24
H05 Calcium Homeostasis 19,212 4.90 8,106,117 2.65
J Anti-infectives for Systemic Use 14,141 3.61 16,776,173 5.48
J01 Antibacterials for Systemic Use 2,906 0.74 6,120,506 2.00
J02 Antimycotics for Systemic Use 1,151 0.29 2,757,254 0.90
J05 Antivirals for Systemic Use 6,178 1.58 3,826,095 1.25
J06 Immune Sera and Immunoglobulins 3,906 1.00 4,072,318 1.33
L Antineoplastic and Immunomodulating Agents 280,487 71.50 224,563,615 73.31
L01 Antineoplastic Agents 18,562 4.73 25,533,168 8.33
L02 Endocrine Therapy 58,177 14.83 16,066,531 5.25
L03 Immunostimulants 47,889 12.21 53,993,491 17.63
L04 Immunosuppressive Agents 155,859 39.73 128,970,425 42.10
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 959 0.24 260,366 0.09
M05 Drugs for treatment of Bone Diseases 959 0.24 260,366 0.09
N Nervous System 2,160 0.55 735,539 0.24
N07XX Other Nervous System Drugs 2,160 0.55 735,539 0.24
R Respiratory System 4,359 1.11 4,072,793 1.33
R05CB Mucolytics (Inhaled) 4,359 1.11 4,072,793 1.33
V Various 930 0.24 829,257 0.27
V03AC Iron Chelating Agents 930 0.24 829,257 0.27
TOTAL 392,249 100% €306,307,037 100%
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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Health Service 
Executive
Average Panel Ranges in 2010
0-100 101-250 251-500 501-1,000 1,001-1,500 1,501-2,000 2,001 and 
Over
€ € € € € € €
East Coast Area 15,672 (72) 73,958 (31) 143,325 (45) 217,503 (64) 333,373 (14) – –
South Western Area 18,365 (57) 61,301 (21) 111,421 (28) 200,327 (94) 292,354 (56) 392,519 (26) 546,324 (1)
Northern Area 18,186 (52) 60,712 (19) 112,269 (35) 207,850 (65) 314,096 (45) 346,504 (24) 537,374 (2)
Midland 16,215 (17) 104,141 (2) 111,775 (13) 230,483 (41) 346,098 (35) 411,480 (18) 530,869 (5)
Mid-Western 19,140 (31) 43,608 (7) 122,768 (32) 227,816 (71) 304,862 (43) 459,871 (13) 444,102 (6)
North Eastern 5,702 (18) 34,240 (8) 119,851 (7) 190,327 (58) 289,720 (58) 362,763 (22) 494,427 (7)
North Western 40,099 (9) 71,187 (6) 138,792 (17) 207,229 (50) 329,541 (39) 385,105 (14) 518,496 (4)
South Eastern 4,674 (21) 61,655 (8) 122,454 (21) 217,205 (110) 323,419 (60) 393,430 (22) 484,486 (2)
Southern 16,395 (68) 61,372 (52) 118,306 (67) 223,383 (151) 358,432 (69) 436,933 (14) 573,963 (4)
Western 12,812 (27) 56,464 (18) 126,168 (38) 233,405 (94) 325,548 (55) 466,261 (19) 607,731 (5)
NATIONAL 2010 €16,162 (372) €61,913 (172) €123,338 (303) €216,604 (798) €320,873 (474) €400,641 (172) €521,585 (36)
NATIONAL 2009 €15,285 (413) €66,456 (169) €133,757 (341) €237,477 (846) €348,688 (428) €451,852 (120) €531,336 (18)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) The number of Doctors in each range is shown in brackets.
 (iii) The average payment to Doctors in each panel range is the gross payments divided by the number of Doctors in that range.
 (iv) Doctors payment is exclusive of superannuation paid to retired DMOs.
Table 21 GMS: Average Payment to Doctors in Panel Ranges
119 120
Table 21.1 GMS: Number of Doctors in Payment Ranges
2010 (2009 in brackets)
Health 
Service 
Executive
Up to 
€30,000
€30,001- 
€60,000
€60,001-
€90,000
€90,001-
€120,000
€120,001-
€150,000
€150,001-
€180,000
€180,001-
€210,000
€210,001-
€240,000
€240,001-
€270,000
€270,001-
€370,000
€370,001-
€470,000
€470,001 
and Over
East Coast 
Area 25 (24) 19 (15) 22 (19) 13 (20) 20 (19) 13 (16) 16 (11) 19 (21) 19 (17) 13 (18) 1 (2) 1 (1)
South Western 
Area 27 (21) 13 (21) 23 (16) 10 (13) 21 (25) 28 (18) 23 (22) 25 (17) 20 (20) 45 (47) 11 (20) 6 (5)
Northern Area 20 (21) 15 (11) 17 (21) 17 (14) 16 (11) 16 (17) 15 (15) 15 (18) 18 (22) 49 (40) 9 (13) 4 (6)
Midland 13 (9) 2 (3) 6 (5) 3 (8) 9 (4) 8 (5) 9 (6) 8 (13) 15 (12) 34 (35) 12 (13) 4 (4)
Mid-Western 23 (17) 6 (7) 8 (6) 10 (11) 17 (15) 12 (16) 18 (16) 24 (22) 16 (18) 39 (37) 11 (17) 4 (4)
North Eastern 10 (9) 5 (3) 4 (8) 11 (5) 10 (14) 14 (10) 20 (18) 13 (16) 14 (17) 45 (47) 16 (13) 2 (2)
North 
Western 4 (5) 4 (4) 6 (5) 6 (8) 8 (11) 13 (7) 14 (11) 14 (13) 10 (13) 37 (31) 14 (23) 6 (7)
South Eastern 6 (9) 6 (4) 8 (8) 10 (12) 11 (10) 25 (19) 20 (28) 34 (30) 20 (19) 65 (66) 21 (15) 7 (10)
Southern 34 (33) 36 (30) 41 (30) 22 (24) 28 (22) 33 (27) 30 (28) 43 (38) 24 (35) 63 (63) 28 (33) 8 (9)
Western 15 (20) 18 (8) 15 (14) 15 (17) 17 (15) 16 (15) 16 (19) 27 (24) 16 (21) 56 (53) 19 (24) 9 (9)
NATIONAL 177 (168) 124 (106) 150 (132) 117 (132) 157 (146) 178 (150) 181 (174) 222 (212) 172 (194) 446 (437) 142 (173) 51 (57)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) Above table relates to the payments listed in Table 3.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
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Table 22 GMS: Number of Pharmacists in Dispensing Fee Ranges
2010 (2009 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 7 (6) 3 (5) 15 (12) 19 (16) 14 (15) 15 (20) 15 (8) 12 (15) 11 (7) 7 (5) 6 (7) 2 (6) 6 (10)
South Western 
Area 2 (5) 13 (13) 12 (20) 15 (15) 18 (22) 17 (17) 20 (17) 15 (15) 13 (8) 15 (18) 13 (7) 5 (7) 29 (36)
Northern Area 4 (6) 5 (9) 14 (17) 14 (17) 16 (16) 15 (13) 18 (15) 19 (18) 9 (12) 9 (8) 7 (6) 5 (7) 35 (38)
Midland – 4 (1) 2 (4) 5 (5) 7 (7) 6 (7) 7 (4) 10 (6) 10 (12) 9 (6) 4 (9) 11 (4) 21 (27)
Mid-Western 1 (2) 5 (5) 5 (12) 14 (9) 6 (5) 12 (12) 11 (14) 15 (14) 14 (11) 14 (10) 11 (10) 10 (13) 20 (25)
North Eastern 1 (3) 8 (8) 4 (11) 8 (11) 13 (7) 11 (15) 22 (14) 14 (13) 14 (14) 10 (11) 8 (8) 6 (4) 23 (26)
North 
Western 1 (–) 1 (5) 5 (4) 4 (3) 8 (6) 10 (11) 10 (8) 9 (6) 7 (9) 8 (6) 7 (9) – (2) 22 (21)
South Eastern 2 (2) 2 (2) 3 (8) 6 (7) 8 (4) 11 (18) 14 (17) 18 (15) 17 (10) 10 (15) 19 (11) 11 (16) 41 (45)
Southern 2 (4) 7 (10) 9 (11) 16 (16) 16 (19) 23 (22) 27 (20) 27 (27) 26 (15) 19 (29) 11 (8) 13 (10) 34 (46)
Western 1 (2) 4 (4) 8 (13) 12 (10) 12 (12) 14 (12) 10 (15) 19 (12) 15 (13) 14 (7) 5 (9) 9 (11) 36 (38)
NATIONAL 21 (30) 52 (62) 77 (112) 113 (109) 118 (113) 134 (147) 154 (132) 158 (141) 136 (111) 115 (115) 91 (84) 72 (80) 267 (312)
Note:  Pharmacies that entered or left the Scheme during the year are not included in the above table.
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Table 23 DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Health Service 
Executive
*Number 
of Persons 
Covered
Unique 
Number of 
Claimants
Number of 
Items
Cost per Item 
€
Gross Cost 
€
Net Cost  
per Claimant 
€
Paid by HSE 
€
Eastern Areas 525,606 183,305 4,525,100 30.88 139,723,559 406.31 74,477,827
Midland 99,784 32,567 700,339 29.16 20,421,823 320.74 10,445,520
Mid-Western 164,541 41,486 849,815 29.87 25,385,689 305.16 12,659,796
North Eastern 139,757 44,413 932,729 29.81 27,801,281 320.74 14,245,063
North Western 58,727 18,022 370,775 30.37 11,261,716 313.93 5,657,576
South Eastern 143,700 50,330 1,131,497 29.14 32,974,239 325.75 16,394,868
Southern 260,032 80,012 1,704,690 30.54 52,068,667 326.60 26,131,558
Western 164,901 44,415 855,501 30.84 26,381,795 302.21 13,422,864
NATIONAL 2010 1,557,048 494,550 11,070,446 €30.35 €336,018,769 €350.69 €173,435,072
NATIONAL 2009 1,587,448 663,127 13,372,525 €33.78 €451,707,314 €391.97 €259,928,189
Note:  * As at 31st December 2010.
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Table 23.1 DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
2010 (2009 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast Area 43 (14) 37 (34) 33 (21) 11 (23) 4 (15) 4 (8) 1 (6) – (3) 1 (6) – – (2) – (1) –
South Western 
Area 59 (27) 62 (47) 28 (37) 23 (25) 9 (13) 4 (15) – (16) 1 (10) 1 (3) – (1) – (2) – (1) 1 (3)
Northern Area 59 (29) 47 (42) 29 (33) 18 (11) 10 (23) 3 (16) 2 (5) 2 (5) 2 (6) – (5) – (1) – (1) – (5)
Midland 32 (11) 42 (25) 13 (23) 6 (13) 3 (4) – (8) – (4) – (2) – (2) – – – –
Mid-Western 66 (24) 54 (47) 12 (36) 4 (19) 2 (7) – (4) – (2) – (2) – (1) – – – –
North Eastern 63 (30) 47 (45) 18 (26) 13 (13) 1 (10) – (9) – (7) – (5) – – – – –
North Western 63 (33) 22 (30) 5 (18) 1 (3) – (4) – (1) – – (1) – – – – –
South Eastern 72 (35) 64 (42) 18 (42) 6 (24) 1 (15) 1 (5) – (5) – (1) – – – – (1) –
Southern 83 (28) 90 (66) 38 (58) 13 (40) 5 (17) 2 (11) – (7) – (3) – (3) – (3) – – – (1)
Western 82 (44) 57 (43) 18 (33) 3 (18) 1 (11) – (6) – (3) – – – – – –
NATIONAL 622 (275) 522 (421) 212 (327) 98 (189) 36 (119) 14 (83) 3 (55) 3 (32) 4 (21) – (9) – (5) – (4) 1 (9)
Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.
 (ii) The above figures do not include the monthly co-payment of €120 paid by an individual or family to the Pharmacist.
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Table 24 LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Health Service Executive *Number of 
Eligible Persons
Unique 
Number of 
Claimants
Number of 
Items
Cost per Item 
€
Total Cost 
€
Cost per 
Claimant 
€
Eastern Areas 66,911 27,904 1,177,531 47.14 55,503,977 1,989.10
Midland 8,056 4,197 179,196 42.29 7,578,007 1,805.58
Mid-Western 9,025 4,650 183,652 40.87 7,505,324 1,614.05
North Eastern 10,967 6,090 262,108 44.17 11,577,379 1,901.05
North Western 7,489 4,163 171,856 44.02 7,564,925 1,817.18
South Eastern 14,355 7,094 310,575 41.83 12,992,635 1,831.50
Southern 10,180 8,227 332,569 46.61 15,501,349 1,884.20
Western 7,943 5,167 190,270 45.71 8,698,183 1,683.41
NATIONAL 2010 134,926 67,492 2,807,757 €45.20 €126,921,779 €1,880.55
NATIONAL 2009 127,636 65,731 2,855,361 €48.95 €139,759,172 €2,126.23
Note:  * As at 31st December 2010.
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Table 24.1 LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
2010 (2009 in brackets)
Health Service Executive Up to €10,000
€10,001-
€20,000
€20,001-
€30,000
€30,001-
€40,000
€40,001-
€50,000
€50,001-
€60,000
€60,001  
and over
East Coast Area 20 (12) 39 (28) 28 (31) 9 (17) 15 (12) 11 (10) 11 (23)
South Western Area 18 (19) 50 (40) 48 (47) 25 (23) 12 (17) 15 (20) 19 (34)
Northern Area 23 (23) 47 (36) 28 (29) 21 (29) 27 (16) 12 (20) 12 (29)
Midland 21 (15) 29 (27) 23 (15) 11 (15) 5 (9) 4 (5) 3 (6)
Mid-Western 51 (42) 58 (46) 18 (37) 6 (7) 3 (5) 2 (2) 0 (3)
North Eastern 34 (31) 43 (33) 25 (32) 16 (12) 17 (15) 3 (5) 4 (17)
North Western 23 (18) 23 (16) 17 (19) 14 (11) 8 (7) 3 (11) 3 (8)
South Eastern 45 (40) 45 (33) 39 (35) 23 (34) 5 (13) 3 (9) 2 (6)
Southern 60 (51) 93 (77) 46 (54) 21 (31) 8 (10) 2 (10) 0 (4)
Western 63 (52) 56 (50) 28 (25) 9 (22) 1 (5) 1 (2) 1 (2)
NATIONAL 358 (303) 483 (386) 300 (324) 155 (201) 101 (109) 56 (94) 55 (132)
Note:  Pharmacies that entered or left the Scheme during the year are not included in the above table.
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Table 25 EEA: Number and Cost of Pharmacists Claims
Health Service Executive Number of Items Cost per Item €
Total Cost 
€
East Coast Area 3,227 19.48 62,869
South Western Area 5,759 20.41 117,566
Northern Area 3,574 19.75 70,599
Midland 4,776 21.47 102,548
Mid-Western 9,398 19.72 185,344
North Eastern 5,221 22.40 116,941
North Western 10,689 20.28 216,811
South Eastern 9,605 19.86 190,734
Southern 19,669 19.55 384,585
Western 14,527 20.41 296,449
NATIONAL 2010 86,445 €20.18 €1,744,446
NATIONAL 2009 85,520 €22.89 €1,957,613
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Table 26 DTS: Number of Treatments
Health Service Executive Above the Line Below the Line Total
Eastern Areas 348,006 21,867 369,873
Midland 78,461 7,004 85,465
Mid-Western 116,353 9,965 126,318
North Eastern 120,419 9,197 129,616
North Western 85,765 5,713 91,478
South Eastern 173,387 16,961 190,348
Southern 226,653 17,529 244,182
Western 155,296 16,110 171,406
NATIONAL 2010 1,304,340 104,346 1,408,686
NATIONAL 2009 1,439,431 145,167 1,584,598
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Table 26.1 DTS: Number of Dentists in Payment Ranges
2010 (2009 in brackets)
Health 
Service 
Executive
Up to 
€10,000
€10,001-
€20,000
€20,001-
€30,000
€30,001-
€40,000
€40,001-
€50,000
€50,001-
€60,000
€60,001-
€70,000
€70,001-
€80,000
€80,001-
€90,000
€90,001-
€100,000
€100,001-
€110,000
€110,001-
€120,000
€120,001 
and over
Eastern Areas 37 (14) 35 (17) 35 (23) 26 (16) 28 (21) 33 (10) 20 (20) 19 (7) 17 (14) 10 (12) 11 (19) 5 (10) 37 (51)
Midland 3 (6) 2 (–) 3 (2) 3 (–) 3 (3) 3 (1) 3 (3) 6 (–) 5 (3) 4 (4) 1 (2) 3 (6) 14 (19)
Mid-Western 15 (8) 9 (6) 6 (8) 15 (8) 4 (6) 10 (10) 7 (3) 3 (7) 5 (7) 5 (4) 6 (6) 2 (2) 15 (18)
North Eastern 3 (–) 6 (3) 5 (3) 4 (–) 5 (6) 6 (3) 8 (4) 6 (7) 4 (10) 2 (5) 1 (1) 2 (3) 18 (21)
North Western 2 (4) 1 (2) 2 (1) – (1) – 4 (1) 1 (3) 3 (1) 4 (2) 2 (2) 1 (1) 1 (–) 16 (17)
South Eastern 8 (6) 6 (1) 7 (1) 10 (4) 14 (3) 7 (9) 10 (5) 12 (8) 9 (2) 6 (5) 4 (5) 5 (3) 28 (36)
Southern 33 (18) 28 (21) 35 (30) 28 (24) 19 (17) 24 (15) 18 (19) 15 (17) 11 (17) 21 (10) 6 (13) 4 (7) 13 (26)
Western 19 (22) 5 (7) 11 (3) 15 (7) 11 (4) 7 (8) 10 (3) 12 (6) 5 (8) 10 (4) 8 (5) 5 (4) 21 (41)
NATIONAL 120 (78) 92 (57) 104 (71) 101 (60) 84 (60) 94 (57) 77 (60) 76 (53) 60 (63) 60 (46) 38 (52) 27 (35) 162 (229)
Note:  Dentists who entered or left the Scheme during the year are not included in the above table.
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Health Service Executive Number of Treatments Cost of Claims €
Eastern Areas 167,293 6,872,946
Midland 42,544 1,757,890
Mid-Western 61,252 2,375,310
North Eastern 52,344 2,004,039
North Western 46,967 1,753,750
South Eastern 93,790 3,612,768
Southern 100,234 3,968,192
Western 73,426 2,833,107
NATIONAL 2010 637,850 €25,178,002
NATIONAL 2009 564,606 €22,184,541
Note:  Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €75,870; Optical services for Teenagers €230,715; Optical services for Children €1,401,894.
Table 27 HSE-COS: Number of Treatments and Cost of Claims
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Table 27.1 HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges
2010 (2009 in brackets)
Health 
Service 
Executive
Up to 
€10,000
€10,001-
€20,000
€20,001-
€30,000
€30,001-
€40,000
€40,001-
€50,000
€50,001-
€60,000
€60,001-
€70,000
€70,001-
€80,000
€80,001-
€90,000
€90,001-
€100,000
€100,001-
€110,000
€110,001-
€120,000
€120,001 
and over
Eastern Areas 56 (52) 29 (29) 19 (17) 10 (12) 9 (6) 6 (3) 2 (7) 4 (–) 1 (1) – (1) 1 (2) 3 (–) 7 (7)
Midland 12 (9) 6 (5) 4 (2) 2 (2) 5 (7) 2 (1) 1 (2) 1 (1) 1 (–) – – – (1) 2 (1)
Mid-Western 11 (11) 5 (6) 7 (6) 1 (2) 3 (2) – (1) – (2) 2 (–) 1 (1) – – – 3 (3)
North Eastern 23 (22) 12 (12) 9 (4) 2 (3) 1 (2) 3 (2) – 1 (–) – (2) 1 (–) 2 (–) – –
North Western 5 (6) 6 (4) 4 (5) 3 (1) 2 (5) 6 (3) 2 (1) – – (1) 1 (–) – – 1 (1)
South Eastern 18 (13) 9 (12) 9 (5) 2 (3) 3 (4) 4 (2) 1 (3) 5 (2) 1 (3) 2 (2) 1 (–) – (1) 5 (4)
Southern 10 (11) 10 (16) 15 (11) 7 (3) 6 (7) 5 (5) 2 (–) 3 (2) 1 (–) – – (1) – 4 (3)
Western 10 (11) 6 (10) 16 (15) 11 (9) 6 (4) – 1 (–) – – – – (1) – 2 (1)
NATIONAL 145 (135) 83 (94) 83 (65) 38 (35) 35 (37) 26 (17) 9 (15) 16 (5) 5 (8) 4 (3) 4 (4) 3 (2) 24 (20)
Note:  Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.
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Health Service Executive 2010
€
2009
€
Eastern Areas 833,626 1,285,694
Midland 69,921 71,214
Mid-Western 205,723 191,193
North Eastern 128,681 110,980
*North Western – –
South Eastern 331,563 209,684
Southern 159,198 247,531
Western 310,168 767,437
NATIONAL €2,038,880 €2,883,733
Note: The above are payments from the Indicative Drug Target Savings.
 * No funds available to draw down in 2010.
Table 28 GMS: Investment in General Practice Development

